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Abstract
There is currently an unmet need for treatments to enhance healing of human chronic skin
wounds. Previously, therapy development has focused on growth factors and physical
matrices, often resulting in disappointing clinical outcomes. In this thesis, we approached
chronic skin wound treatment with a focus on fibrosis and matricellular proteins.
Fibrosis is a pathological condition where tissue repair continues, unchecked, resulting in
excess contraction, matrix accumulation and fibrogenic growth factor activity; features
critically reduced in chronic skin wounds. Identifying factors that promote fibrosis may
offer new therapeutic targets for use in chronic skin wounds. Two such factors are the
matricellular proteins periostin and CCN2. As a group, matricellular proteins have
established roles in acute wound healing; facilitating growth factor signaling, matrix
production and contraction. However, as of yet, matricellular proteins represent an
uninvestigated resource for modulating chronic skin wound healing. The objective of this
thesis was to determine the potential of periostin and CCN2 as therapeutics for
accelerating skin wound healing. Periostin is up-regulated during skin healing but its
function was unknown. Using periostin knockout mice, we observed a delay in fullthickness excisional wound closure in the absence of periostin. This delay was attributed
to a lack of myofibroblast differentiation, central to wound contraction, both in vivo and
in vitro. Next we examined the expression patterns of periostin and CCN2 in tissue
samples from human chronic skin wounds. Within these wounds CCN2 was not induced
and periostin was decreased. These expression patterns were likely due to the
environment of the wounds since fibroblasts cultured from wound tissue expressed
periostin and CCN2, responded to TGFβ, proliferated and contracted collagen gels;
consistent with a fibrotic phenotype. Using a mouse model of impaired diabetic skin
healing, we found that delivery of recombinant periostin or CCN2 accelerated wound
healing. The mechanisms through which periostin and CCN2 delivery influenced wound
healing were distinct, and combination of the two treatments produced synergistic
outcomes. These findings represent the first report of using matricellular proteins to
enhance healing of diabetic skin wounds in an animal model, with an aim to improve
healing of human chronic skin wounds.
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Chapter 1

1

General Introduction
1.1

Skin healing, chronic skin wounds and fibrosis

Development of non-healing skin lesions, which for simplicity will be referred to as
chronic skin wounds, represent an increasing burden on today’s health care systems. The
burden of chronic skin wounds is further exacerbated by the increasing worldwide
prevalence of diabetes. The need for novel and alternate therapeutics for the healing of
chronic skin wounds is essential in order to reduce patient suffering and the significant
costs associated with treatment. Chronic skin wounds result from a failure of the natural
healing process to occur. In contrast, fibrosis results when the healing process continues,
unchecked, to the point of scarring and impaired tissue function. As research in the fields
of chronic skin wounds and fibrosis move forward, important parallels can be drawn
between the cellular dysfunctions in fibrotic diseases and the apparent needs of chronic
skin wounds, including increased proliferation, increased matrix synthesis and increased
matrix contraction. Curiously, inflammation is a major contributing factor in both
pathologies, but at this point they diverge. However, recent advances in our
understanding of the processes underlying fibrosis may be applicable for the treatment of
chronic skin wounds. Recently identified molecules in fibrosis, such as periostin or
CCN2, could represent potential therapeutics for chronic skin wound healing. The theme
of this introduction is to highlight the role of these molecules in the development of
fibrosis and whether such cues could kick-start chronic skin wound healing. To identify
the current limitations and potential for new therapeutics in the area of skin wound
healing, it is first necessary to understand molecules that are essential for normal wound
healing.

1.1.1

Acute wound healing

The process of cutaneous wound healing is very complex and dynamic, involving the coordination of multiple cell types and a plethora of growth factors, cytokines and their
interactions. The aim of this introduction is not to review the intricate details of acute
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wound healing. For such information, the reader is directed to comprehensive reviews on
the subject (Clark, 1996; Singer and Clark, 1999; Diegelmann and Evans, 2004;
Barrientos et al., 2008; Schultz and Wysocki, 2009).
Briefly, acute (normal) wound healing consists of three overlapping phases:
inflammation, proliferation and tissue remodeling (Figure 1.1). Upon tissue injury,
damage to blood vessels results in the aggregation of platelets and the formation of a
fibrin clot. The clot is essential for restoring hemostasis but also acts as a provisional
matrix for infiltrating cells (Clark, 1996). Platelets secrete several soluble factors
including platelet-derived growth factor (PDGF), which initiates chemotaxis of
neutrophils, macrophages and fibroblasts (Clark, 1996; Diegelmann and Evans, 2004).
Neutrophils and macrophages debride the wound. Secretion of transforming growth
factor (TGF) β by platelets and macrophages facilitates migration and activation of
fibroblasts. Fibroblast infiltration of the granulation tissue is essential for transition from
the inflammatory stage to the proliferation/tissue-building phase (Roberts and Sporn,
1993). Concurrently, keratinocytes proliferate and migrate from the wound edge,
isolating the wound from the external environment (re-epithelialization).
The proliferation phase involves the formation of granulation tissue by simultaneous
perfusion of the wound site with new vasculature and matrix turnover by fibroblasts
(Singer and Clark, 1999). Fibroblast proliferation, migration and matrix synthesis is
stimulated by PDGF and TGFβ (Clark, 1996). The fibrin clot is replaced by cellular
fibronectin, collagen type-III and progressively more collagen type-1 (Midwood et al.,
2004). Differentiation of fibroblasts into the α-smooth muscle actin (α-SMA)-positive
contractile, myofibroblast phenotype allows the contraction and compaction of the
granulation tissue into a matrix dense scar (Tomasek et al., 2002).
The transition from granulation tissue to scar formation marks the beginning of the
remodeling phase. During this phase collagen is degraded, synthesized and rearranged at
a slower rate. Increasingly, collagen is organized into large bundles and cross-linked. The
resulting scar tissue is relatively acellular and achieves only about 80% of the breaking
strength of normal skin (Levenson et al., 1965). Therefore, acute healing does not
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Figure 1.1: Acute wound healing consists of three overlapping phases:
inflammation, proliferation and remodeling. The inflammation phase is dominated by
neutrophils and macrophages, which serve to remove foreign debris, bacteria and
damaged tissue. The proliferative phase includes the formation of granulation tissue and
reduced inflammatory signals. The dominant cell types are fibroblasts and
myofibroblasts. Matrix turnover and contraction are key features of this phase. The
remodeling phase serves to rearrange and strengthen the newly formed tissue, producing
a matrix-dense, relatively acellular, scar. Development of chronic skin wounds and
fibrotic lesions are both driven by increased inflammation. (A) However, in chronic skin
wounds sustained inflammation and failed progression to proliferative and remodeling
phases result. (B) Fibrosis results from failure of the remodeling process to terminate at
an appropriate point. Instead, continued matrix secretion and contraction by
myofibroblasts results in excessive scarring.
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Figure 1.1: Acute wound healing consists of three overlapping phases:
inflammation, proliferation and remodeling
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perfectly regenerate the affected tissue, but instead strikes a favorable balance between a
“good enough” repair and rapid wound closure. However, the inability of patients with
existing medical conditions such as diabetes to heal skin wounds rapidly, or at all, is
becoming more and more of a burden on healthcare systems.

1.1.2

The burden of chronic skin wounds

Chronic skin wounds are a diverse set of pathologies that are fundamentally defined by a
severely compromised ability to heal. The majority of chronic skin wounds can be
classified as either diabetic ulcers, venous ulcers or pressure sores (Mustoe et al., 2006),
with arterial wounds being less prevalent. The underlying pathophysiologies of these
wound types are quite distinct (extensively reviewed by Bryant and Nix, 2012). Yet they
are all complicated by a combination of patient age, repeated ischemia-reperfusion injury,
bacterial colonization and hypoxia (Mustoe, 2004; Schreml et al., 2010). Diabetic ulcers
develop as a result of the neuropathy and compromised immune system present in people
with diabetes. Neuropathy inhibits the perception of pain following minor injury or the
discomfort following prolonged pressure. As a result there is repeated aggravation to the
site, which, combined with reduced ability to fight infection, overwhelms the bodies
ability to repair the tissue. Venous ulcers are the consequence of inadequate venous
return due to faulty valves within the veins, leading to excess fluid build up and venous
hypertension. In addition to impeding the flow of fresh blood, venous hypertension
promotes leaking of blood proteins into the extravascular space. These proteins prevent
oxygen and nutrients from reaching the tissue in addition to initiating a sustained immune
response. Pressure sores, similarly to diabetic ulcers, result when tissue is starved of
oxygen and nutrient rich blood as a result of prolonged pressure. Often referred to as
bedsores, these wound are common in bed-ridded or paralyzed people. Arterial wounds
are a result of impeded blood flow due to arterial dysfunctions. Blood vessel hardening
and blockage leads to ischemia and tissue necrosis. The differences in the underlying
causes for these wounds requires specialized and distinct corrective interventions (offloading for diabetic and pressure, reperfusion for arterial, compression for venous ulcers)
before wound healing can be expected to occur. Those wounds that persist even after
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corrective interventions have been attempted become the focus of adjunct therapies, such
as those described below.
In general, chronic skin wounds in healthy individuals are rare (Sen et al., 2009).
However, in medically compromised patients, such as those suffering from diabetes, the
risk of developing chronic skin wounds is greatly increased. The lifetime incidence of
foot ulcers in diabetic patients has been estimated to be 15-25% (Reiber, 1996; Singh et
al., 2005). The overall prevalence of pressure ulcers within Canadian healthcare
institutions was estimated at 26% (Woodbury and Houghton, 2004). The estimated
prevalence of chronic skin wounds encompassing all etiologies within the healthcare
system is closer to 35.5% (Woodbury and Houghton, 2005). Unfortunately, failure of
current treatment strategies to heal chronic skin wounds commonly leads to amputation
of the effected limb (Cavanagh et al., 2005; Wu et al., 2007). In 1993, Siitonen and
colleagues reported the occurrence of lower extremity amputation (LEA) to be 10 times
higher in diabetic persons than in non-diabetics (Siitonen et al., 1993). Sixteen years later
this trend had shown no signs of leveling off. In fact, LEA occurs 19 times as often in
diabetic Canadians than in the general population (Canada Diabetes Report, 2009). Sixty
percent of non-traumatic amputations in the US occurred in diabetic patients (CDC
Diabetes Fact Sheet 2007), with 80% of amputations in diabetic patients being preceded
by a chronic skin wound (Driver et al., 2010). The risks associated with LEA are of great
clinical concern. Perioperative mortality rates following above knee LEA were reported
to be as high as 18.6% in 2003 (Moxey et al., 2010) and 18% in 2005 (Ploeg et al., 2005).
Recently, Aragón-Sánchez and colleagues reported 14.7% post-operative mortality
following above knee amputations (Aragon-Sanchez et al., 2010). In England, a
significant decrease occurred in mortality rates, from 18.6% in 2003 to 15.2% in 2007,
supporting a promising trend (Moxey et al., 2010). Long term mortality following LEA,
however, remains unacceptably high. Several recent reports place five-year survival rates
following any LEA at approximately 50% (Hambleton et al., 2009; Papazafiropoulou et
al., 2009). When major amputations (above knee) are considered alone, five-year survival
rates are as low as 11% (Morbach et al., 2009).
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An estimated 2.4 million Canadians were living with diabetes in 2009 (Public Health
Agency of Canada, 2011). The prevalence of diabetes in Canada has increased steadily
from 4.9 to 6.2% from 2002-03 to 2006-07, representing over 2 million Canadians
(Canada Diabetes Report, 2009). Current estimates suggest that 347 million people
worldwide have diabetes, surpassing previous projections of 336 million people living
with diabetes by the year 2030 (Wild et al., 2004; Danaei et al., 2011). There is no
indication that the burden of chronic skin wounds is shrinking. With the growing
prevalence of diabetes, obesity and an aging population, the impact of chronic skin
wounds is deserving of greater attention in healthcare research (Armstrong et al., 2007;
Harding and Queen, 2010). Selection of target molecules for treatment of chronic skin
wounds based on studies of acute wound healing can be difficult and time consuming due
to the complexity of acute wound healing. To expedite the search for target molecules we
can take advantage of the accumulating knowledge of fibrotic skin lesions, such as keloid
scars, hypertrophic scars and scleroderma. Careful dissection of these conditions may
offer hints towards treating chronic skin wounds.

1.1.3

Chronic skin wounds vs. fibrosis

Fibrosis is a general term describing pathological conditions in which the healing process
has continued, unchecked, to the point where normal tissue is replaced by scar tissue,
resulting in impaired or lost function. The central features of fibrotic diseases include
increased growth factor activity, decreased protease activity and decreased fibroblast
senescence (Figure 1.1) (Wynn, 2007). The culmination of these features is excess matrix
deposition and scar formation. Although the etiology of chronic skin wounds is not fully
understood, three major differences have been described between chronic and acute skin
wounds; 1) reduced growth factor activity, 2) increased protease activity and 3) increased
fibroblast senescence (Schultz and Mast, 1998; Harding et al., 2002). Interestingly,
excessive inflammation is common to both chronic skin wounds (Cochrane, 1977;
Trengove et al., 2000) and fibrosis (Abraham and Varga, 2005). The key difference is
that chronic skin wounds become stalled in an inflammatory state, but fibrotic diseases
progress beyond the initial inflammation and enter an aggressive fibrotic state (Abraham
and Varga, 2005). In bleomycin-induced fibrosis, the initial stage of excessive
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inflammation is characterized by increased numbers of macrophages (Kraling et al.,
1995). Being a major source of the pro-fibrotic growth factors PDGF and TGFβ,
increased macrophage numbers promote an elevated fibrotic response (Yamamoto and
Nishioka, 2005). The elevated fibrotic response results in the increased and sustained
activity of myofibroblasts, which are responsible for elevated collagen production, matrix
contraction and continued secretion of TGFβ (Tomasek et al., 2002; Yamamoto and
Nishioka, 2005). In contrast, chronic skin wounds suffer from reduced expression of key
growth factors, such as PDGF and TGFβ, which impedes fibroblast activation and
construction of the granulation tissue (Robson, 1997; Galkowska et al., 2006). Increased
protease activity, originating from excessive neutrophil infiltration (Cochrane, 1977) and
compounded by reduced protease inhibitor levels, serves to degrade important matrix
components such as collagens (Wysocki et al., 1993; Vaalamo et al., 1999; Liu et al.,
2009; Yang et al., 2009) and growth factors (Chen et al., 1997). These deficiencies are
further exacerbated by the senescent state of fibroblasts within the wound, which impairs
the response to the already scarce growth factors (Hasan et al., 1997; Stanley et al., 1997;
Hehenberger et al., 1998; Mendez et al., 1998; Loot et al., 2002; Yang et al., 2009). A
question of critical importance is why, or how, do fibrotic skin lesions progress beyond
the initial excessive inflammation, whereas chronic skin wounds become stalled (Figure
1.1)?

1.2
Current targets for treatment of chronic skin
wounds
1.2.1

Platelet-derived growth factor-BB

Does increased recruitment of macrophages in bleomycin-induced fibrosis provide the
answer to progressing chronic skin wounds beyond inflammation? Fibrosis results from
excessive extracellular matrix (ECM) production, primarily by a specialized type of
activated fibroblasts, termed myofibroblasts, so-called as they highly express the protein
α-SMA (Trojanowska, 2008). Macrophages release the pro-fibrotic growth factor PDGF
(Yamamoto and Nishioka, 2005), which plays a key role in the expansion and persistence
of myofibroblast populations (Bostrom et al., 1996; Heldin and Westermark, 1999;
Trojanowska, 2008) by modulating fibroblast migration, proliferation and activation
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(Barrientos et al., 2008). Elevated PDGF also contributes to TGFβ expression and thus
represents a crucial initiator of granulation tissue formation (Heldin and Westermark,
1999).
PDGF includes a family of homo and heterodimeric proteins (PDGF-AA, PDGF-AB,
PDGF-BB, PDGF-CC and PDGF-DD), which bind to transmembrane tyrosine kinase
receptors (Bennett et al., 2003; Barrientos et al., 2008). In the fibrotic disorder systemic
sclerosis (SSc), expression of PDGF-BB receptors is increased within and around dermal
vasculature (Klareskog et al., 1990). Bronchoalveolar lavage fluid from SSc patients
contains significantly elevated levels of PDGF-AA and -BB (Ludwicka et al., 1995).
Fibroblasts isolated from SSc skin biopsies express elevated PDGF-B and PDGF
receptor, compared to normal patients (Zheng et al., 1998). The c-Abl inhibitors imatinib
(Distler et al., 2007), dasatinib and nilotinib (Akhmetshina et al., 2008), act downstream
on non-receptor tyrosine kinases of both TGFβ and PDGF to block the production of
ECM proteins (Daniels et al., 2004). Bleomycin-induced dermal thickening and
myofibroblast accumulation is prevented by oral administration of these inhibitors in a
mouse model (Distler et al., 2007; Akhmetshina et al., 2008), suggesting that PDGF may
be an excellent target for the treatment of fibrosis (Beyer et al., 2010; Leask, 2010), but
also highlighting PDGF as an obvious therapeutic agent for treating chronic skin wounds.
As a chemoattractant for fibroblasts (Seppa et al., 1982), PDGF is important for the
progression of wound healing beyond inflammation and into the proliferation phase (Gao
et al., 2005). In animal models, delivery of PDGF to skin wounds increases fibroblast
infiltration, TGFβ expression, collagen deposition and granulation tissue formation
(Pierce et al., 1988; Pierce et al., 1989; Mustoe et al., 1990); resulting in accelerated
wound healing. Moreover, these benefits are also achieved in models of chronic skin
wounds (Mustoe et al., 1989; Mustoe et al., 1991). It has since been shown that PDGFBB is absent in chronic skin wounds, but present in actively healing pressure ulcers
(Pierce et al., 1995).
PDGF is currently the only growth factor approved for use by the FDA in the treatment
of diabetic foot ulcers and is marketed under the name Regranex®. Application of
rhPDGF-BB is preceded by debridement, or wound bed preparation, which is the attempt
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to remove the infected and necrotic components of an ulcer and establish a pseudo-acute
wound environment (Kirshen et al., 2006). Delivery of rhPDGF-BB to debrided wounds
improved closure of non-diabetic chronic pressure ulcers (Robson et al., 1992) and deep
pressure ulcers (Mustoe et al., 1994). In neurotrophic diabetic ulcers, treatment resulted
in 48% of wounds closing compared to 25% of wounds closed in the placebo group
(Steed, 1995) (Table 1.1). In a multi-center study, administration of 100 µg/g
becaplermin (rhPDGF-BB) to diabetic ulcers resulted in closure of 50% vs. 35%
(treatment vs. placebo) of wounds (Wieman et al., 1998). The smaller effect size reported
by Wieman in comparison with Steed possibly reflects inherent variability in the larger,
multi-center study, thus more closely representing a realistic effect size with wide spread
use. The addition of rhPDGF-BB to diabetic wounds has therefore produced statistically
significant, although modest, increases in wound healing over placebo. At best, 50% of
wounds treated with rhPDGF-BB closed, the majority of which can be attributed to
standard wound care (placebo) alone. Perhaps a limitation of PDGF based treatments is
that the presence of PDGF results in recruitment of inflammatory cells such as
macrophages and neutrophils (Deuel et al., 1982). Whereas macrophages are one of the
major sources of TGFβ (Roberts and Sporn, 1993) and are required for wound healing
(Leibovich and Ross, 1975), neutrophils are not required for wound healing in the
absence of non-specific infection (Simpson and Ross, 1972). Neutrophils are a source of
inflammatory cytokines (IL-1, -6 and TNFα) (Barrientos et al., 2008), reactive oxygen
species and damaging proteolytic enzymes (Diegelmann and Evans, 2004). Without
additional signals, which are absent in chronic skin wounds, it is possible that the proinflammatory role of PDGF may prevail. Thus complex interaction of the multitude of
growth factors and matrix elements present in acute wounding may not be suitably
recapitulated with rhPDGF-BB alone.

1.2.2

Platelet releasate

Platelet rich blood plasma contains multiple growth factors (Schultz and Grant, 1991) and
the components of a fibrin matrix (Mosesson, 2005). Administration of autologous
plasma to chronic skin wounds more closely mimics the complexity of the initial stages
of natural wound healing, including structural matrix components. Platelet rich plasma
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Table 1.1: Summary of reviewed therapeutic targets for chronic skin wounds
Factor

Role in acute skin wounds

Fibrosis
Increased

Chronic
skin
wounds
Decreased

Treatment options and
outcomes (treatment vs.
control)*
Becaplermin:
Steed et al 1995: 48% vs. 25%
incidence of closure
Wieman et al 1998: 50% vs.
35% incidence of closure

PDGF-BB

Migration and activation of
macrophages
Migration, proliferation and
activation of fibroblasts
Granulation tissue formation

Platelet
Releasate

Numerous due to inclusion of
various growth factors and
components of the fibrin
matrix

N/A

N/A

Autologel™:
Driver et al 2006: 81% vs. 42%
incidence of closure (in a subset
of patients)
Margolis et al 2001: 50% vs.
41% incidence of closure

TGFβ

Decreases protease activity
Migration, proliferation and
activation of fibroblasts
Granulation tissue formation

Increased

Decreased

Bovine TGFβ2:
Robson et al 1995: open-label
study increased closure rate,
closed-label study no efficacy

CCN2

Not clear, may contribute to
angiogenesis, cell recruitment
and matrix accumulation

Increased

Unknown

No treatments currently target
CCN2

Periostin

Unknown, but contributes to
collagen fibrillogenesis, matrix
accumulation, cell migration,
proliferation

Increased

Unknown

No treatments currently target
periostin

*Outcomes are listed as percent incidence of closure in the treatment group vs. percent incidence of closure
in the control group.	
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(PRP) has been used for the treatment of chronic skin wounds for over 20 years.
Autologel™, a PRP product, is prepared from a small sample of the patient’s blood
plasma mixed with a gel base, which is immediately applied to the wound. Despite its
long history of use, very few randomized controlled clinic studies on the efficacy of PRP
have been documented. Driver and colleagues carried out the first FDA approved
prospective, randomized, blinded, placebo-controlled clinical trial of PRP (Autologel™)
for diabetic foot ulcers (Driver et al., 2006). Although this study showed significance
(81% vs. 42% of wounds closed, treatment vs. placebo) (Table 1.1), many of its
participants were excluded from analysis for a variety of reasons. As the vast majority of
persons with chronic skin wounds are likely to fall outside of the numerous exclusion
criteria employed in this study, the applicability of this data would appear to be very
limited. Margolis et al, in a retrospective, randomized, controlled study of nearly 27,000
patients (of which 21% were treated with platelet releasate), reported the overall
proportion of chronic skin wounds healed at 50% vs. 41% (Margolis et al., 2001). This is
likely a much more realistic outcome since it reflects the effectiveness of the treatment
across a very large patient demographic, not the efficacy within a very idealized
treatment group.
Use of platelet releasate for the treatment of chronic skin wounds offers benefits over
placebo, however, similar to rhPDGF-BB, the increased incidence of wound healing is
modest. The limited success of platelet releasate may be due to pro-inflammatory
influences, which may undermine the pro-fibrotic effects of growth factors contained
within. PDGF is a chemoattractant for fibroblasts (Seppa et al., 1982; Lin et al., 2006),
however, it does not significantly increase expression of collagen type-1, a key
component of granulation tissue and scars (Tan et al., 1995; Jinnin et al., 2005). Instead,
PDGF increases expression of matrix metalloproteinase (MMP)-1, which contributes to
collagen degradation (Tan et al., 1995). Interestingly, whereas the presence of PDGF-BB
results in increased MMP-1 expression in human dermal fibroblasts, TGFβ1 in the matrix
results in decreased MMP-1 expression and significantly increased collagen synthesis,
contributing to matrix accumulation (Ignotz and Massague, 1986; Edwards et al., 1987;
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Tan et al., 1995). Thus TGFβ is a logical alternative to PDGF as a pro-fibrotic therapeutic
agent.

1.2.3

Transforming growth factor β

Transforming Growth Factor β expression during acute wound healing contributes to
progression of granulation tissue formation and matrix deposition. Its presence in the
matrix results in increased collagen production and elevated levels of TGFβ are
associated with fibrosis (Barrientos et al., 2008). Platelets and macrophages are the major
sources of TGFβ during the inflammatory phase (Clark, 1996). Fibroblasts are the key
TGFβ target cells during the proliferation phase of wound healing. Cellular binding of
PDGF and TGFβ promotes myofibroblast differentiation, however, PDGF binding does
not stimulate α-SMA expression (Tomasek et al., 2002). Cellular binding to TGFβ
significantly increases α-SMA expression and is required for differentiation of fibroblasts
into myofibroblasts, the major cell type that produces collagen and remodels the matrix
(Desmouliere et al., 1993; Tomasek et al., 2002; Desmouliere et al., 2005). Increased
signaling in response to TGFβ results in decreased expression of proteases such as
MMPs, and increased expression of tissue inhibitors of MMPs (TIMPs) in fibroblasts
(Edwards et al., 1987), thereby further contributing to matrix accumulation. TGFβ
signaling has been extensively reviewed elsewhere (Leask and Abraham, 2004; Varga
and Abraham, 2007). Briefly, there are three isoforms of TGFβ: TGFβ1, TGFβ2 and
TGFβ3. The actions of these isoforms are largely overlapping with the possible exception
of TGFβ3, which has been shown to have anti-fibrotic influences (Shah et al., 1995).
Activated TGFβ binds to heteromers of the TGFβ type-I and type-II receptors. Type-I
receptors (ALK5) phosphorylate Smad2 and Smad3 which go on to bind Smad4 and
translocate to the nucleus. Once in the nucleus, the Smad complex binds to Smad binding
elements in target genes (Figure 1.2) (Massague and Wotton, 2000). TGFβ has also been
known to signal through focal adhesion kinase (FAK), extracellular signal-regulated
kinases (ERK), c-Jun N terminal kinases (JNK) and p38 (Leask, 2008). Target genes of
TGFβ signaling include α-SMA, MMPs, TIMPs, periostin, connective tissue growth
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Figure 1.2: Canonical pro-fibrotic TGFβ signaling is initiated by the binding of active
TGFβ to TGFβ receptors. Type-I receptors phosphorylate receptor-Smads 2 and 3, which
associate with Smad4 and translocate to the nucleus. In the nucleus the Smad complex
interacts with Smad binding elements, promoting gene expression. Among the many
genes influenced by TGFβ signaling are collagens I and III, α-SMA, fibronectin, TIMPs
and periostin. Additionally, increased Smad7 expression creates a negative feedback
loop, limiting pathway activation. The pro-fibrotic roles of periostin are summarized
here. Via interactions with the ECM and BMP-1, periostin facilitates collagen
crosslinking through activation of lysyl oxidase. Periostin’s influences on cell behaviours
include altered proliferation, migration and adhesion. Recent evidence suggests that
periostin plays a role in liberation of TGFβ from the latency-associated proteins (LAP) in
an MMP-2/9 dependent manner.
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Figure 1.2: Canonical pro-fibrotic TGFβ signaling
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factor (CCN2) and collagen type-I (Kocher and Madri, 1989; Igarashi et al., 1993;
Takeshita et al., 1993; Holmes et al., 2001; Verrecchia et al., 2001).
TGFβ secretion and activation is central to development of fibrosis, where its cellular
binding results in excessive collagen production and prolonged myofibroblast
differentiation (Wei et al., 2010), leading to matrix accumulation and contraction. The
involvement of TGFβ in fibrosis has received a lot of attention and is the topic of several
reviews (Leask and Abraham, 2004; Pannu and Trojanowska, 2004; Varga and Pasche,
2009). Accumulating evidence implicates inappropriately elevated TGFβ signaling in the
progression of SSc. Examples include: increased TGFβ receptor expression (Kawakami
et al., 1998; Kubo et al., 2002; Pannu et al., 2004), increased Smad3 mRNA, protein
levels and phosphorylation levels (Mori et al., 2003). Additionally, Smad3/4 nuclear
localization is increased in SSc fibroblasts, both in the absence of TGFβ stimulation and
in the presence of TGFβ blocking antibodies (Mori et al., 2003). The targeting of TGFβ
directly in fibrosis has been successful in animal models. Injection of TGFβ neutralizing
antibodies to the edges of dermal wounds in rats, results in reduced scar formation, where
as addition of TGFβ increases scarring (Shah et al., 1992). Topical application of the
P144 peptide, which interferes with TGFβ/receptor association, reduces bleomycin
induced dermal thickening, Smad2/3 phosphorylation and α-SMA positive myofibroblast
numbers (Santiago et al., 2005). Clinical strategies that target TGFβ in fibrosis are
numerous (Varga and Pasche, 2009), but have so far had limited success (Denton et al.,
2007).
TGFβ’s pro-fibrotic role in acute skin wounds and in fibrosis makes it a realistic target
for enhancing chronic skin wound healing. Indeed, TGFβ1 expression is reduced in
diabetic and venous foot ulcers, compared to uninjured skin (Jude et al., 2002). In a rabbit
ischemic ulcer model, topical application of rhTGFβ1 increased wound healing
significantly (Beck et al., 1990; Zhao et al., 1994). These studies used young ischemic
rabbits for their experiments. The combined effect of age and ischemia was addressed by
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Wu et al. They found that 60-month-old ischemic rabbits did not response to application
of rhTGFβ (Wu et al., 1999). From this observation they concluded that TGFβ signaling
must be defective in the aged ischemic model and topical application of TGFβ may not
benefit healing of human chronic skin wounds. However, due to the cartilage within the
rabbit ear, the model chosen in this series of experiments does not allow for a significant
contribution of contraction in healing (Mustoe et al., 1991). Perhaps this feature of the
model masks the effects of TGFβ with respect to myofibroblast differentiation and
activity. Nevertheless, the limited benefit of TGFβ treatments in animal models has been
mirrored by the studies of Robson and colleagues, who investigated the application of
TGFβ2 on human chronic venous ulcer healing. The study incorporated an open-label
trial in which patients received either 0.5 µg/cm2 bovine TGFβ2 (bTGFβ2) in a
lyophilized collagen matrix or placebo (matrix only). Bovine TGFβ2 treatment resulted
in a significant increase in wound healing after a 6-week regime (Robson et al., 1995). In
the parallel closed-label trial, however, 2.5 µg/cm2 bTGFβ2 treatment offered no benefit
over the placebo (Table 1.1). The authors suggest that increased variation in the control
groups undermined the effect of treatment in the closed-label study (Robson et al., 1995).
With a small number of patients (n = 12/group) it is possible that sampling error played a
significant role. We must be cautious, however, of how we interpret open-label trial data
since the placebo effect has been shown in earlier examples to dominate the effectiveness
of treatments. At a minimum, this study stresses the requirement for large-scale
randomized, blinded, multi-center, placebo-controlled clinical trials.
Recent evidence suggests that the very limited efficacy of TGFβ in chronic skin wound
treatment may be due to dysregulation of the TGFβ signaling cascades within the wounds
and in wound fibroblasts (Hasan et al., 1997; Cowin et al., 2001; Jude et al., 2002; Pastar
et al., 2010). Together these studies establish a trend towards reduced TGFβ receptor
expression, although the data is somewhat conflicting when looking at the expression of
specific receptors. Convincingly, TGFβ responsive genes are significantly reduced in
venous ulcers (Pastar et al., 2010). A growing body of evidence now clearly identifies
additional, or accessory, signaling pathways activated by TGFβ and necessary for
appropriate context-specific TGFβ signaling. As will be discussed in the coming sections,
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these non-canonical TGFβ signaling pathways are of particular importance to wound
healing and fibrosis. Moreover, context-specific modulation of these pathways is
increasingly becoming a role of matricellular proteins.

1.3
Old players, but new rules in chronic skin wound
healing
1.3.1

Non-canonical TGFβ signaling

In addition to Smad signaling, TGFβ is known to influence cellular functions through
Smad independent, non-canonical pathways, which have been implicated in
myofibroblast differentiation, matrix contraction and fibrosis. Serini and colleagues
showed that adhesion to the ED-A splice variant of fibronectin (ED-A FN) is required for
myofibroblast differentiation of human subcutaneous fibroblasts (Serini et al., 1998).
Although binding to ED-A FN is not sufficient to cause differentiation, blocking specific
ED-A FN binding disrupts TGFβ-induced α-SMA expression (Serini et al., 1998);
demonstrating a role for adhesive signaling in the cell’s response to TGFβ. Stimulation of
adherent human lung fibroblasts with TGFβ results in increased FAK phosphorylation
and α-SMA expression (Thannickal et al., 2003). TGFβ-induced α-SMA and collagen
type-1 expression has been shown to require FAK and JNK activation in mouse
embryonic fibroblasts (Liu et al., 2007b). When human fibroblasts are maintained in
suspension or treated with the FAK/Src inhibitor, PP2, FAK phosphorylation is lost and
TGFβ-induced α-SMA expression is abolished (Thannickal et al., 2003). Interestingly,
phosphorylation of Smad2 following treatment with TGFβ is maintained, even when cells
are maintained in suspension (Thannickal et al., 2003); suggesting non-canonical
signaling critically regulates myofibroblast differentiation: one of the core features of
fibrosis. Fibroblasts isolated from fibrotic lesions in patients with SSc show an increased
ability to contract a collagen matrix. This increased contractility can be reduced by
treatment with inhibitors of TGFβ type-1 receptor activation, ERK activation and
proteoglycan synthesis (Chen et al., 2005). Furthermore, genetic deletion of the heparin
sulphate

proteoglycan,

syndecan

4,

results

in

loss

of

TGFβ-induced

ERK
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phosphorylation, α-SMA incorporation into stress fibers, and contractility (Chen et al.,
2005).
Non-canonical TGFβ signaling has been suggested to modulate, or fine tune, the response
to TGFβ in a gene and context specific manner (Leask and Abraham, 2004). As a result,
these accessory pathways have gained the interest of fibrosis researchers since they offer
potential targets for the treatment of fibrosis without disrupting the pleiotropic
TGFβ/Smad pathway, which may be problematic for basal tissue functioning (Leask,
2008). Modulation of TGFβ’s impact on healing via non-canonical signaling is a function
that is becoming more and more prominent based on the identification of a group of
proteins known as matricellular proteins. Moreover, the combination of TGFβ and
matricellular proteins may represent a promising direction for development of new
therapeutics for chronic skin wounds.

1.3.2

Matricellular proteins in fibrosis and acute wound healing

Matricellular proteins are non-structural ECM components which bind cell surface
receptors to mediate interactions between the cell and the ECM, modulating essential
events such as migration, proliferation and adhesion during wound healing (Bornstein,
1995; Midwood et al., 2004; Hamilton, 2008). Although genetic deletion of matricellular
proteins typically results in very mild phenotypes (Hamilton, 2008), wound healing can
be severely compromised (Midwood et al., 2004; Hamilton, 2008). Matricellular proteins
have diverse roles that span all phases of wound healing. For example, efficient reepithelialization is facilitated by tenascin-C, where keratinocyte migration is decreased in
tenascin-C knockout mice (Matsuda et al., 1999). Thrombospondin-1 has been shown to
activate latent TGFβ (Schultz-Cherry and Murphy-Ullrich, 1993). Macrophage
infiltration is increased in the presence of the matricellular protein osteopontin (Denhardt
et al., 2001).
The role of matricellular proteins in myofibroblast behaviour has received considerable
attention. Osteopontin serves as a ligand for αvβ3 integrins where binding leads to
activation of FAK and numerous downstream pathways (Sodek et al., 2000).
Furthermore, osteopontin has been postulated to be required for TGFβ-induced
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myofibroblast differentiation, where deletion of osteopontin attenuates TGFβ-dependent
increases in α-SMA and ED-A FN expression (Lenga et al., 2008). CCN2 (further
discussed below) promotes myofibroblast differentiation in the presence of TGFβ (Leask,
2008). Although CCN2 is considered to be a cofactor in fibrosis and not a fibrotic agent
itself (Leask, 2010), it serves as a marker for severity of fibrosis in SSc (Takehara, 2003).
CCN2 is required for maximal induction of α-SMA and collagen type-1 by TGFβ, where
TGFβ-induced FAK and Akt activation is reduced in CCN2 null fibroblasts (Shi-wen et
al., 2006). Furthermore, cellular binding to CCN2 results in activation of ERK through a
syndecan-4-dependent mechanism (Kennedy et al., 2007). Syndecan-4, which was
previously discussed as being required for many facets of TGFβ-induced myofibroblast
behaviour, is considered by some to be a matricellular protein (Woods, 2001). In
addition, human dermal fibroblasts are unable to contract a collagen matrix in the
presence of neutralizing antibodies against the matricellular protein vitronectin (Sethi et
al., 2002). Vitronectin incorporation into the ECM is inhibited by exogenous galectin-1,
yet another matricellular protein (Moiseeva et al., 2003). Finally, CCN1 (CYR61) can
bind integrins, leading to activation of ERK and p38 to cause myofibroblast senescence,
thus serving as a natural brake on fibrotic tissue remodeling (Jun and Lau, 2010).
Matricellular proteins can therefore both facilitate and inhibit critical events of acute and
fibrotic healing. Despite mounting evidence for the importance of matricellular proteins
in wound contraction and re-epithelialization, no clinical trials are currently employing
these proteins for the treatment of chronic skin wounds. The various influences of
matricellular proteins provide several potential targets for fibrosis and treatment of
chronic skin wounds.

1.3.3

CCN2/Connective tissue growth factor

Connective tissue growth factor, otherwise known as CCN2, modulates TGFβ signaling,
myofibroblast differentiation and collagen induction. Perhaps best known for its
pervasive emergence in a multitude of fibrotic tissues and diseases, CCN2 represents a
potential target for treatment of fibrosis (ClinicalTrial.gov #NCT01262001). Based on
CCN2’s role in fibrosis and evidence from several models of tissue repair, there is
considerable support for CCN2 as a therapeutic for resolution of chronic skin wounds.
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CCN2 was originally identified as a 38-kDa cysteine-rich mitogen and chemoattractant
secreted from endothelial cells (Bradham et al., 1991). Structurally, CCN2 consists of a
typical signal sequence and four conserved domains with sequence homology to 1)
insulin-like growth factor-binding proteins, 2) the von Willebrand factor C domain, 3)
thrombospondin type-1 repeat, and 4) a carboxy-terminal cysteine-knot (Figure 1.3)
(Bork, 1993). The four domains each participate in complex interactions with other
matrix elements and with cell surface molecules. These interactions, summarized in
numerous review articles (Chen and Lau, 2009; Oliver et al., 2010; Arnott et al., 2011;
Jun and Lau, 2011; Tran et al., 2013), are the basis of the influence CCN2 has on cellular
functions such as adhesion, migration, proliferation, survival, apoptosis and angiogenesis.
Of particular importance is CCN2’s role in fibrosis.
CCN2 has been implicated in several fibrotic conditions affecting tissues including skin,
lungs, kidneys, heart, liver and retina (Table 1.2). CCN2 has emerged as a reliable
clinical marker for the degree of fibrosis (Dendooven et al., 2011). CCN2 is significantly
induced by the presence of TGFβ and the presence of CCN2 seems to be required for the
fibrotic effects of TGFβ. In rat kidney fibroblasts, CCN2 is required for TGFβ-induced
collagen expression (Duncan et al., 1999). TGFβ-induced anchorage-independent growth
is attenuated in the presence of an anti-CCN2 antibody or following expression of an
antisense CCN2 gene, whereas CCN2 alone cannot induce anchorage-independent
growth (Kothapalli et al., 1997). Similarly, CCN2 is required for TGFβ-induced
myofibroblast differentiation and subsequent gel contraction (Garrett et al., 2004). Yet
CCN2 alone is not sufficient to induce myofibroblast differentiation and gel contraction.
CCN2 has thus been described as a cofactor in fibrosis, in that it is indispensible for
fibrotic responses yet it alone cannot induce fibrosis. Additional support for the cofactor
account of CCN2 comes from mouse models where injection of TGFβ into the
subcutaneous tissue produced only transient skin fibrosis, whereas injections of TGFβ
and CCN2 resulted in sustained skin fibrosis (Mori et al., 1999). Podocyte (Yokoi et al.,
2008) and hepatocyte (Tong et al., 2009) specific over-expression of CCN2 in mice failed
to induce spontaneous fibrosis and only after further insult do these mice exhibit
enhanced fibrosis. There is, however, a growing body of evidence challenging the
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Figure 1.3: Domain structures of human periostin and CCN2. (A) Human full length
periostin (isoform 1) consists of a typical signal peptide (SP) sequence, an EMI domain
responsible for binding to fibronectin, four tandem fasciclin-like domains that are
responsible for integrin binding and a C-terminal region (CTR) where multiple splice
variants originate. Tryptophan 65 within the EMI domain is required for fibronectin
binding. The CTR has been shown to inhibit binding of periostin to several binding
partners. (B) Human CCN2, shown on same scale as periostin first and then expanded for
detail below, consists of a signal peptide (SP) sequence followed by four conserved
domains with sequence homology to 1) insulin-like growth factor-binding proteins
(IGFBP), 2) the von Willebrand factor C domain (VWC), 3) thrombospondin type-1
repeat (TSP_1) and 4) a carboxy-terminal cysteine-knot. Each domain comes with a
compliment of binding sites for both cell surface receptors and matrix components. The
diversity of these interactions may explain CCN2’s diverse influences. The hinge region
is vulnerable to proteolytic cleavage. Numbers represent amino acid residues flanking
each domain.
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Figure 1.3: Domain structures of human periostin and CCN2

24

Table 1.2: Fibrotic conditions associated with periostin and CCN2
Periostin

CCN2, Connective Tissue Growth Factor

Condition

References

Condition

References

Keloid scar

(Supp et al., 2012)

Keloid scar

(Smith et al., 2008)

Hypertrophic scar

Systemic sclerosis

Dupuytren’s disease

Pulmonary fibrosis

(Zhou et al., 2010)

(Khoo et al., 2006)

(Wang et al., 2007)

(Igarashi et al., 1996)

(Naitoh et al., 2005)

Hypertrophic scar

(Colwell et al., 2005)

(Zhou et al., 2010)

Systemic sclerosis

(Dziadzio et al., 2005)

(Wang et al., 2007)

(Sato et al., 2000)

(Naitoh et al., 2005)

(Shi-wen et al., 2000)

(Yamaguchi et al., 2013)

(Igarashi et al., 1996)

(Yang et al., 2012)

(Igarashi et al., 1995)

(Shih et al., 2009)

Dupuytren’s disease

(Igarashi et al., 1996)

(Vi et al., 2009)

Pulmonary fibrosis

(Pan et al., 2001)

(Naik et al., 2012)
(Uchida et al., 2012)

(Sato et al., 2000)
Kidney fibrosis

(Ito et al., 2010)

Sub-epithelial fibrosis

(Takayama et al., 2006)

(Tam et al., 2009)

Kidney fibrosis

(Guerrot et al., 2012)

(Cheng et al., 2006)

(Sen et al., 2011)

(Nguyen et al., 2006)

Bone marrow fibrosis

(Oku et al., 2008)

(Andersen et al., 2005)

Fibrous dysplasia

(Kashima et al., 2009)

(Roestenberg et al., 2004)

Peritoneal fibrosis

(Braun et al., 2013)

(Gilbert et al., 2003)

Muscular dystrophy

(Lorts et al., 2012)

Cardiac fibrosis

(Koitabashi et al., 2008)

Cardiac fibrosis

(Stansfield et al., 2009)

Retinopathy

(Kuiper et al., 2008)

(Litvin et al., 2006)
Retinopathy

(Yoshida et al., 2011)

(Hinton et al., 2002)
Liver fibrosis

(Takada et al., 2010)

(Morikawa et al., 2007)
(Gressner et al., 2006)
(Tamatani et al., 1998)

Pancreatic fibrosis

(di Mola et al., 1999)
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cofactor explanation of CCN2’s influence. Fibroblast-specific over-expression of CCN2
leads to kidney fibrosis (basement membrane thickening and excess matrix accumulation
around blood vessels), lung fibrosis and skin fibrosis, including an increased population
of myofibroblasts in the dermis (Sonnylal et al., 2010). Fibroblast and smooth musclespecific deletion of CCN2 protected mice from bleomycin induced skin fibrosis,
including a reduction in the number of myofibroblasts present in the skin (Liu et al.,
2011). However, fibroblasts isolated from these mice responded appropriately to TGFβ in
terms of collagen and α-SMA expression. The conclusion was that CCN2 is required for
bleomycin induced skin fibrosis but was not required for TGFβ response. Instead, the
authors proposed that CCN2 was responsible for myofibroblast recruitment. Therefore, it
is more accurate to say that CCN2 influences cellular activities in TGFβ-dependent and
TGFβ-independent ways to promote fibrosis.
The role of CCN2 in acute wound healing has been difficult to assess since the Ccn2-/genotype is lethal in mice. In 1993, Igarashi and colleagues demonstrated that CCN2 is
up-regulated six and nine days following dermal wounding (Igarashi et al., 1993) and
CCN2 up-regulation has since been confirmed in human skin wounds (Rittie et al., 2011).
However, antisense inhibition of CCN2 mRNA in rabbit ear wounds had no detrimental
effect on closure rate but did reduce hypertrophic scarring, suggesting CCN2 does not
play a critical role in skin healing (Sisco et al., 2008). Despite this, there is mounting
evidence that CCN2 is an important mediator of vascularization during tissue remodeling.
Antibody blockade of CCN2 resulted in reduced granulation tissue formation and
vascularity in mesenchymal stem cell-loaded sponges placed in excisional mouse wounds
(Alfaro et al., 2013). Growth plates of Ccn2-/- mice exhibit defective vascularization,
linked to reduced Vegfa expression in hypertrophic zones (Ivkovic et al., 2003). The
presence of CCN2 has since been shown to up-regulate Vegfa at the transcriptional level
by increasing HIF-1α activity in a chondrocytic cell line (Nishida et al., 2009). HallGlenn and colleagues have shown that CCN2 is required for stable association and
retention of perivascular cells (pericytes) by endothelial cells (Hall-Glenn et al., 2012).
By inducing PDGF-B expression in endothelial cells, CCN2 indirectly promotes pericyte
recruitment and basement membrane formation during angiogenesis. Although the role of
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CCN2 in skin healing is not clear, its influence on angiogenesis and matrix accumulation
make it an interesting candidate for use in the treatment of chronic skin wounds.
To date, several groups have studied CCN2 as a therapeutic for aiding in tissue repair.
Administration of rhCCN2 to a non-human primate burn wound model resulted in an
increased wound closure rate, increased fibroblast and collagen content within the wound
area and accelerated re-epithelialization (Liu et al., 2007a). CCN2 loaded fibrin glue has
been shown to enhance meniscal repair by increasing Col1a1, Col2a1 and Vegfa mRNA
in the avascular zone of rabbit menisci following tearing defects (He et al., 2011).
Furthermore, it was reported that 10 weeks after treatment, the density of capillaries was
significantly higher in the defects of the CCN2 group. A patent has been filed on a
polypeptide referred to as CTGF-2 (US Patent #20060052328 A1), which shares 49%
identity and 67% similarity to mouse CCN2 (Pradhan et al., 2007), based on the
observations of increased endothelial cell migration and pro-angiogenic outcomes in
rabbit hind limb ischemia experiments. The authors of the patent suggest potential for
CTGF-2 in enhancing wound healing. Therefore, there is clear evidence that CCN2 could
be useful in the treatment of chronic skin wounds. In fact, recent evidence from a nonhuman primate model of diabetic wound healing showed that CCN2 is reduced in
diabetic healing compared to that in control animals, concomitantly with delayed wound
closure and reduced granulation tissue formation (Thomson et al., 2010). It is unknown,
however, if the same is true for human chronic skin wounds. It is also unknown whether
the reparative effects of recombinant CCN2 can be applied to human chronic skin
wounds.

1.3.4

Periostin

The matricellular protein periostin is a molecule that has not yet been investigated for the
treatment of fibrosis and chronic skin wounds. The presence of periostin can modulate
many key aspects of acute healing and fibrosis. Collagen synthesis, fibril assembly and
myofibroblast behaviour have all been increasingly linked to periostin. Furthermore, the
expression pattern of periostin following tissue injury in various systems, including heart,
bone and vasculature, suggests that it may play a common role in various models of acute
wound healing (Hamilton, 2008).
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Periostin is a secreted 90-kDa disulfide-linked, TGFβ-inducible protein, originally
designated osteoblast specific factor 2 (Takeshita et al., 1993; Horiuchi et al., 1999).
Structurally, periostin consists of a typical signal sequence, an EMI domain responsible
for binding to fibronectin, four tandem fasciclin-like domains that are responsible for
integrin binding (Kim et al., 2002) and a C-terminal region where multiple splice variants
originate (Litvin et al., 2004) (Figure 1.3). Additionally, periostin has been shown to bind
collagen, tenascin-C, BMP-1 and itself (Kii et al., 2006; Takayama et al., 2006; Norris et
al., 2007; Kii et al., 2009; Maruhashi et al., 2010). The ability of periostin to interact with
various integrin pairs (Gillan et al., 2002; Bao et al., 2004; Shao et al., 2004; Baril et al.,
2007; Butcher et al., 2007) allows it to influence such biological effects as cell
proliferation, cell migration, cell adhesion and epithelial to mesenchymal transformation
(Horiuchi et al., 1999; Katsuragi et al., 2004; Lindner et al., 2005; Yan and Shao, 2006;
Vi et al., 2009; Li et al., 2010).
Nakazawa and colleagues showed an increase in periostin mRNA following induced
tibial fractures in mice. Periostin expression was significantly increased by day 3 and
peaked at day 7 in preosteoblasts of the periosteum and undifferentiated mesenchymal
cells within the soft callus (Nakazawa et al., 2004). Periostin expression was significantly
increased following eight days of balloon injury to rat carotid arteries, eventually
decreasing by 4 weeks post injury (Lindner et al., 2005). Li and colleagues confirmed
that periostin peaks at 7 days post injury in this model (Li et al., 2006). To determine if
periostin induction is a feature common in other connective tissue injuries, Lindner and
colleagues created full-thickness incisional wounds in the skin of rats. Indeed, periostin
expression was detected in the fibroblasts, but not keratinocytes, of the wound site
(Lindner et al., 2005). The expression pattern of periostin during dermal wounding has
since been further defined (Jackson-Boeters et al., 2009; Zhou et al., 2010). After
incisional wounding, periostin is expressed in the dermis and basement membrane within
the dermal-epidermal junction (DEJ) (Zhou et al., 2010). In full-thickness excisional
wounds, in which the dermis and epidermis are completely removed, periostin expression
is found throughout the newly formed granulation tissue (Jackson-Boeters et al., 2009).
With expression beginning at day 3, peaking by day 7 and eventually returning to basal
levels by 4 weeks (Jackson-Boeters et al., 2009), the temporal expression pattern of
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periostin in skin mimics that seen in vascular balloon injury and bone fracture. These
observations suggest that a common role for periostin may exist in all connective tissue
repairs. Interestingly, periostin expression in skin healing coincides with the expression
of α-SMA expression in the granulation tissue (Jackson-Boeters et al., 2009).
The functional role(s) of periostin are not fully understood. Several studies have
highlighted a role in collagen deposition and myofibroblast differentiation. In murine
models of myocardial infarction and ventricular hypertrophy (thickening of the
myocardium), increased periostin expression results in increased collagen deposition
(Katsuragi et al., 2004; Oka et al., 2007; Shimazaki et al., 2008; Stansfield et al., 2009).
Genetic ablation of periostin results in increased incidence of ventricular rupture
following myocardial infarction, which correlates with fewer α-SMA positive cells and
decreased collagen fibril formation (Shimazaki et al., 2008). Addition of recombinant
periostin to pancreatic stellate cells results in increased expression of key fibrotic proteins
such as α-SMA, collagen type-1, fibronectin, TGFβ1 and periostin itself (Erkan et al.,
2007). Collagen fibrils from the skin of periostin knockout mice are reduced in diameter
and display decreased crosslinking (Norris et al., 2007). As a result, periostin knockout
skin has a reduced tensile strength and an alteration of the visco-elastic properties (Norris
et al., 2007). Recent insights into the functional role of periostin in collagen crosslinking
implicate periostin as a scaffold protein, aiding in the incorporation of BMP-1 into the
ECM where it can activate lysyl oxidase (an enzyme involved in collagen fibril
crosslinking) (Maruhashi et al., 2010).
With respect to fibrosis, periostin has been strongly correlated with several conditions
(Table 1.2). Periostin is the single most up-regulated gene in keloid scars, assessed using
cDNA microarray analysis (Naitoh et al., 2005). Wang and colleagues reported increased
periostin expression in keloid and hypertrophic scars, relative to normal human skin,
where periostin expression was positively correlated with TGFβ1 expression (Wang et
al., 2007). Periostin is highly expressed in tissues affected by Dupuytren's disease, a
progressive disease that results in a scar-like, collagen-rich cord within the palmar fascia
and permanent contracture of the hand (Vi et al., 2009). Fibroblasts isolated from
diseased tissue have an increased ability to contract a collagen matrix, which is further
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enhanced by addition of recombinant periostin (Vi et al., 2009). Periostin-induced
contractility is accompanied by an increase in α-SMA protein. In addition to skin
fibrosis, periostin has been associated with bone marrow fibrosis, where it correlates with
the severity of fibrosis (Oku et al., 2008). Periostin has also been implicated with subepithelial fibrosis of bronchial asthma (Takayama et al., 2006), where recently it has been
shown to facilitate TGFβ signaling (Sidhu et al., 2010). Over-expression of periostin in
human bronchial epithelial cells results in increased periostin secretion, collagen
synthesis and TGFβ expression/protein/activity (Sidhu et al., 2010). Addition of
recombinant periostin to primary human bronchial epithelial cells increased collagen
expression in a TGFβ-dependent manner. Finally, in several models of fibrosis, disease
progression is attenuated in Postn-/- mice, compared to wild-type littermates (Naik et al.,
2012; Uchida et al., 2012; Yang et al., 2012).
The role of periostin in acute wound healing and in fibrotic diseases has received a lot of
attention in the past ten years (Table 1.2). However, research into its role in chronic skin
wounds is lacking and very few studies have looked at periostin expression in this
context. Of particular importance, expression of periostin following injury coincides with
fibrotic, not inflammatory, stages of healing (Jackson-Boeters et al., 2009). In fact,
chronically inflamed skin contains very little periostin, below that of normal skin (Zhou
et al., 2010).
Future work must make use of the influences of matricellular proteins, like periostin and
CCN2, on acute wound healing and apply them to the treatment of chronic skin wounds.
Matricellular proteins are expressed during development, but are typically absent in the
adult, except during tissue remodeling or repair (Bornstein, 1995). Their tight regulation
during wound healing and absence in adult tissues makes matricellular proteins an ideal
localized target for therapies (Midwood et al., 2004).

1.4

Future therapeutic design

Creating a favorable wound environment, via debridement, will certainly form the
foundation of any future treatment strategies. To date, healing of chronic skin wounds via
administration of growth factors has produced limited benefits. Future treatment
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strategies must integrate the wealth of knowledge available from studies of acute and
fibrotic healing, particularly the importance of cross talk between cells, structural matrix
components, growth factors and matricellular proteins. The importance of the matrix on
cell behaviour should not be underestimated in choosing alternative target molecules.
Historically, the introduction of physical matrices to chronic skin wounds has primarily
focused on maintaining a moist environment to encourage healing (Queen et al., 2004).
Examples of these modern dressings include hydrocolloid dressings, alginates and foam
dressings (Qin and Gilding, 1996; Chaby et al., 2007). Despite weak evidence of clinical
efficacy, these products have obtained widespread use (Chaby et al., 2007). One
limitation of these dressings is their lack of biological activity, although hybrids
containing biologically active components are now available (Donaghue et al., 1998;
Murakami et al., 2010). Introduction of exogenous ECM components, such as collagens,
fibronectin and fibrin, provide a scaffold on which cells can migrate into the wound area
(Greiling and Clark, 1997), while also greatly influencing the behaviour of cells through
binding of surface receptors and activation of signaling pathways (Schultz and Wysocki,
2009). One currently available ECM based product is de-cellularized porcine small
intestine submucosa (SIS), which is marketed under the name OASIS® Wound Matrix
(Mostow et al., 2005). In a randomized clinical trial, OASIS® Wound Matrix was shown
to be at least as effective as Regranex® (rhPDGF-BB) in healing diabetic foot ulcers
(Niezgoda et al., 2005). Interestingly, growth factors embedded within SIS can influence
cell behaviours such as proliferation and cell morphology (Voytik-Harbin et al., 1997). It
is proposed here that an ECM based bioactive scaffold can also provide a vehicle for
delivery of matricellular proteins, where the choice of matricellular proteins can be
tailored to the etiology of the target wound. Realization of such a treatment, however,
depends on a greater understanding of the role of matricellular proteins in the
pathogenesis of chronic skin wounds.
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1.5

Rationale, Hypothesis and Objectives

Development of effective treatments to close chronic skin wounds has been hampered by
a lack of thorough understanding of the dysfunctions present in these wounds.
Matricellular proteins have received little attention despite their ability to modulate all
aspects of wound healing. The overall hypothesis of this thesis is that the matricellular
proteins periostin and CCN2, two matricellular proteins associated with fibrotic healing,
can enhance the healing of chronic skin wounds.
The functional role of periostin is not fully understood, however, several lines of
evidence have established a positive correlation between periostin expression and the
extent of tissue repair. On the side of fibrosis, periostin has been implicated in bone
marrow fibrosis (Oku et al., 2008), sub-epithelial fibrosis of bronchial asthma (Takayama
et al., 2006), idiopathic pulmonary fibrosis (Naik et al., 2012; Uchida et al., 2012),
systemic sclerosis (Yang et al., 2012; Yamaguchi et al., 2013), renal fibrosis (Sen et al.,
2011) and fibrous dysplasia (Kashima et al., 2009). Moreover, POSTN is the single most
up-regulated gene in keloid scars (Naitoh et al., 2005). In the context of acute healing,
genetic ablation of periostin results in increased incidence of ventricular rupture
following myocardial infarction due to reduced α-SMA positive cells and impaired
collagen fibril formation (Shimazaki et al., 2008). Interestingly, periostin expression in
dermal healing coincides with the expression of α-SMA expression within the
granulation tissue (Jackson-Boeters et al., 2009). The causal relationship between
periostin expression and a myofibroblast phenotype in skin healing remains to be
established.
Therefore it is hypothesized that periostin is essential for normal dermal wound healing,
contributing to myofibroblast differentiation, matrix production and matrix compaction.
Furthermore, based on periostin’s theorized role in wound healing, we hypothesize that
delivery of rhPN to a model of impaired diabetic wound healing will enhance closure.
CCN2 represents an interesting adjunct or alternative to periostin in treating chronic skin
wounds.

CCN2 has been demonstrated to positively influence matrix production,
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myofibroblast differentiation and angiogenesis, positioning it as an excellent candidate
for enhancing wound healing. At least one model of diabetic wound healing has shown
that CCN2 is inappropriately reduced in this pathological state, and previous attempts to
deliver recombinant CCN2 to a variety of wound models have produced favorable
results. It is therefore hypothesized that delivery of rhCCN2 to a model of impaired
diabetic wound healing will enhance healing of said wounds.
The specific objectives of this project were:
1. To determine how genetic deletion of periostin alters dermal wound healing
kinetics and the underlying changes in regulation of dermal and epithelial
behaviours.
2. To determine mRNA and protein expression patterns of periostin and CCN2 in
human chronic skin wound tissue.
3. To quantify the phenotypic response of human chronic skin wound fibroblasts by
exogenous TGFβ and TNFα.
4. To assess the efficacy of local delivery of periostin and CCN2 containing
electrospun scaffolds as a therapeutic for enhancing wound healing, using a
diabetic murine model.

A version of this chapter has been published (Appendix A):
Elliott, C.G. and Hamilton, D.W. (2011) Deconstructing Fibrosis Research: Do Profibrotic Signals Point the Way for Chronic Dermal Wound Regeneration? J. Cell
Commun Signal. 5(4): 301-15
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Chapter 2

2

Periostin modulates myofibroblast differentiation during
full-thickness cutaneous wound healing

Abstract
The matricellular protein periostin is expressed in the skin. Although periostin has been
hypothesized to contribute to dermal homeostasis and healing, this hypothesis has not
been directly tested. To assess the contribution of periostin to dermal healing, 6 mm fullthickness excisional wounds were created in the skin of periostin knockout and wildtype/sex-matched control mice. In wild-type mice, periostin was potently induced 5-7
days post-wounding. In the absence of periostin, day 7 wounds showed a significant
reduction in myofibroblasts, as visualized by α-smooth muscle actin (α-SMA) expression
within the granulation tissue. Delivery of recombinant human periostin via electrospun
collagen scaffolds restored α-SMA expression. Isolated wild-type and knockout dermal
fibroblasts did not differ in in vitro assays of adhesion or migration; however, in 3D
culture, periostin knockout fibroblasts showed significantly reduced ability to contract a
collagen matrix, and adopted a dendritic phenotype. Recombinant periostin, in a fashion
which was sensitive to a neutralizing anti-β1-integrin and to the FAK/Src inhibitor PP2,
restored the defects in cell morphology and matrix contraction displayed by periostindeficient fibroblasts. We propose that periostin promotes wound contraction by
facilitating myofibroblast differentiation and contraction.

A version of this chapter has been published (Appendix B):
Elliott, C.G., Wang, J., Guo, X., Shi-wen, X., Eastwood, M., Guan, J., Leask, A.,
Conway, S.J., and Hamilton, D.W. (2012) Periostin modulates myofibroblast
differentiation during full-thickness cutaneous wound repair. J. Cell Sci. 125: 121-32
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2.1

Introduction

Periostin is a secreted 90 kDa, disulfide-linked protein, which has structural similarity
with the insect adhesion protein, fasciclin-1 (Takeshita et al., 1993). During development,
periostin is expressed by cardiac fibroblasts in the embryonic heart (Kruzynska-Frejtag et
al., 2001), where it facilitates organization of the extracellular matrix (ECM) (Snider et
al., 2009) and differentiation of mesenchymal cushion progenitor cells into contractile
myofibroblasts (Conway and Molkentin, 2008). Recent research has now associated
increases in periostin expression with various disease states, including myocardial
infarction (Iekushi et al., 2007; Oka et al., 2007; Shimazaki et al., 2008), and cancer
(Gillan et al., 2002; Baril et al., 2007; Erkan et al., 2007). In particular, periostin is
heavily implicated in fibrosis including in bone marrow (Oku et al., 2008), sub-epithelial
fibrosis of bronchial asthma (Takayama et al., 2006), fibrous dysplasia (Kashima et al.,
2009), and keloid and hypertrophic scarring of the skin (Naitoh et al., 2005; Wang et al.,
2007a). Additionally, induction of periostin expression has been described following
acute injury to numerous tissues (Goetsch et al., 2003; Nakazawa et al., 2004; Lindner et
al., 2005; Li et al., 2006), including skin (Lindner 2005, Jackson-Boeters 2009, Zhou
2010), where expression peaks at 7-8 days and returns to basal levels by 4 weeks. Our
previous reports on skin healing show that periostin expression is absent during
inflammation, but instead corresponds with the proliferative and remodeling phases of
healing (Jackson-Boeters et al., 2009; Zhou et al., 2010), suggesting a role for periostin
during these later phases.
Fibroblasts are central to the proliferative and remodeling phases of skin (Ross, 1968).
Dysregulation of fibroblast function in skin can result in inadequate healing (Shimazaki
et al., 2008; Blumbach et al., 2010) or excessive matrix production (fibrosis) (Babu et al.,
1992; Leask, 2010). Activated fibroblasts, or myofibroblasts, are fibroblasts which have
differentiated into a contractile phenotype, characterized by the expression of α-SMA
(Gabbiani et al., 1972). During wound healing they serve to expedite wound closure by
drawing the edges of the wound together through generation of contractile forces
(Gabbiani et al., 1971; Majno et al., 1971; Gabbiani et al., 1972), which are transmitted to
the ECM through integrin-containing adhesion complexes known as focal adhesions
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(Burridge and Chrzanowska-Wodnicka, 1996). Numerous studies have implicated
periostin with α-SMA expression (Shimazaki et al., 2008; Jackson-Boeters et al., 2009;
Vi et al., 2009), including in skin healing.
Induction of the myofibroblast phenotype depends on a combination of three major
factors (Tomasek et al., 2002): engagement of integrin cell surface receptors with the EDA splice variant of fibronectin (Serini et al., 1998), stimulation with transforming growth
factor β (TGFβ) (Desmouliere et al., 1993) and mechanical tension (Hinz et al., 2001;
Cevallos et al., 2006). However, recent work suggests that fine-tuning of myofibroblast
differentiation involves a complex interaction of many other factors (Shi-wen et al., 2004;
Blumbach et al., 2010; Liu et al., 2010), including matricellular proteins such as
connective tissue growth factor (Liu et al., 2011), osteopontin (Lenga et al., 2008) and
tenascin-C (Tamaoki et al., 2005). Matricellular proteins are a functionally related group
of secreted proteins that have important roles in all phases of skin healing (Bornstein,
1995; Midwood et al., 2004). Often these proteins influence cell behaviour through
adhesive signaling, typically through integrin binding and focal adhesion kinase (FAK)
activation (Sodek et al., 2000; Shi-wen et al., 2006; Jun and Lau, 2010). Periostin is a
matricellular protein which is known to modulate adhesive signaling through various
integrins and FAK (Gillan et al., 2002; Bao et al., 2004; Shao et al., 2004; Baril et al.,
2007; Butcher et al., 2007). Furthermore, periostin has been correlated with α-SMA
expression in skin healing (Jackson-Boeters et al., 2009). However, the use of genetic
deletion to determine the specific role of periostin in skin healing has not previously been
attempted.
We therefore hypothesized that periostin facilitates myofibroblast differentiation during
dermal wound healing and that the loss of periostin wound impede wound resolution. By
use of a periostin knockout (Postn-/-) mouse (Rios et al., 2005), we show that the loss of
periostin results in altered wound closure kinetics, corresponding to the time of peak
periostin expression. Histological analysis of wound tissue reveals that the granulation
tissue of Postn-/- wounds is deficient in α-SMA. Furthermore, dermal fibroblasts isolated
from Postn-/- mice are unable to contract a collagen matrix. This deficiency is corrected
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by addition of exogenous periostin, via a β1-integrin and Src/FAK dependent
mechanism.

2.2
2.2.1

Results
Loss of periostin results in altered wound closure kinetics

Periostin is up-regulated following acute injury to skin in wild-type mice (Lindner et al.,
2005; Jackson-Boeters et al., 2009; Zhou et al., 2010). To investigate the contribution of
periostin to the dermal wound healing process, full-thickness excisional wounds were
created in Postn-/- mice and their sex- and age-matched Postn+/+ littermates. At 5 and 7
days post wounding, Postn+/+ wound size had reduced to 30% and 17%, respectively, of
their initial wound area (Figure 2.1). In Postn-/- mice, however, wounds were
significantly larger than those in Postn+/+ mice (64% at day 5 and 41% at day 7, p <
0.001) (Figure 2.1). Histological analysis of sections from the centre of day 7 wounds
confirmed that Postn-/- wounds were significant larger than those of Postn+/+ littermates
(p < 0.05) (Table 2.1). Epithelial migration distance was not significantly different in day
7 wounds (p = 0.25) (Table 2.1). Wounds in both wild-type and knockout animals had
closed by day 11.
We have previously reported that periostin protein is evident in granulation tissue of
excisional wounds by day 3, peaking at day 7 (Jackson-Boeters et al., 2009), which we
have confirmed in this study in Postn+/+ mice (Figure 2.2A,B). Analysis of in vivo Postn
gene expression by in situ hybridization and real-time quantitative polymerase chain
reaction (RT-qPCR) confirmed that Postn mRNA is significantly and selectively
increased during cutaneous wound healing at day 7 (p < 0.01) (Figure 2.2A,C).
Inflammatory cell infiltration was similar between day 5 Postn+/+ and Postn-/- wounds
(Figure 2.3), suggesting that the influence of periostin is not here.
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Figure 2.1: Loss of periostin results in altered wound closure kinetics. Full-thickness
excisional punch wounds were created in the skin of Postn+/+ and Postn-/- mice using a 6
mm biopsy tool. (A) Wounds were photographed at 0, 3, 5, 7 and 11 days post-wounding.
Four pairs of mice (four wounds per mouse) were followed for the 11-day time course.
(B) Quantification of wound area was from photographs. Postn-/- wounds are delayed in
closure at days 5 and 7 (p < 0.01). Data is expressed as a fraction of the initial wound
area; error bars represent s.d. (* = p < 0.01; two-way ANOVA).
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Table 2.1: Re-epithelialization of day 7 wounds in Postn+/+ and Postn-/- mice
Measure

Genotype

p value

Postn+/+

Postn-/-

Wound size (mm)

2.036 ± 0.306

2.579 ± 0.319

0.041

Epithelial migration distance (mm)

0.723 ± 0.148

0.806 ± 0.134

0.254

Percent epithelialized (%)

82.2 ± 18.9

66.8 ± 12.6

0.358
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Figure 2.2: α-SMA expression is reduced in the granulation tissue of Postn-/- mice.
(A) Postn message detection in day 7 Postn+/+ wounds via in situ hybridization showing
periostin expression selectively in the wound. Arrowheads indicate the wound borders.
(B) Histological analysis of day 7 wounds from Postn+/+ and Postn-/- animals. Sections
were incubated with antibodies for periostin or α-SMA. Detection was with peroxidase
conjugated 2° antibodies and DAB. Day 7 Postn-/- wounds have reduced α-SMA staining
(n = 5). (C) Healthy skin or wound tissue biopsies were analyzed for Postn and (D) Acta2
mRNA via RT-qPCR. Target gene expression was normalized to 18S using the ΔΔCt
method. Postn expression is significantly increased at day 7 (p < 0.001, n = 5). Postn
mRNA was not detected in Postn-/- specimens. Increased Acta2 expression was observed
at day 7 in Postn+/+ wounds, but not in Postn-/- wounds (p < 0.001, n = 5). Data is
expressed relative to day 0 Postn+/+ expression; error bars represent s.e.m. (* = p < 0.001;
two-way ANOVA).
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Figure 2.2: α-SMA expression is reduced in the granulation tissue of Postn-/- mice
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Figure 2.3: Inflammatory cell infiltration is not altered in Postn-/- wounds.
Histological analysis of day 5 wounds from Postn+/+ and Postn-/- animals. Sections were
incubated with antibodies for CD68 (macrophage marker) or neutrophil elastase
(neutrophil marker). Detection was with peroxidase conjugated 2° antibodies and DAB.
Day 5 Postn+/+ and Postn-/- wounds do not differ with respect to inflammatory cell
infiltration (n = 5).
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Figure 2.3: Inflammatory cell infiltration is not altered in Postn-/- wounds
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2.2.2

α-Smooth muscle actin expression is reduced in the
granulation tissue of Postn-/- mice

Our previous work has shown that increased levels of periostin protein in the granulation
tissue of excisional punch wounds is paralleled by an increase in α-SMA protein
(Jackson-Boeters et al., 2009). It is not clear, however, whether periostin is required for
α-SMA expression. Therefore, we assessed the level of α-SMA in Postn+/+ and Postn-/wounds via immunohistochemistry (IHC). Immunoreactivity for α-SMA was evident at
the wound edge and within the granulation tissue of Postn+/+ wounds at day 5 (Figure
2.4). At day 7, increased levels of α-SMA were detected at the wound border, throughout
the granulation tissue and in blood vessel walls (Figure 2.2B). In day 7 Postn-/- wounds,
α-SMA immunoreactivity was significantly reduced when compared to sex-matched
littermate controls (Figure 2.2B). Reduced α-SMA (Acta2) expression in Postn-/- wounds
was confirmed by RT-qPCR, where excised day 7 Postn-/- wound tissue contained
significantly less Acta2 mRNA than day 7 Postn+/+ wounds (Figure 2.2D) (p < 0.01).
This deficit in α-SMA immunoreactivity was specific to the granulation tissue of Postn-/wounds (Figure 2.5A), with wound borders and vasculature positive for α-SMA in both
Postn+/+ and Postn-/- wounds. To determine if the reduction in α-SMA immunoreactivity
was due to impaired fibroblast recruitment into the granulation tissue, sections were
labeled for fibroblast-specific protein-1 (Figure 2.5B). Indeed, fibroblasts dominated the
granulation tissue of both Postn+/+ and Postn-/- day 7 wounds (Figure 2.5B). Additionally,
tissue sections were stained for nuclei with 4',6-diamidino-2-phenylindole (DAPI)
(Figure 2.5C). No significant differences in cell number were found between Postn+/+
and Postn-/- wounds at the wound borders or within the granulation tissue (Figure 2.5C)
(p = 0.28). To further rule out a defect in fibroblast recruitment we assessed fibroblast
migration in vitro using a scratch wound assay. Scratch wounds in monolayers of
Postn+/+ and Postn-/- were resolved by 20 hours. No difference in migratory ability was
observed between cell types (Figure 2.6) (p = 0.34).
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Figure 2.4: Postn-/- wounds contain reduced α-SMA protein. Histological analysis of
wounds from Postn+/+ and Postn-/- animals. Sections were incubated with a primary
antibody α-SMA. Detection was with peroxidase conjugated 2° antibodies and DAB.
Postn-/- wounds display reduced α-SMA immunoreactivity at all time-points, relative to
Postn+/+ littermates (n = 4).
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Figure 2.4: Postn-/- wounds contain reduced α-SMA protein
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Figure 2.5: Decreased α-SMA expression is restricted to the granulation tissue of
Postn-/- mice. (A) Histological analysis of day 7 wounds from Postn+/+ and Postn-/animals. Sections were incubated with an antibody for α-SMA (B) or fibroblast-specific
protein-1. Detection was with peroxidase conjugated 2° antibodies and DAB. α-SMA is
absent in the granulation tissue of Postn-/- wounds, but is present at the wound border (n =
4). Granulation tissue is dominated by fibroblasts in both Postn+/+ and Postn-/- day 7
wounds. (C) Quantification of cell number at the wound border and within the
granulation tissue from high power fields of view. Cell number was not different between
Postn+/+ and Postn-/- wounds at either location (p = 0.28). Data is expressed as mean
number of cells per field of view; error bars represent s.d. (two-way ANOVA).
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Figure 2.5: Decreased α-SMA expression is restricted to the granulation tissue of
Postn-/- mice
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Figure 2.6: Migration is not altered in Postn-/- fibroblasts. Dermal fibroblasts were
isolated from Postn+/+ and Postn-/- healthy skin biopsies. (A) Migration was assessed
using the scratch wound method (n = 4). Scratch wounds were made in a confluent
monolayer of Postn+/+ or Postn-/- fibroblasts on glass bottom culture dishes. Migration
was documented via time-lapse video microscopy. Images were generated from frames at
0, 8 and 16 hours. Yellow lines indicate the cell front. (B) Quantification of scratch area
measured from images at four-hour intervals. No difference in fibroblast migration was
detected (p = 0.34; two-way ANOVA). Data is expressed as a fraction of the initial
scratch area; error bars represent s.d.
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Figure 2.6: Migration is not altered in Postn-/- fibroblasts
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2.2.3

Canonical TGFβ signaling is not altered in Postn-/- fibroblasts

TGFβ is known to cause an increase in α-SMA expression, via Smad3 phosphorylation
(Gu et al., 2007), and plays a major role in myofibroblast differentiation (Desmouliere et
al., 1993). Therefore, to determine if the reduction in α-SMA expression and
immunoreactivity in Postn-/- granulation tissue was due to defective TGFβ/Smad3
signaling, we assessed the number of nuclei positive for phosphorylated Smad 2/3 (pSmad2/3) within the granulation tissue. The number of p-Smad2/3 positive nuclei was
similar in both Postn+/+ and Postn-/- wounds (Figure 2.7A,B) (p = 0.25), suggesting
canonical TGFβ signaling is active in Postn-/- wounds. This assay was limited in that it
could not discriminate between subtle quantitative differences in p-Smad2/3 levels.
However, collagen production in the granulation tissue of both Postn+/+ and Postn-/wounds, as evidenced by hydroxyproline content, was not significantly different (Figure
2.7C,D) (p = 0.69), a process for which TGFβ signaling is of great importance (Ignotz
and Massague, 1986; Roberts et al., 1986; Wang et al., 2007b). These observations,
combined with fibroblast-specific protein-1 staining and in vitro migration data, strongly
refute a migratory explanation for the absence of α-SMA staining in day 7 Postn-/granulation tissue.

2.2.4

Exogenous periostin is sufficient to induce a contractile
phenotype

The reduced α-SMA expression observed in vivo indicated that a defect might exist in
differentiation of fibroblasts to myofibroblasts and induction of contraction in Postn-/wounds. Postn+/+ and Postn-/- primary dermal fibroblasts were isolated and assayed for
their ability to contract a floating collagen gel, as well as exert contractile forces across a
collagen gel matrix (Figure 2.8A). Postn+/+ cells were able to generate contractile forces
across the collagen gel lattice, but Postn-/- fibroblasts showed a significant reduction in
ability to contract the lattice. The anchored matrix gel contraction assay was then used, as
it more closely resembles the mechanical environment of granulation tissue (Grinnell,
1994). Quantification of contraction through measurement of gel weight confirmed that
Postn+/+ fibroblasts were able to significantly contract the collagen matrix (Figure 2.8B,
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Figure 2.7: Canonical TGFβ signaling is not altered in Postn-/- fibroblasts. (A)
Histological analysis of day 7 wounds from Postn+/+ and Postn-/- animals. Sections were
incubated with an antibody for p-Smad2/3. Detection was with peroxidase conjugated 2°
antibodies and DAB (n = 3) (B) Number of positively stained nuclei per high power field
of view were not significantly different between Postn+/+ and Postn-/- wounds (p = 0.37;
Student’s t-test). (C) Masson’s trichrome staining of day 7 wound sections. (D)
Hydroxyproline content (g/100 g dry tissue) of excised day 7 wounds was not different
between Postn+/+ and Postn-/- animals (p = 0.60; Student’s t-test). Data is expressed as
means; error bars represent s.d.
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Figure 2.7: Canonical TGFβ signaling is not altered in Postn-/- fibroblasts
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Figure 2.8: Exogenous periostin is sufficient to induce a contractile phenotype. (A)
The effect of periostin deletion on the ability of dermal fibroblasts to exert contractile
force in a fixed, tethered floating collagen gel lattice was investigated using a Culture
Force Monitor. Forces generated by fibroblasts were measured over 24 hours; a
representative trace is shown (n = 3). Units are dynes (10-5 N) (B) Cells contracted
collagen gels over an additional 24 hours at 37°C, 5% CO2. (C) Gel contraction was
quantified by loss of gel weight, compared to gels lacking cells. Postn-/- fibroblasts were
unable to significantly contract collagen gels. Note that Postn+/+ fibroblasts were able to
contract collagen gels. Addition of 5 µg/mL rhPN to the collagen gels rescued the
contractile ability of Postn-/- fibroblasts (n = 3). Data is expressed as a fraction of the
initial gel weight; error bars represent s.d. (* = p < 0.05; two-way ANOVA). (D) Gels
were treated with 10 µM PP2 (or DMSO vehicle) or 10 µg/mL β1-integrin blocking
antibody (mouse IgG for controls). Data is expressed as a fraction of the initial gel
weight; error bars represent s.d. (* = p < 0.05; one-way ANOVA, n = 3). A Dunnett’s
multiple comparison test was employed where KO + PN + DMSO was used as the
reference group. Extracellular periostin influences contractility through a β1integrin/FAK dependent mechanism in vitro. (E) Fluorescent labeling of fibroblast
populated collagen gels for α-SMA (green) and nuclei (blue). α-SMA positive cells were
counted from high power fields of view. Percentage of α-SMA positive cells was
significantly reduced in Postn-/- fibroblast populated gels (p < 0.01, n = 3). Addition of 5
µg/mL rhPN to the collagen gels restored the percentage of α-SMA positive cells. Data is
expressed as mean; error bars represent s.d. (# = p < 0.01; one-way ANOVA).
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Figure 2.8: Exogenous periostin is sufficient to induce a contractile phenotype
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C), in comparison with Postn-/- fibroblasts (Figure 2.8B), indicating that periostin is
required for contraction of a collagen matrix by dermal fibroblasts (p < 0.01). To further
investigate this finding, recombinant human periostin (rhPN) was added to the collagen
matrix and was sufficient to induce contraction of the gels by Postn-/- dermal fibroblasts.
Addition of 5 µg/mL rhPN fully recovered the contractile ability of Postn-/- cells (Figure
2.8C), supporting the notion that periostin facilitates wound healing by promoting wound
contraction.
In order to understand the mechanism by which periostin induces contraction we
attempted to reverse the effect of rhPN on Postn-/- fibroblast contraction with various
inhibitors of signal transduction. As in Figure 2.8C, Postn-/- fibroblasts were unable to
contract the collagen matrix. With the addition of rhPN, however, these cells contracted
gels to the same extent as Postn+/+ fibroblasts (Figure 2.8D). Blockade of β1-integrin
ligation by incorporation of a β1-integrin neutralizing antibody (10 µg/mL) completely
reversed the rhPN-induced gel contraction (Figure 2.8D) (p < 0.01). As a negative
control, non-specific mouse IgG was instead incorporated into gels at the same
concentration. Gels containing IgG contracted to the same degree as Postn-/- fibroblast
populated gels with rhPN. Additionally, inhibition of Src/FAK phosphorylation with PP2
completely reversed the influence of rhPN on contraction of Postn-/- fibroblast populated
collagen gels (p < 0.01).
To assess whether the differences in collagen matrix contraction were the result of
differences in α-SMA levels, fibroblast-populated collagen gels were immunolabeled for
α-SMA (Figure 2.8E). Postn+/+ fibroblasts were generally more spread and displayed
strong α-SMA labeling. In comparison, the number of Postn-/- fibroblasts positive for αSMA was significantly reduced (89% positive in Postn+/+, 40% in Postn-/-, p < 0.01)
(Figure 2.8E). In line with gel contraction data, addition of 5 µg/mL rhPN to the collagen
matrix resulted in an increase in the number of α-SMA positive Postn-/- cells (93%, p <
0.01) (Figure 2.8E).
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Periostin is known to influence cell adhesion (Takeshita et al., 1993). Therefore, it was
conceivable that the lack of matrix contraction by Postn-/- fibroblasts was simply due to a
defect in adhesion. To determine the influence of periostin on dermal fibroblast adhesion,
we conducted adhesion assays with fibronectin, collagen type-1 and periostin coated
tissue culture plates. Postn+/+ and Postn-/- cells adhered to all matrix molecules tested
equally, following two hours of incubation (Figure 2.9). Adhesion was higher on
fibronectin than on collagen type-1, as anticipated (p < 0.01). Adhesion on periostin was
significantly lower than on either fibronectin or collagen type-1 (p < 0.01). Coating wells
with a combination of rhPN and fibronectin had no effect on dermal fibroblast adhesion
compared to fibronectin alone. Coating with rhPN/collagen type-1, however, greatly
reduced adhesion of dermal fibroblasts (Figure 2.9) (p < 0.001). This effect was
consistent between Postn+/+ and Postn-/- cells. Therefore, it is unlikely that periostin’s
influence on contractility is simply due to cell adhesion.

2.2.5

Periostin influences fibroblast morphology in 3D, but not 2D,
culture

The presence of α-SMA immunoreactivity in the borders of day 7 Postn-/- wounds (but
not within the granulation tissue) implies that alternative signals for myofibroblast
differentiation are at work in these regions. Differentiation of fibroblasts into
myofibroblasts requires TGFβ dependent signaling but also depends heavily on matrix
stiffness (Tomasek et al., 2002). To explore the contribution of matrix stiffness on
myofibroblast differentiation, dermal fibroblasts were seeded onto either collagen type-1
coated tissue culture plates or anchored collagen gels. Fibroblasts seeded on collagen
coated tissue culture plates adopted a planar, well-spread morphology typical of
fibroblasts in culture (Figure 2.10A). These cells developed very distinct stress fibers,
which often incorporated α-SMA, indicating myofibroblast differentiation. Postn-/fibroblasts grown on collagen-coated tissue culture plates were indistinguishable from
Postn+/+ fibroblasts. Moreover, α-SMA expression, as assessed by western blot, was not
significantly different between Postn+/+ and Postn-/- cells. Addition of 5 ng/mL
recombinant human TGFβ1 did not further increase α-SMA levels (Figure 2.10B),
indicating that the cultures might have already become maximally differentiated.
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Figure 2.9: Periostin is a modulator of dermal fibroblast attachment. Wells of a 96
well tissue culture plate were precoated with 10 µg/mL of fibronectin, collagen-1 or
rhPN. Additionally, wells were coated with combination of fibronectin + rhPN or
collagen-1 + rhPN (all at 10 µg/mL). Prior to seeding cells, wells were washed with PBS
and blocked with BSA. Isolated dermal fibroblasts were seeded and incubated for two
hours before non-adhering cells were washed away. Cell number was determined by
methylene blue staining, followed by dye extraction and measurement of absorbance at
650 nm. Values were compared to a standard curve. Data is expressed relative to
adhesion of Postn+/+ fibroblasts to fibronectin, with BSA adhesion subtracted; error bars
represent s.d. Letters indicate treatment that are statistically similar (p < 0.01; two-way
ANOVA, n = 3).
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Figure 2.9: Periostin is a modulator of dermal fibroblast attachment
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Figure 2.10: Periostin influences fibroblast morphology in 3D, but not 2D, culture.
Isolated dermal fibroblasts were seeded on collagen coated tissue culture plates or onto
precast collagen anchored gels. Cells were incubated for 48 hours before fixation or
harvesting lysates. (A) Filamentous actin was visualized with rhodamine-conjugated
phalloidin. Distinct stress fibers were observed in both Postn+/+ and Postn-/- fibroblasts (n
= 3). (B) Western blot analysis of lysates was carried out to quantify the level of α-SMA.
Equal loading was confirmed by blotting for GAPDH. No difference was detected
between Postn+/+ and Postn-/- fibroblasts. (C) Fibroblasts seeded on 3D collagen gels
were labeled with rhodamine-conjugated phalloidin and assessed for cell morphology (n
= 3). Postn-/- fibroblasts were more likely to adopt a dendritic phenotype, characterized
by a lack of stress fibers and extension of thin branching cytoplasmic extensions (p <
0.01). Addition of 5 µg/mL rhPN to the gels restored the percentage of dendritic
fibroblasts to Postn+/+ levels. Data is expressed as mean; error bars represent s.d. (* = p <
0.01; one-way ANOVA). (D) 3D collagen gels were homogenized and cells were lysed
by sonication. α-SMA levels were assessed by western blot.
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Figure 2.10: Periostin influences fibroblast morphology in 3D, but not 2D, culture

83

Tissue culture plastic provides an exceedingly stiff environment, whereas 3D collagen
gels provide a much more compliant matrix, reminiscent of granulation tissue (Grinnell,
1994). The surface of the anchored collagen gels used in this study provides a
mechanically intermediate environment (Arora et al., 1999), which produced mainly
planar cells (Figure 2.10C). Twenty-one percent of Postn+/+ cells, however, adopted a
dendritic phenotype, characterized by poor spreading, lack of stress fibers and extension
of numerous thin branching processes (Grinnell, 2003) (Figure 2.10C). Interestingly, the
proportion of Postn-/- cells adopting the dendritic phenotype was significantly higher at
39% (p < 0.01). Furthermore, addition of 5 µg/mL rhPN to the collagen gels decreased
the proportion of dendritic cells to the level of Postn+/+ cultures. α-SMA protein was
reduced in Postn-/- fibroblasts cultured on compliant collagen gels, but increased with the
addition of rhPN to the gel (Figure 2.10D).

2.2.6

Periostin facilitates α-SMA expression on compliant
substrates, but is not required with increasing substrate
stiffness

Since Postn-/- fibroblasts showed altered spreading and a deficit in α-SMA protein when
cultured on compliant collagen gels but not on collagen coated plastic, we sought to
further assess periostin-induced myofibroblast differentiation in the context of matrix
stiffness. Postn+/+ and Postn-/- fibroblasts were seeded on collagen-coated flexible
polyacrylamide gels of varying stiffness. On soft substrates (Young’s modulus of 4800
Pa), 64% of Postn+/+ fibroblasts were positive for α-SMA (Figure 2.11B). The proportion
of α-SMA positive Postn+/+ fibroblasts peaked on 19,200 Pa substrates at 90%, with no
additional increase on the stiff 50,000 Pa substrates. The percentage of α-SMA positive
Postn-/- fibroblasts increased with an increase in substrate stiffness (p < 0.01). Compared
with Postn+/+ fibroblasts, however, the proportion of α-SMA positive Postn-/- fibroblasts
was significantly lower on 4,800 Pa and 19,200 Pa substrates, 29% and 57% respectively
(p < 0.05) (Figure 2.11B). On 50,000 Pa substrates, the proportion of α-SMA positive
Postn-/- fibroblasts was equivalent to that of Postn+/+ fibroblasts (Postn+/+ 87%, Postn-/84%). To further investigate the mechanism by which periostin facilitates α-SMA
expression, we focused on the soft, 4,800 Pa substrates. Postn-/- fibroblasts showed an
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Figure 2.11: Periostin facilitates α-SMA expression on a soft substrate, but is
compensated for by increased substrate stiffness. Isolated dermal fibroblasts were
seeded on collagen-coated flexible polyacrylamide substrates with Young’s moduli of
4,800, 19,200 or 50,000 Pa. Cells were incubated for 48 hours before fixation. (A)
Fibroblasts were fluorescently labeled for α-SMA (green), filamentous actin (red) and
nuclei (blue). α-SMA positive cells were counted from high power fields of view. (B)
Percentage of α-SMA positive cells was significantly reduced in Postn-/- fibroblasts
grown on the soft 4,800 and 19,200 Pa substrates (p < 0.05, n = 3). On the stiff 50,000 Pa
substrates, however, the proportion of α-SMA positive Postn-/- fibroblasts was equivalent
to that of Postn+/+ fibroblasts. Data is expressed as mean; error bars represent s.d. (* = p
< 0.05; two-way ANOVA). (C) Western blot analysis of lysates from Postn-/- fibroblasts
grown on 4,800 Pa substrates was carried out to quantify the level of pFAKY397 and αSMA. Loading was corrected by blotting for total FAK and GAPDH. pFAKY397/FAK and
α-SMA/GAPDH indicate results of densitometry, relative to control. Incorporation of
rhPN on 4,800 Pa substrates resulted in an increase in pFAKY397 and α-SMA protein.
Increased α-SMA was attenuated by 10 µM PP2.
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Figure 2.11: Periostin facilitates α-SMA expression on a soft substrate, but is
compensated for by increased substrate stiffness
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increase in α-SMA protein and phosphorylated FAKY397 when polyacrylamide gels were
coated with 100 µg/mL collagen + 5 µg/mL rhPN, compared to gels coated with 100
µg/mL collagen alone (Figure 2.11C). This increase was attenuated by 10µM PP2.

2.2.7

Delivery of recombinant periostin via electrospun collagen
scaffolds stimulates α-SMA expression

Since rhPN was sufficient to restore α-SMA expression and contractility in Postn-/fibroblasts in vitro, we attempted to reintroduce periostin into Postn-/- wounds in vivo. We
incorporated rhPN into electrospun collagen scaffolds (Figure 2.12A,B) and these
scaffolds (or control scaffolds lacking periostin) were laid into Postn-/- wounds
immediately following wounding. Immunohistochemical analysis of day 7 wounds
revealed a marked increase in α-SMA immunoreactivity within the wounds that received
collagen/periostin scaffolds, compared to collagen-only controls (Figure 2.12C).
Moreover, α-SMA immunoreactivity was detected throughout the granulation tissue of
collagen/periostin treated wounds, mimicking the wild-type expression pattern.

2.3

Discussion

In this report we show that the loss of periostin, by use of the periostin knockout mouse
(Rios et al., 2005), results in altered dermal wound closure kinetics, specifically during
the pro-fibrotic phase of wound healing. The alteration in wound closure corresponds
with

the

onset

and

peak

of

periostin

expression

in

Postn+/+

animals.

Immunohistochemistry and RT-qPCR reveal that α-SMA is strikingly reduced in the
granulation tissue of day 7 Postn-/- wounds. Altered wound closure kinetics in Postn-/mice may therefore be due to a reduction in α-SMA positive myofibroblasts within the
granulation tissue, and thus a reduction in wound contraction. Other phases of wounds
healing appeared to be unaffected by the loss of periostin. Infiltration of inflammatory
cells (macrophages and neutrophils) was similar between Postn+/+ and Postn-/- wounds.
The eventual closure of both Postn+/+ and Postn-/- wounds by day 11 indicates that Postn/-

animals are able to close dermal wounds by a method other than contraction, possibly

re-epithelialization. Recently, Nishiyama and colleagues reported reduced re-
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Figure 2.12: Delivery of recombinant periostin via electrospun collagen scaffolds
recovers α-SMA expression in PN KO mice. (A) Collagen type-1 electrospun
scaffolds, with and without rhPN, were cut into 6 mm disks to match the size of punch
wounds. (B) Periostin (green) protein was detected throughout the collagen + periostin
scaffolds, but not the control collagen scaffolds. (C) Punch wounds were created in
Postn-/- animals and scaffolds were immediately laid into the wounds. Half of the wounds
received two control (collagen only) scaffolds and the other half of the wounds received
two collagen + periostin scaffolds. Wounds were harvested for IHC at day 7. Addition of
periostin to Postn-/- wounds via electrospun collagen scaffolds resulted in a marked
increase in α-SMA immunoreactivity throughout the granulation tissue, when compared
to wounds receiving control collagen scaffolds (n = 3).
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Figure 2.12: Delivery of recombinant periostin via electrospun collagen scaffolds
recovers α-SMA expression in PN KO mice
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epithelialization following dermal wounding in an independently derived Postn-/- mouse
(Nishiyama et al., 2011). We observed no significant difference in re-epithelialization of
Postn-/- wounds, when compared to Postn+/+ controls. As would be expected, wound size
(measured from histological sections) was greater in Postn-/- animals. Due to this
difference in wound size, the calculated percentage of epithelialization appeared to be
lower in Postn-/- wounds (not significant), yet the epithelial migration distance was
actually higher.

Therefore we feel that percent epithelialization is an inappropriate

measurement for wounds of different sizes (Gorin et al., 1996) and epithelial migration
distance is the more reliable method. Using this more reliable method we did not detect a
difference in re-epithelialization.
Reduced α-SMA specifically within the granulation tissue of Postn-/- wounds, with
wound borders and vasculature positive for α-SMA, raised the question of whether
fibroblast recruitment was deficient in Postn-/- wounds. In fact, fibroblasts were observed,
via immunohistochemical detection of fibroblast-specific protein-1, to dominate the
newly formed granulation tissue of both Postn+/+ and Postn-/- wounds. Cell number was
also similar for Postn+/+ and Postn-/- wounds in the granulation tissue and at wound
borders. Moreover, fibroblast migration, as assessed by scratch wound assays in vitro,
revealed no difference in migration between Postn+/+ and Postn-/- fibroblasts. Together
these results suggest fibroblast recruitment is not the underlying cause for the pattern of
α-SMA expression in Postn-/- wounds. Collagen content from day 7 wounds, as assessed
by hydroxyproline content, was not significantly different between Postn+/+ and Postn-/wounds. Therefore, we suggest that the granulation tissue of Postn-/- wounds harbors a
synthetic fibroblast population, which is deficient, however, in contractile machinery.
As fibroblast recruitment did not appear to be altered in Postn-/- wounds, we sought to
determine if reduced α-SMA within Postn-/- granulation tissue was the result of a defect
in differentiation of fibroblasts into myofibroblasts. Supporting this hypothesis, isolated
dermal fibroblasts from Postn-/- animals were unable to significantly contract anchored
collagen gels, which assess contractility rather than tractional forces of migration
(Grinnell, 1994). However, addition of exogenous rhPN fully rescued the phenotype of
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the Postn-/- fibroblasts. Immunocytochemistry revealed that the degree of gel contraction
corresponded to the number of α-SMA positive cells within the gel. Therefore, we
conclude that periostin is required for gel contraction and its presence in the extracellular
matrix is sufficient to induce a contractile myofibroblast phenotype. Previous reports
support a role for periostin in gel contraction. Incorporation of purified periostin
increased the ability of atrioventricular cushion mesenchymal cells to contract a collagen
gel (Butcher et al., 2007). Similarly, addition of rhPN to collagen gels increased the
contractility of fibroblasts isolated from patients suffering from Dupuytren's disease, a
disease of connective tissue contracture (Vi et al., 2009). In both of these studies,
increased contraction was associated with increased α-SMA protein.
Culturing isolated dermal fibroblasts on collagen type-1 coated tissue culture plates
resulted in abundant α-SMA production, irrespective of periostin expression, showing
that Postn-/- fibroblasts are capable of α-SMA expression. The pattern of α-SMA
expression within day 7 Postn-/- wounds must, therefore, be due to the environment
provided by the granulation tissue itself. Mechanical tension (Hinz et al., 2001; Cevallos
et al., 2006) and TGFβ (Desmouliere et al., 1993) induce α-SMA expression and promote
myofibroblasts differentiation (Tomasek et al., 2002). Induction of α-SMA by TGFβ is
primarily through activation of canonical TGFβ signaling, specifically Smad3 (Gu et al.,
2007). Interestingly, within the granulation tissue of Postn+/+ and Postn-/- wounds,
nuclear p-Smad2/3 was detected at equal levels. Although we cannot rule out Smadindependent TGFβ pathways (Derynck and Zhang, 2003), nor can we rule out subtle
quantitative differences in p-Smad2/3 levels between Postn+/+ and Postn-/- wounds, TGFβ
signaling appears to be active within the granulation tissue of Postn-/- wounds. Therefore,
we suspected that the mechanical environment might be the determining factor for
periostin-induced myofibroblast differentiation.
Mathematical models of fibroblast-driven dermal wound healing predict that the wound
border is a region of peak matrix stiffness (Murray, 2003). Of particular importance, the
tangential stiffness modulus of this region is greatly elevated over that of the central
granulation tissue (Murray, 2003). The potential correlation between predicted tissue
stiffness and α-SMA immunoreactivity in Postn-/- wounds prompted us to test if periostin
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influences fibroblast behaviour in a mechanically dependent manner. On collagen coated
tissue culture plates, no difference in cell morphology or α-SMA expression was
apparent. In contrast to 2D culture, when isolated dermal fibroblasts were cultured on the
more compliant collagen gels, a greater percentage of Postn-/- cells adopted a dendritic
phenotype and α-SMA protein was reduced. Incorporating rhPN into the collagen gels
reversed both of these effects. Tissue culture plates provide an enormously stiff
environment for cell growth, with a reported elastic modulus of 2.78 GPa (Callister and
Rethwisch, 2000), whereas 2 mg/mL collagen gels have an elastic modulus of
approximately 300-400 Pa (Paszek et al., 2005; Marenzana et al., 2006). The elastic
modulus of anchored collagen gels has not been reported. However, they are believed to
more closely represent the mechanical environment of the granulation tissue (Grinnell,
1994), which has been reported as having an elastic modulus of 18.5 kPa in day 7 rat
wounds (Goffin et al., 2006).
We propose that periostin facilitates myofibroblast differentiation and matrix contraction
in a compliant 3D environment, such as in the granulation tissue. However, in a rigid
environment such as in 2D culture or at the wound border, the effects of periostin are
overshadowed by the influence of mechanical tension. Multiple studies looking at the
effect of matrix stiffness on fibroblasts morphology agree that above 3-6 kPa fibroblasts
assemble stress fibers and that above 15 kPa α-SMA incorporation occurs (Wells, 2005;
Yeung et al., 2005; Solon et al., 2007). To refine our assessment of myofibroblast
differentiation in the context of matrix stiffness, we adopted the widely used matrixcoated flexible polyacrylamide substrate (Aplin and Hughes, 1981; Pelham and Wang,
1997). While the stiffness of collagen gels can be modulated by increasing or decreasing
the collagen concentration, this method introduces ligand density as a confounding
variable (Paszek et al., 2005). In this study, all substrates were coated with the same
concentration of collagen, thereby ensuring that differences in cell differentiation were
due to substrate stiffness and not ligand density. Using collagen-coated polyacrylamide
gels of varying stiffness, we observed a significant reduction in the proportion of Postn-/fibroblasts positive for α-SMA compared to wild-type controls. This reduction was
present on the more compliant 4,800 Pa and 19,200 Pa substrates but not on the stiff
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50,000 Pa substrates, thus clearly showing that the lack of periostin can be compensated
for by matrix stiffness. Furthermore, this supports the hypothesis that increased matrix
stiffness is responsible for α-SMA expression at the borders of day 7 Postn-/- wounds.
Interestingly, Sidhu and colleagues recently reported that incorporation of periostin, in
the absence of any cell type, was sufficient to increase the elastic modulus of collagen
type-1 gels (Sidhu et al., 2010). Based on this evidence it is possible that periostin itself
may contribute to the stiffness of the granulation tissue via collagen cross-linking,
thereby indirectly promoting myofibroblast differentiation. Such an effect would surely
be a confounding variable in the collagen gel contraction assays employed here, although
the concentrations of periostin used by Sidhu and colleagues were substantially higher
(20 and 200 µg/mL) than the concentration used in our assays (5 µg/mL) (Sidhu et al.,
2010). If the mechanism by which periostin facilitates myofibroblast differentiation is
simply by increasing matrix stiffness, we would expect that Postn+/+ and Postn-/fibroblasts would behave similarly on 2D matrix-coated polyacrylamide substrates, where
stiffness is controlled independent of collagen cross-linking. Our results however do not
support such a mechanism, as Postn-/- fibroblast differentiation was significantly lower on
soft substrates. Our results instead favour a mechanism where periostin facilitates
myofibroblast differentiation in compliant substrates and its influence is overshadowed
by increased matrix stiffness.
Although we had established a “niche” in which periostin promotes myofibroblast
differentiation in compliant matrices, the mechanism for periostin’s influence remained
unclear. In gel contraction assays, we found that inhibition of β1-integrin ligation and
inhibition of Src/FAK signaling reversed the periostin-induced increase in gel
contraction. Moreover, coating polyacrylamide substrates with a combination of collagen
and rhPN increased the level of α-SMA protein and phosphorylation of FAKY397. The
rhPN-induced increase in α-SMA protein was attenuated by PP2. In addition to providing
attachment to the ECM, integrin ligation is known to activate numerous signaling
pathways (Giancotti and Ruoslahti, 1999). We cannot rule out the possibility that β1integrin functioning is required for gel contraction and myofibroblast differentiation
through a mechanism parallel to, but independent of, periostin. However, periostin has
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been shown to bind β1-integrins, an event that is required for cushion mesenchyme cell
invasion into collagen type-1 gels (Butcher et al., 2007).
Periostin was initially classified as an adhesion molecule (Takeshita et al., 1993; Horiuchi
et al., 1999). However, more recent work (Katsuragi et al., 2004), as well as adhesion
data presented in this report do not support the notion that periostin is an adhesion
molecule per se. We suggest instead that the binding of periostin to surface receptors in
vivo serves to modulate intracellular signaling, and that periostin’s role is not strictly to
increase attachment. Ligation of most integrin pairs results in activation of FAK
(Giancotti and Ruoslahti, 1999). Indeed, periostin has been shown to influence
intracellular FAK activation in an integrin dependant manner (Shimazaki et al., 2008; Li
et al., 2010). Our data favours a mechanism by which periostin influences intracellular
signaling of myofibroblast differentiation in a β1-intergrin/FAK dependent manner.
Myofibroblasts are at the core of many fibrotic diseases including systemic sclerosis
(Leask, 2010b), hypertrophic scars (Baur et al., 1975) and sub-epithelial fibrosis in
bronchial asthma (Brewster et al., 1990). To date, periostin has been implicated in subepithelial fibrosis (Takayama et al., 2006) and hypertrophic scars (Wang et al., 2007a;
Zhou et al., 2010). The role of periostin in these diseases is not fully understood,
however, our data supports the hypothesis that periostin facilitates myofibroblast
differentiation, thereby contributing to disease progression. The ability of periostincontaining electrospun collagen scaffolds to increase α-SMA immunoreactivity in Postn/-

wounds may have important implications for treatment of non-healing skin lesions, or

chronic skin wounds. By definition, chronic skin wounds are unable to close and,
therefore, represent a massive burden on today’s healthcare systems (Elliott and
Hamilton, 2011). There is therefore an immediate need for therapeutics capable of
expediting wound closure. Using recombinant material and collagen scaffolds, we have
demonstrated the feasibility of using periostin to influence wound healing. Future work
will focus on the employment of periostin-containing electrospun collagen scaffolds to
determine if the increased α-SMA immunoreactivity translates into increases in wound
closure rates.

94

2.4
2.4.1

Materials and Methods
Animals

All animal procedures were in accordance with protocols approved by the University
Council on Animal Care at The University of Western Ontario. Periostin knockout mice
(Postn-/-) were generated and described previously (Rios et al., 2005). Heterozygous mice
were crossed with C57BL/6J (JAX® Mice and Services, Bar Harbor, Maine) for a
minimum of six generations to ensure an incipient congenic strain. Backcrossed
heterozygous mice were used for breeding and offspring were genotyped as described
previously (Rios et al., 2005). Postn-/- mice and sex-matched littermate Postn+/+ control
mice were weaned at 3 weeks and provided with powdered food to reduce the effects of
tooth defects on growth rate (Rios et al., 2005). All animals were subjected to 12 h
light/dark cycle and temperature in accordance with the guidelines of the Canadian
Council on Animal Care.

2.4.2

Punch Wounds

For experiments, Postn-/- and sex-matched littermate Postn+/+ mice (12 weeks of age
weighing approximately 25 g) were anesthetized with an intraperitoneal injection of
buprenorphine (50 µg/kg), followed by an injection of ketamine (100 mg/kg) and
xylazine (5 mg/kg). Backs were shaved, depilated and sterilized with iodine. Two fullthickness excisional wounds were made on each side of the dorsal midline with a 6 mm
punch biopsy. Removed tissue was considered day 0 and was retained for further
analysis. Wounds were photographed immediately after wounding and again at 3, 5, 7, 9
and 11 days post wounding. Wound area was assessed from photographs using Northern
Eclipse v7.0 software (Empix Imaging Inc., Mississauga, Ontario) and expressed as a
fraction of initial area. Mice were caged individually following wounding and were
sacrificed at day 11 for histology and gene expression assays.

2.4.3

Tissue Preparation and Immunohistochemistry

Additional animals were wounded as described above and sacrificed at days 5 and 7. At
various time-points wounds were excised and either snap frozen in liquid nitrogen, or
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fixed in 10% neutral buffered formalin (Sigma Aldrich, St. Louis, Missouri). Tissues
were stained as previously described (Jackson-Boeters et al., 2009). Sections were
blocked with 10% horse serum and incubated with goat anti-periostin (sc49480, Santa
Cruz Biotechnology, Santa Cruz, California) primary antibody overnight at 4°C. For
negative controls, periostin primary antibody was pre-absorbed for 1 hour with the
immunizing peptide. Detection was by ImmPRESS Ig peroxidase kits (Vector
Laboratories, Burlingame, California) and visualized with 3,3-diaminobenzidine (Vector
Laboratories). Sections were counterstained with haematoxylin. Staining of α-SMA was
with the rabbit anti-α-SMA primary antibody (ab5694, Abcam, Cambridge, United
Kingdom), fibroblast-specific protein-1 was with anti-FSP1/S100A4 (Millipore, Billerica,
Massachusetts), CD68 was with MCA1957 (AbD Serotec, Oxford, United Kingdom),
neutrophil elastase was with ab68672 (Abcam). Negative controls excluded the primary
antibody. For immunofluorescence, nuclei were labeled with DAPI (Vector
Laboratories). Detection of p-Smad2/3 (sc11769-R, Santa Cruz Biotechnology) positive
nuclei on paraffin sections was carried out as above excluding haematoxylin
counterstaining. Trichrome staining was carried out as previously described (Liu et al.,
2008). For assessment of re-epithelialization, sections from the centre of the wounds were
stained with haematoxylin and photographed. Wound size and epithelial migration
distance were measured using Northern Eclipse v7.0 software. Epithelial migration
distance was defined as the unilateral distance between the wound border and the
migrating front of keratinocytes. Percent epithelialization was determined from bilateral
epithelial migration distance, normalized to wound size.

2.4.4

In Situ Hybridization

In situ hybridization for periostin message was performed on 10 µm paraffin serial skin
sections using [35S]-labeled riboprobe transcribed from a 574 bp fragment of mouse
periostin cDNA (Kruzynska-Frejtag et al., 2001). Hybridization with sense probe was
performed in parallel as negative control.
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2.4.5

RT-qPCR

Snap frozen tissue samples were homogenized in 1 mL of TRIzol® reagent (Invitrogen,
Carlsbad, California). Total RNA was extracted as per the manufacturer’s
recommendations. Real-time quantitative PCR was carried out on 50 ng of total RNA
using TaqMan® One-Step RT-PCR Master Mix and gene-specific TaqMan® probes
(Applied Biosystems, Carlsbad, California). Postn and Acta2 gene expression was
normalized to the endogenous control gene 18S. PCR efficiency was verified to fall
between 90 and 110%, via dilution series, and relative expression was calculated using
the ΔΔCT method (Livak and Schmittgen, 2001).

2.4.6

Hydroxyproline

Hydroxyproline content of excised dermal wounds was determined as an indicator of
collagen content essentially as previously described (Samuel, 2008). Hydroxyproline
content was determined using a standard curve and normalized to tissue dry weight.
Values were expressed as grams of hydroxyproline per 100 g of tissue.

2.4.7

Isolation of Primary Dermal Fibroblasts

Excised tissue from punch wounds were immediately transferred to Dulbecco’s Modified
Eagle Medium (High Glucose) supplemented with 10% fetal bovine serum and 2% AA
(200 units penicillin/200 µg streptomycin/0.5 µg/mL amphotericin B) (Gibco, Carlsbad,
California). Skin was washed with five changes of media then incubated at 37°C, 5%
CO2 to allow fibroblasts to migrate onto the culture surface. For use, skin was removed
and cells were cultured for two to three passages.

2.4.8

Gel Contraction

Gel contraction assays were conducted essentially as previously described (Shi-wen et
al., 2004). Collagen was prepared as follows: 10% 0.2 M HEPES (pH 8), 40% bovine
collagen type-1 (Advanced BioMatrix Inc., San Diego, California) and 50% 2X
Dulbecco’s Modified Eagle Medium (High Glucose). Dermal fibroblasts were suspended
in 0.5% FBS DMEM and mixed 1:1 with the collagen preparation to a final density of
100,000 cells/mL. Either 5 µg/mL rhPN (R&D Systems Inc., Minneapolis, Minnesota) or
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an equivalent volume of PBS was incorporated into the collagen/cell mix. 24 well tissue
culture plates were pre-coated with BSA overnight then washed with PBS. Collagen/cell
mix (0.5 mL) was added to each well and allowed to set at 37°C. Following
polymerization, wells were flooded with 1 mL 0.5% FBS DMEM. After 24 hours, gels
were separated from the surface of the plate and incubated for an additional 24 hours. To
ensure that contraction of gels horizontally and vertically was accounted for,
quantification of gel contraction was assessed by loss of gel weight, whereby contraction
of the collagen matrix excluded growth media, thus reducing the weight of the gel
(Tingstrom et al., 1992).
The Src/FAK inhibitor, PP2 (Calbiochem, Darmstadt, Germany), was added at 10 µM to
the collagen/cell mix during preparation and to the media following polymerization. An
equal volume of dimethyl sulfoxide (DMSO) (Sigma Aldrich) was added to untreated
control gels. Additionally, integrin β1 signaling was inhibited by addition of 10 µg/mL
blocking antibody (MA2253, Millipore) or mouse IgG (PP100, Millipore) to the
collagen/cell mix..

2.4.9

Fibroblast Populated Collagen Lattice (FPCL) Contraction
Assay

Experiments were performed essentially as previously described (Shi-wen et al., 2004).
Briefly, cells (1×106 cells/ml) were seeded into a collagen gel (First Link Ltd.,
Birmingham, United Kingdom) floated in DMEM, 0.5% FBS. Gels were anchored at one
end and attached to a force transducer at the other end. Forces generated across the
collagen lattice were measured over a 24 hour period. Graphical readings are produced
every 15 seconds providing continuous measurements of generated forces (Dynes: 1×10−5
N) which are logged into a personal computer.

2.4.10

Adhesion

Tissue culture treated 96 well plates were coated overnight at 4°C with 10 µg/mL human
fibronectin (Sigma Aldrich), 10 µg/mL bovine collagen type-1 (Advanced BioMatrix), 10
µg/mL rhPN (R&D Systems) or a combination of periostin and collagen or fibronectin.
Plates were subsequently blocked with 3% BSA at 37°C for 2 hours. Dermal fibroblasts
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were suspended in serum free media, seeded and allowed to attach for 2 hours. Adherent
cells were fixed with 10% neutral buffered formalin (Sigma Aldrich) and stained with
methylene blue. Adhesion was quantified by dye extraction and measurement of
absorbance at 650 nm (Oliver et al., 1989). Cell number was determined from a standard
curve.

2.4.11

Migration

Migration was assessed by scratch wound assays essentially as previously described
(Liang et al., 2007). Dermal fibroblasts were seeded on glass bottom culture dishes and
allowed to reach confluence. Scratches were created with a P200 tip and disrupted cells
were washed away with PBS. Growth media was replaced with 0.5% FBS DMEM to
reduce proliferation. Closure of scratches was documented by time-lapse video
microscopy using a Zeiss Axio Observer Z.1 inverted microscope equipped with a
temperature and CO2 controlled incubation chamber (Carl Zeiss, Oberkochen, Germany).

2.4.12

Immunocytochemistry

Dermal fibroblasts were suspended in 0.5% FBS DMEM and seeded at 30,000 cells/well
on pre-coated collagen type-1 6-well plates (BD Biosciences, Franklin Lakes, New
Jersey). Cells were left to attach overnight before treatment with 5 ng/mL recombinant
human TGFβ1 (R&D Systems) for 24 hours. Alternatively, cells were seeded on top of
polymerized collagen gels (prepared as described above) in 24-well plates and incubated
for 48 hours. Cells were fixed with 4% paraformaldehyde, permeablized with 0.1%
Triton X-100 and blocked with 3% BSA. Filamentous actin was visualized using
rhodamine-conjugated phalloidin (Molecular Probes, Carlsbad, California). α-SMA was
labeled with a mouse monoclonal primary antibody (A5228, Sigma Aldrich) and detected
with a goat anti-mouse IgG conjugated to Alexa Fluor 488 secondary antibody
(Molecular Probes). Fibroblast morphology was assessed as dendritic or planar by a
blinded observer from random fields of view. Fibroblasts were considered as displaying
the dendritic morphology based on the lack of stress fibers and extension of thin
branching cytoplasmic extensions. Cells displaying planar morphology were well-spread
and showed prominent stress fibers.
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2.4.13

Western Blotting

Cell lysates were harvested at 48 hours with RIPA buffer (Sigma Aldrich) containing
protease and phosphatase inhibitor cocktails (Sigma Aldrich). Protein concentration was
determined by BCA assay (Pierce, Waltham, Massachusetts). For 3D collagen gels, gels
were homogenized and cells were lysed by sonication. Proteins were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
nitrocellulose membranes. Membranes were washed with tris-buffered saline containing
0.05% tween-20 (TBST). Membranes were blocked with 5% milk TBST. Primary
antibodies were anti-α-SMA (ab5694, Abcam), anti-FAKY397 (BD611722, BD
Biosciences), anti-FAK (sc-558, Santa Cruz Biotechnology) and anti-GAPDH (MAB374,
Millipore). Detection was with appropriate peroxidase-conjugated secondary antibodies
(Jackson ImmunoReaserch, West Grove, Philadelphia) and enhanced chemiluminescence
(Pierce). Bands were quantified using Image J software, using GAPDH to correct for
loading.

2.4.14

Polyacrylamide Substrates

Matrix-coated flexible polyacrylamide substrates were created on glass cover slips using
methods described previously (Pelham and Wang, 1997; Bhana et al., 2010; Tilghman et
al., 2010). Polyacrylamide gels of varying stiffness were prepared with 7% (4,800 and
19,200 Pa) or 15% (50,000 Pa) acrylamide (Sigma Aldrich) and 0.05% (4,800 Pa), 0.24%
(19,200 Pa) or 0.3% (50,000 Pa) N,N’-methylenebis(acrylamide) (Sigma Aldrich) (Bhana
et al., 2010; Tilghman et al., 2010). Gels were coated with either 100 µg/mL collagen
type-1 (Advanced BioMatrix Inc) or 100 µg/mL collagen type-1 and 5 µg/mL rhPN
(R&D Systems) using the heterobifunctional crosslinker Sulfo-SANPAH (Pierce). Gels
were washed with PBS and equilibrated with growth media before seeding cells.

2.4.15

Scaffolds

Collagen type-1 (Sigma-Aldrich) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol to
make a 15% (w/v) solution. Periostin (R&D Systems) was dissolved in PBS to make a 1
mg/ml solution. 20 µl of the periostin (concentration of 100 µg/ml) was mixed with 3 ml
of collagen solution, and the mixture injected at a speed of 1 ml/h by a syringe pump into
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a capillary charged with a voltage of +15 kV. The generated nanofibers were collected on
a negatively charged (-10 kV) rotation mandrel. Control scaffolds contained 20 µl of
PBS. To crosslink the scaffolds, they were immersed in 5% glutaraldehyde/ethanol
solution for 30 min. Scaffolds were spun onto aluminum foil, and a 6 mm biopsy punch is
used to cut the scaffolds to ensure they were the same size as the wound. Each scaffold
was sterilized in 100% ethanol and rinsed 3 times with PBS. Two 6 mm diameter
scaffolds were inserted into each wound immediately following wounding.

2.4.16

Statistical Methods

Statistical analysis was by one-way or two-way ANOVA, as appropriate, followed by a
Bonferroni correction, using Graphpad Software v4 (Graphpad Software, La Jolla,
California) (p ≤ 0.05 was considered significant). Student’s t-tests were used for pSmad2/3 and hydroxyproline data. A Dunnett’s multiple comparison test was used for gel
contraction assays including inhibitors to compare all treatments to the reference group,
KO + PN + DMSO. In total, 16 Postn-/- and 16 Postn+/+ wounds were tracked for wound
area over the 11-day time course. Data is expressed as a fraction of the original wound
area (mean ± s.d.). In vivo gene expression data represents the mean ± s.e.m. of at least 5
Postn-/- and 5 Postn+/+ wounds for each time point. In vitro data is expressed as the mean
± s.d. of three individual experiments with three independent sex-matched littermate
primary cultures. Individual experiments included at least three replicates.
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Chapter 3

3

Evaluation of periostin and CCN2 as potential
therapeutics for the treatment of human chronic skin
wounds

Abstract
Development of effective treatments to close non-healing skin lesions, or chronic skin
wounds, has been hampered by a lack of thorough understanding of the dysfunctions
present in these wounds. Matricellular proteins have received little attention despite their
known role in modulating many important aspects of normal wound healing. The
matricellular proteins periostin and CCN2 promote fibrotic aspects of wound healing but
their state in chronic skin wounds is unknown. The objective of this study was to
determine the expression patterns of periostin and CCN2 in human chronic skin wounds.
Periostin and CCN2 were reduced within the wound bed of human chronic skin wounds.
This might be due to the inflammatory microenvironment since wound edge fibroblasts
showed no deficits in inducible fibrotic phenotype in vitro. Administration of rhPN or
rhCCN2, electrospun with collagen, accelerated wound closure in a model of impaired
diabetic healing. We propose that matricellular proteins, particularly periostin and CCN2,
are promising therapeutic options for the treatment of human chronic skin wounds.

A version of this chapter is in preparation for submission to Nature Biotechnology:
Elliott, C.G., Li, X., Guan, J., Dunmore-Buyze, J., Drangova, M., Forbes, T., Leask, A.,
and Hamilton, D.W. (In preparation) Evaluation of periostin and CCN2 as potential
therapeutics for the treatment of human chronic skin wounds.
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3.1

Introduction

The skin’s ability to heal is fundamentally important to maintaining proper barrier
function and ultimately our survival. However, certain human populations including the
elderly and those with systemic conditions such as diabetes often demonstrate an
impaired ability to heal skin wounds. Failed wound healing results in what is broadly
termed a chronic skin wound. As of 2009/10, 2.4 million Canadians (Public Health
Agency of Canada, 2011) and 25.8 million Americans were living with diabetes (Centers
for Disease Control and Prevention, 2011). It is estimated that 25% of people with
diabetes will develop a chronic skin wound in their lifetime (Singh et al., 2005). The
consequences of developing a chronic skin wound are severe, with complications
including increased risk of infection, sepsis, osteomyelitis, amputation, and even death
(Sen et al., 2009). The financial costs of chronic skin wounds are estimated to be as high
as $25 billion annually in the United States alone (Brem et al., 2007). With the incidence
of diabetes and its associated clinical complications projected to rise significantly, it is
imperative that new treatment modalities are developed. However, developing effective
treatments has been hindered by our limited knowledge of the dysfunctions present in
chronic skin wounds.
Chronic skin wounds, regardless of etiology, are classified based on an absence of
healing after 4 weeks (Sheehan et al., 2003). They are complicated by a combination of
patient age, repeated ischemia-reperfusion injury, bacterial colonization and hypoxia
(Mustoe, 2004; Schreml et al., 2010). Common features of chronic skin wounds include
reduced growth factor activity, decreased matrix accumulation, increased fibroblast
senescence and a general failure to progress beyond the inflammatory phase of healing
(Elliott and Hamilton, 2011). Many different treatment strategies have been investigated
for the treatment of chronic skin wounds; including protease inhibitors, numerous growth
factors, decellularized matrices, skin grafts, negative pressure, hyperbaric-oxygen, stem
cell delivery and even ultrasound (Game et al., 2012). Of these, very few are supported
by strong evidence of efficacy (Hinchliffe et al., 2008; Game et al., 2012). One of the
most promising treatments evaluated in clinical trials, rhPDGF-BB (marketed under the
name Regranex®) has received criticism due to the limited applicability and moderate
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effectiveness compared to placebo (Hinchliffe et al., 2008; Elliott and Hamilton, 2011).
Trials of the profibrotic growth factor TGFβ showed no efficacy in closed label trials
(Robson et al., 1995), despite promising results in animals (Beck et al., 1990; Zhao et al.,
1994). Perhaps the somewhat disappointing results from growth factor based therapies
may be explained, in part, by another group of proteins; the matricellular proteins.
Matricellular proteins are secreted non-structural matrix components which have been
shown to influence all aspects of wound healing (Midwood et al., 2004; Hamilton, 2008;
Elliott and Hamilton, 2011). They modulate the interactions between the cell and its
extracellular environment, further regulating cellular behaviour including growth factor
response. The matricellular proteins periostin and CCN2 have been heavily implicated in
the fibrotic and proliferative stages of tissue repair; including collagen production, matrix
contraction and fibroblast differentiation (Elliott and Hamilton, 2011). Moreover, it has
been shown that extracellular periostin (Sidhu et al., 2010; Lorts et al., 2012) and CCN2
(Kothapalli et al., 1997; Duncan et al., 1999; Shi-wen et al., 2006) are required for proper
TGFβ signaling in a context-dependant manner. We have shown that a loss of periostin
results in a delay in wound closure attributed to attenuation of wound contraction (Elliott
et al., 2012). Additionally, periostin may have a positive influence on re-epithelialization
and fibroblast proliferation (Nishiyama et al., 2011; Ontsuka et al., 2012). CCN2 is
required for appropriate myofibroblast recruitment in skin (Sonnylal et al., 2010; Liu et
al., 2011) and positively influences angiogenesis in a variety of tissues (Hall-Glenn et al.,
2012; Alfaro et al., 2013).
Local delivery of both of these proteins as therapeutics for the treatment of chronic skin
wounds shows potential. Delivery of periostin into full-thickness excisional wounds of
periostin knockout mice increases both closure rate (Ontsuka et al., 2012) and
myofibroblast differentiation (Elliott et al., 2012). Administration of recombinant CCN2
in a burn model of wound healing results in increased closure rate and fibroblast
recruitment (Liu et al., 2007). However, the relative expression levels of periostin and
CCN2 in human chronic skin wound tissue have never been investigated. We hypothesize
that these profibrotic matricellular proteins are significantly reduced in human chronic
skin wounds. In the current study we show that in human chronic skin wound tissue
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periostin expression is significantly reduced and CCN2 expression is not induced.
Additionally, we demonstrate that fibroblasts from the edge of chronic skin wounds can
be induced to express the profibrotic phenotype required for wound healing in vitro.
Finally, in a model of impaired diabetic healing, we show that recombinant human
periostin (rhPN) and CCN2 (rhCCN2) electrospun with collagen can rescue wound
closure rates in diabetic db/db mice.

3.2
3.2.1

Results
Periostin and CCN2 are not induced in human chronic skin
wounds

Immunohistochemical detection of periostin in human tissue samples (Table 3.1) showed
strong reactivity within the dermis of the skin proximal to the wound edge (within 2 cm),
as well as skin from a non-involved region of the limb (Figure 3.1a). At the wound edge,
a sharp drop in periostin immunoreactivity occurred, which was also evident in the
wound bed. CCN2 immunoreactivity was noted in the vasculature and epidermis of noninvolved and proximal skin. CCN2 was present in the dermis/granulation tissue at the
wound edge but was diminished within the wound bed. α-SMA immunoreactivity was
restricted to blood vessels and exocrine glands in the non-involved and proximal tissue.
At the wound edge, immunoreactivity was present in the blood vessels and dermis.
Within the wound bed, both vasculature and stromal immunoreactivity of α-SMA was
absent, indicating a lack of myofibroblast populations that would be expected within a
remodeling wound. Furthermore, the density of blood vessels (visualized by α-SMA) was
increased in proximal and wound edge tissue compared to non-involved skin. Masson’s
trichrome staining demonstrated a lack of collagen accumulation within the wound. A
semi-quantitative comparison of periostin and CCN2 staining on the proximal and distal
sides of the leading epithelial front (Figure 3.1b) confirmed that CCN2 was not increased
beyond the epithelial front (n = 14, p = 0.50, two-tailed paired t-test). The percentage of
area positively stained for periostin was significantly decreased distal to the leading
epithelial front, compared to the intact skin on the proximal side of the epithelial front (n
= 15, p = 0.0004, two-tailed paired t-test).
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Table 3.1: Patient samples and demographics
Sex

Age

Diabetic

Diagnosis

Location (amputation, wound location, cells obtained)

01

Male

74

No

PVD

Above knee, heel, wound cells

02

Female

79

No

PVD

Above knee, site of previous amp, wound cells

03

Male

34

Type One

Infection

Below knee, back of heel

04

Female

46

Type Two

PVD

Below knee, side of foot

05

Male

55

Type Two

PVD

Above knee, site of previous amp, wound cells

06

Male

70

Type Two

PVD

Below knee, side of foot, wound edge cells

07

Female

83

Type Two

PVD

Below knee, side of foot, wound edge cell

08

Male

65

Type Two

PVD

Above knee, side of calf

09

Male

78

Type Two

PVD

Foot amputated, sole of foot

10

Male

66

Type Two

PVD

Below knee, anterior ankle/foot

11

Male

56

Type Two

PVD

Below knee, previous toe amp

12

Male

86

Type Two

PVD

Below knee, base of big toe

13

Male

58

Type Two

PVD

Below knee, side of heel

14

Male

47

Type Two

PVD

Below knee, site of previous amp mid foot

15

Male

73

Type Two

PVD

Below knee, side of foot

16

Male

79

Type Two

PVD

Below knee, side of foot

17

Male

88

Type Two

PVD

Above knee, heel of foot, wound edge cells

18

Female

87

Type Two

PVD

Below knee, between toes, wound edge cells

PVD: Peripheral vascular disease
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Figure 3.1: Periostin and CCN2 are not induced in human chronic skin wounds.
Human chronic skin wound tissues were examined with (a) Masson’s trichrome for
collagen, IHC for periostin, α-SMA and CCN2 on sections from regions varying in
distance from the wound edge (top). The Proximal region is approximately 2 cm from the
wound edge. Scale bar = 200 µm. (b) To quantify periostin and CCN2 staining, images
were masked for background or empty space (yellow) and positive DAB staining (red).
Periodontal ligament (top), stained for periostin, is shown for illustration of the masking
technique. The area of each mask was recorded separately for the wound bed and the
intact tissue, demarcated by a vertical line at the leading edge of the epidermis (red
arrowheads). Percent tissue area positively stained was calculated as per Methods (n =
15, * = p < 0.001, red arrows indicate the median, paired t-test). (c) RNA was extracted
from human tissues and analysis of gene expression via RT-qPCR was carried out with
probes specific for POSTN, COL1A2, ACTA2 and CCN2, normalized to the endogenous
control gene, 18S. POSTN expression was significantly lower in wound edge tissue
compared to non-involved tissue (n = 10, p = 0.046, Friedman test). COL1A2, ACTA2
and CCN2 expression were not increased at the wound edge.
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Figure 3.1: Periostin and CCN2 are not induced in human chronic skin wounds
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To confirm our histological findings, we performed RT-qPCR on frozen human tissue
samples (Figure 3.1c). ACTA2 (n = 9, p = 0.28, Freidman test), COL1A2 (n = 10, p =
0.37, Freidman test) and CCN2 (n = 10, p = 0.32, Freidman test) transcripts showed a
downward trend with proximity to the wound, although not significantly decreased.
POSTN was significantly decreased at the wound edge, compared to non-involved tissue
(n = 10, p = 0.046, Friedman test).

3.2.2

Human Chronic skin wounds are stalled in an inflammatory
stage of wound healing

Previous studies with mouse models have shown that both periostin and CCN2 should be
significantly induced during skin healing (Igarashi et al., 1993; Elliott et al., 2012),
however, this was not evident in the human chronic skin wound tissue used in this study
(Figure 3.1). To understand why, we next investigated cellular components and
inflammatory mediators in the tissue samples. Immunoreactivity for TNFα, CD68
(macrophages) and neutrophil elastase all increased progressively with proximity to the
wound bed (Figure 3.2). The profibrotic cytokine, TGFβ (using a pan-specific antibody),
was detected at increasingly higher levels towards the wound bed. In non-involved skin
immunoreactivity for TGFβ, neutrophil elastase and CD68 was largely absent. In
addition, TNFα immunoreactivity remained present, albeit at much lower levels than in
the wound bed tissue. Vimentin, a marker for mesenchymal cells such as fibroblasts and
smooth muscle, was sparsely distributed throughout the dermis of non-involved and
proximal regions, with increased density near the dermal-epidermal junction and the
wound edge. Beyond the leading epithelial front there was a sharp decline in vimentinpositive cells, indicating a deficit in fibroblast infiltration into the wound bed. Periostin
was strongly associated with mesenchymal cells at the dermal-epidermal junction up until
the wound edge where periostin immunoreactivity abruptly declined (Figure 3.2). Small
populations of mesenchymal cells were found beyond the wound edge, however they
were not associated with periostin immunoreactivity.
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Figure 3.2: Human chronic skin wounds are stalled in an inflammatory stage of
wound healing. Human chronic skin wound tissues were examined with IHC for TNFα,
CD68 (macrophage marker, ED-1), neutrophils elastase, TGFβ1 and vimentin on sections
from regions varying in distance from the wound edge (top). The chronically inflamed
granulation tissue showed markers for macrophages and neutrophils. TGFβ1 was present
within the wound yet various fibrotic TGFβ1 target genes were not induced. Scale bar =
200 µm. Immunofluorescence for periostin and vimentin (bottom) was used to determine
the extent of mesenchymal cell infiltration beyond the wound edge. A population of
mesenchymal cells persisted beyond the wound edge but did not associate with periostin.
Relative spatial relationship of these images is indicated diagrammatically (top).
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Figure 3.2: Human chronic skin wounds are stalled in an inflammatory stage of
wound healing
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3.2.3

Fibroblasts isolated from human chronic skin wound tissue
can be induced to adopt a pro-fibrogenic phenotype

To determine if fibroblasts from human chronic skin wound tissue were inherently
dysfunctional we cultured fibroblasts from non-involved and wound tissue explants.
Initially, cells were grown from the wound tissue samples that spanned the proximal
region (Figure 3.3a). These cells responded to stimulation with TGFβ1 similarly to noninvolved fibroblasts (Figure 3.3a). Based on histological observations indicating that the
proximal tissue was very similar to non-involved skin (Figure 3.1a,b and 3.2) we chose to
focus our attention on fibroblasts cultured exclusively from the wound edge (Figure
3.3a).
Wound edge fibroblasts were more responsive to TGFβ1 with respect to POSTN (n = 4,
cell source p = 0.023, treatment p = 0.012, interaction p = 0.071, two-way ANOVA) and
ACTA2 (n = 4, cell source p = 0.047, treatment p = 0.0033, interaction p = 0.049, twoway ANOVA) induction, compared to non-involved fibroblasts (Figure 3.3b). TNFα
treatment depressed POSTN and ACTA2 expression in both non-involved and wound
edge fibroblasts. COL1A2 (n = 4, treatment p = 0.011, interaction p = 0.4734, two-way
ANOVA) and CCN2 (n = 4, cell source p = 0.71, treatment p = 0.0004, interaction p =
0.73, two-way ANOVA) gene expression was similarly affected by TGFβ1 and TNFα
stimulation between non-involved and wound edge fibroblasts. However, COL1A2
expression was reduced in wound edge, compared to non-involved fibroblasts (n = 4, cell
source p = 0.0001, two-way ANOVA). TNFα treatment attenuated the response to
TGFβ1.
We next compared wound edge fibroblasts to healthy adult human fibroblasts (HDFa)
(Figure 3.3c). POSTN, COL1A2 and CCN2 expression patterns in HDFa cells treated
with TGFβ1, TNFα, or both were similar to those of the wound edge cells. TGFβ1
increased expression of these genes and TNFα attenuated its effects (n = 3, p < 0.01, oneway ANOVA). ACTA2 expression was not increased in HDFa cells following TGFβ1
treatment, but instead was decreased (n = 3, p = 0.0001, one-way ANOVA). To confirm
that this decrease was not simply due to initial high basal expression levels, we
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performed the same experiments and measured α-SMA protein levels (Figure 3.3d).
Western blots confirmed the lack of α-SMA induction in HDFa cells and clearly
demonstrated that this was not a consequence of high basal expression (n = 4, cell source
p = 0.0004, two-way ANOVA).
Next, we conducted proliferation assays (Fig. 6c) comparing isolated fibroblasts to
HDFa. After 10 days in culture, HDFa cultures underwent 3.55 population doublings (n
= 3). Non-involved and wound fibroblasts (n = 4) underwent 4.09 and 4.11 population
doublings, respectively (cell source p = 0.0017, time p = 0.0001, interaction p = 0.91,
two-way ANOVA).
Finally, we sought to determine if isolated wound fibroblasts were capable of contracting
a collagen matrix. Non-involved and wound fibroblasts were similarly capable of
contracting a fixed matrix collagen gel. Treatment with TGFβ1 provided no additional
increase in gel contraction but treatment with TNFα was found to inhibit gel contraction
(Figure 3.3f). A combination of TGFβ1 and TNFα resulted in an intermediate level of
contraction (n = 4, cell source p = 0.76, treatment p = 0.0001, interaction p = 0.83, twoway repeated measure ANOVA). To determine if the degree of contraction was
comparable to healthy adult fibroblasts, we conducted similar assays with HDFa cells
(Figure 3.3g). HDFa (n = 3) cells contracted collagen gels to 65% of their original mass
(measured from gels lacking cells), whereas wound cells (n = 5) contracted gels to 39%
of their original mass. This difference was found to be significant (p = 0.034, two-tailed
t-test). From this series of experiments we concluded that wound fibroblasts were not
inherently dysfunctional.

3.2.4

Excisional wound healing in the genetically diabetic db/db
mouse closely mimics human chronic skin wounds

Based on defined role of periostin and CCN2 in the proliferative phase of wound healing
and their inappropriate expression patterns in human chronic skin wound tissue (Figure
3.1), we hypothesized that addition of rhPN and rhCCN2 could be used to push chronic
skin wounds into the proliferative phase (Figure 3.4a). To test the effectiveness of adding
rhPN and rhCCN2 to chronic skin wounds, we adopted the widely documented db/db
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Figure 3.3: Fibroblasts isolated from human chronic skin wound tissue can be
induced to adopt a pro-fibrogenic phenotype. (a) Human dermal fibroblasts were
cultured in vitro from skin samples near the site of amputation (non-involved) and an area
extending 2 cm from the wound boarder (wound). Alternatively, the source of cells was
restricted to the tissue directly at the wound edge (n = 4, * = p < 0.05 compared to noninvolved, two-way ANOVA). Cells wound tissue responded similarly to cells from noninvolved tissue, prompting a focus on wound edge cells. (b) Cells (P1) were treated with
5 ng/mL TGFβ1, 1 ng/mL TNFα or both for 24 hours. Quantitative RT-qPCR was
carried out with probes specific for POSTN, COL1A2, ACTA2 and CCN2. Data was
normalized to the endogenous control gene, 18S. COL1A2 expression at baseline was
reduced in cells cultured from the wound edge compared to cells cultured from noninvolved skin (# = p < 0.05, two-way ANOVA). For POSTN and ACTA2, cells harvested
from the wound edge were found to be more robust in response to TGFβ1 (* = p < 0.05).
Treatment with 1 ng/mL TNFα decreased POSTN expression and attenuated the response
to TGFβ1 for POSTN, COL1A2, ACTA2 and CCN2. (c) Adult healthy human dermal
fibroblasts were treated and assessed as above. Letters indicate statistically similar
treatments (n = 3, p < 0.05, one-way ANOVA). (d) Response of α-SMA to TGFβ1 was
confirmed at the protein level by western blot (n = 4). (e) Wound, non-involved and
healthy human dermal fibroblasts were assessed for proliferation. Wound edge and noninvolved fibroblasts were significantly more proliferative than healthy adult human
dermal fibroblasts (n = 4, p = 0.0017 for cell source, two-way ANOVA). (f) Cells (P1)
were assessed for their ability to contract a fixed matrix collagen gel. (g) Wound cells
contracted collagen gels to a further extent than healthy human dermal fibroblasts (n = 4,
p < 0.05, t-test).
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Figure 3.3: Fibroblasts isolated from human chronic skin wound tissue can be
induced to adopt a pro-fibrogenic phenotype
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Figure 3.4: Excisional wound healing in the genetically diabetic db/db mouse closely
mimics human chronic skin wounds. (a) Proposed treatment approach for human
chronic skin wounds using (b) electrospun collagen scaffolds containing rhPN or
rhCCN2. Scaffolds were cut to size and inserted into excisional wounds on the backs of
db/db mice and visualized via sulpho-rhodamine conjugation at day 1 post wounding.
Scale bar = 200 µm. (c) Mice homozygous for the Leprdb allele (db/db), on a C57BL/6
background were obese and hyperglycemic at 12 weeks of age (n = 10, * = p < 0.0001, ttest). (d) Adult wild-type (C57BL/6J) and db/db (B6.BKS(D)Leprdb/J) mice were
subjected to excisional cutaneous wounding and compared at day 7 to human chronic
skin wound samples. The expression pattern of periostin, α-SMA, collagen and TNFα in
db/db wounds closely mimicked that of human chronic skin wounds. Scale bar = 200 µm.
(e) Total RNA was extracted from wild-type and db/db full-thickness excisional punch
wounds at 7 and 11 days post wounding. Excised tissue was used for day 0 samples.
Quantitative RT-qPCR was carried out with probes specific for Postn, Col1a2, Acta2,
Ccn2 and Fn1. Data was normalized to the endogenous control gene, 18s. Compared to
wild-type mice, db/db mice show a failure to appropriately induce fibrotic genes during
wound healing (n = 5, # = p < 0.05 compared to day 0, * = p < 0.05 compared to wildtype, two-way ANOVA).
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Figure 3.4: Excisional wound healing in the genetically diabetic db/db mouse closely
mimics human chronic skin wounds
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mouse model of type-two diabetes and employed our previously described electrospun
collagen scaffold delivery mechanism (Figure 3.4b) (Elliott et al., 2012). Compared to
C57BL/6J control mice (wild-type), db/db mice quickly became obese (wild-type 25.0 g,
db/db 46.1 g at 12 weeks, n = 10, p = 0.0001, two-tailed t-test) and displayed an elevated
fasting blood glucose level (wild-type 8.59 mM, db/db 18.78 mM, n = 10, p = 0.0001,
two-tailed t-test) (Figure 3.4c). Day 7 wounds in db/db mice displayed lower periostin, αSMA and collagen, but increased TNFα, compared to wild-type wounds. Day 7 db/db
wounds closely resembled the histology of human chronic skin wounds with respect to
these proteins (Figure 3.4d). RT-qPCR analysis of day 7 db/db wounds revealed a failed
progression of the profibrotic phase of healing (Figure 3.4e).

3.2.5

Addition of recombinant human periostin or CCN2 increases
the closure rate of excisional skin wounds in db/db mice

Healing of full-thickness excisional punch wounds (Figure 3.5a) was substantially
delayed in db/db mice, compared to wild-type mice (Figure 3.5b). Addition of collagen
scaffolds to either wild-type or db/db wounds did not significantly change the closure
kinetics compared to untreated control wounds. Addition of scaffolds containing rhPN or
rhCCN2 resulted in a significant reduction in wound area size by day 5 post wounding,
and through to day 11 (time p = 0.0001, treatment p = 0.0001, interaction p = 0.0001,
two-way ANOVA) (Figure 3.5b). An analysis of day 7 wound area measurements shows
that collagen scaffolds alone did not affect closure rates in wild-type (n = 5) or in db/db
mice (n = 11) (Figure 3.5c). Treatment with PN-containing or CCN2-containing scaffolds
resulted in increased closure, similar to that in wild-type animals (n = 8, p = 0.0001, oneway ANOVA). Addition of one PN-containing scaffold and one CCN2-containing
scaffold to the same wound (PN+CCN2) resulted in increased closure over controls, but
not over PN or CCN2 alone (n = 6) (Figure 3.5c). At day 11, wound size was found to be
significantly smaller in PN- (p < 0.01), CCN2- (p < 0.05) and PN+CCN2-treated wounds
(p < 0.01) compared to control db/db wounds, as measured on tissue sections from the
centers of the wounds (n = 5, one-way ANOVA) (Figure 3.5d). Granulation tissue
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Figure 3.5: Addition of recombinant human periostin or CCN2 increases the closure
rate of excisional skin wounds in db/db mice. Fully thickness excisional punch wounds
were created in the skin of wild-type and db/db mice using a 6 mm biopsy tool. Wounds
received either no treatment (control), electrospun collagen scaffolds (Collagen, Col),
scaffolds containing rhPN (PN), scaffolds containing rhCCN2 (CCN2) or one scaffold of
each (PN+CCN2). A total of two scaffolds were added per wound. (a) Wound area was
assessed from photographs and expressed as a fraction of initial area. Scale bar = 10 mm.
(b) Quantification of wound area from photographs showed a recovery of wound closure
rates in the db/db wounds treated with PN, CCN2 or PN+CCN2. (c) At day 7, collagen
alone is not sufficient to increase closure rate. PN, CCN2 and PN + CCN2 treated
wounds exhibited accelerated healing. (d) At day 11, wound size measured from sections
of the centre of the wound was significantly reduced in PN, CCN2 and PN+CCN2 treated
wounds compared to db/db control wounds. Granulation tissue thickness was
significantly increased in day 11 PN+CCN2 treated wounds compared to db/db control
wounds. (e) Total RNA from the Collagen, PN, CCN2 and PN+CCN2 treated wounds of
3 db/db mice were used to generate cDNA, which was analyzed with Mouse Gene 2.0 ST
arrays. Gene Ontology (GO), KEGG Pathway and SwissProt and Protein Information
Resource (SP PIR) keyword enrichments were generated using DAVID Bioinformatics
Resources 6.7, NIAID/NIH. Enrichments were filtered by a p-value and the BenjaminiHochberg method was used to control for false discovery rate (FDR). (f) Differentially
expressed genes were filtered based on an ANOVA p-value of less than 0.05 and 1.5 fold
increase or decrease from db/db Collagen samples. (g) Genes that were differentially
expressed and occurred in highly enriched terms were used to verify gene array data via
RT-qPCR (n = 5).
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Figure 3.5: Addition of recombinant human periostin or CCN2 increases the closure
rate of excisional skin wounds in db/db mice
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thickness was significantly increased in PN+CCN2-treated wounds compared to db/db
control wounds, but not in either PN or CCN2 treatments (n = 5, p = 0.0087, one-way
ANOVA) (Figure 3.5d).
To investigate the mechanisms through which these scaffolds were influencing wound
healing, we isolated total RNA from wounds treated with collagen-only scaffolds, as well
as PN-treated, CCN2-treated and PN+CCN2-treated wounds. Total RNA from day 7
wounds was subjected to whole genome transcriptional analysis. Genes for which
expression levels changed by 1.5 fold (up or down, with a p-value ≤ 0.05) relative to
db/db collagen wounds were filtered and analyzed for enriched Gene Ontology, KEGG
Pathway and SwissProt and Protein Information Resource keywords (Figure 3.5e,
Appendices C and D). The number of differentially expressed genes in the PN-treated
wounds was 112 compared to the CCN2-treated wounds, where 535 genes changed
(Figure 3.5f). In the PN+CCN2-treated wounds, a large number of differentially regulated
genes were identified that were not identified in either PN- or CCN2-treated wounds
alone (375) (Figure 3.5f), suggesting some interaction or synergistic effect of the
combined treatment. Gene annotation analysis confirmed an enrichment of up-regulated
genes associated with contractile machinery in all treatments (Figure 3.5e), with further
enrichment still in PN+CCN2-treated wounds. Down-regulated gene lists were enriched
for protease inhibitor terms, with higher enrichments for PN-treated wounds (Figure
3.5e). A large number of genes that were differentially regulated in the PN or CCN2
treatments were lost from the PN+CCN2 list (Figure 3.5f), indicating a loss of some of
the effects of the singular treatments. Two such enrichments are the SP PIR Keyword
acute phase, up-regulated in the PN treatment, and down-regulation of the PPARγ KEGG
pathway with CCN2 treatment (Figure 3.5e). Genes that were differentially expressed
and occurred in highly enriched terms were selected to verify microarray data via RTqPCR (Figure. 3.5g). Actc1, Myh3, Fasl, Csf1 and Pparg were chosen based on their
relevance to tissue repair processes and were present in the most highly enriched terms
from various treatments.
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3.3

Discussion

The burden of chronic skin wounds is a large and growing concern for healthcare systems
around the world. However, development and implementation of new and effective
treatment options has not kept up. Most growth factor treatments have had limited
efficacy when tested in clinical trials and those that do have effects provide only a
moderate benefit (Hinchliffe et al., 2008; Game et al., 2012). Physical matrices, skin
substitutes and cell-based treatments (including stem cell therapies) can be extremely
costly but have thus far shown no competitive advantage for treatment of these skin
wounds. It is becoming widely recognized that combination approaches will become the
successes of the future and that single factor approaches simply do not address the
complexities of these chronic skin wounds. However, in designing these treatments,
matricellular proteins have not yet been included in the discussion. Matricellular proteins
are critically important in facilitating the profibrotic behaviours of cells and their
response to growth factors (Brekken and Sage, 2000; Garrett et al., 2004; Shi-wen et al.,
2006; Lorts et al., 2012). Inclusion of matricellular proteins in therapeutic design may
provide the missing links to facilitate growth factor signaling, cell differentiation and
other important steps in wound healing. Unfortunately, very little is known about the
expression and function of matricellular proteins in chronic skin wounds.
We demonstrate here that the matricellular proteins periostin and CCN2 are
inappropriately expressed in human chronic skin wounds. Studies in mice indicate that
both of these proteins should be induced by day 3 following wounding (Igarashi et al.,
1993; Elliott et al., 2012). Although CCN2 was not reduced at the wound edge compared
to non-involved tissue, it did not significantly increase either, as would be expected.
Interestingly, previous research has shown that CCN2 is reduced in venous ulcers of
greater than 6 month duration, compared to acute wounds of less than 6 weeks duration in
otherwise healthy adults (Minhas et al., 2011). Therefore, depending on the etiology of
the wounds, CCN2 may show different expression patterns but overall it is not upregulated as in acute mouse wounds. We observed an abrupt decrease in periostin
immunoreactivity at the wound edge, confirmed by RT-qPCR. Interestingly, periostin
transcript has been shown to be dramatically up-regulated in laser-captured blood vessels
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from the edge of chronic skin wounds, compared to blood vessels from intact human skin
(Roy et al., 2007). However, it is unclear from that study from exactly where, with
respect to the wound edge, the samples were obtained and how that compares to the
regions we describe surrounding the wound edge.
The underlying cause(s) for reduced expression levels of periostin and CCN2 in chronic
skin wounds are not currently known. We hypothesize that their expression pattern is a
consequence of the inflammatory state of these wounds. We detected increased markers
of inflammation beyond the wound edge, including neutrophil elastase, CD68 and TNFα.
This is in agreement with previous reports showing increased neutrophil elastase in
chronic compared with acute wound fluid (Trengove et al., 1999). Several groups have
documented elevated TNFα levels in chronic skin wound fluid (Wallace and Stacey,
1998; Trengove et al., 2000; Cowin et al., 2006). Furthermore, systemic anti-TNFα or
anti-macrophage treatments have been shown to rescue delayed wound closure in the
leptin deficient ob/ob mouse model of type-2 diabetes (Goren et al., 2007). The antifibrotic influence of TNFα is well documented, including a recent study demonstrating
its ability to inhibit periostin expression both in periodontal ligament and gingival
fibroblasts (Arancibia et al., 2013; Padial-Molina et al., 2013). We show that TNFα
suppresses periostin gene expression and attenuates TGFβ1 induction of periostin and
CCN2 in dermal fibroblasts, in vitro. These results may explain the pattern of periostin
and CCN2 expression found in human chronic skin wound edge and wound bed tissue.
However, based on its role in the normal immune response, inhibition of TNFα for the
treatment of chronic skin wounds is not an option (Wolbing et al., 2009).
An alternative explanation for the expression pattern of periostin and CCN2 (as well as
other fibrotic genes) is that the fibroblasts surrounding the chronic skin wound are
senescent and therefore inherently dysfunctional. There is considerable conflicting
evidence in the literature concerning the physiology of these wound edge fibroblasts.
Cultured chronic skin wound fibroblasts have been shown to produce less collagen, have
lower growth rates, reduced responses to PDGF-BB and TGFβ, reduced ability to
contract collagen gels and exhibit higher levels of the senescence marker SA-beta-Gal
(Telgenhoff and Shroot, 2005). Yet these indicators of senescence are highly dependent
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on where the fibroblasts were harvested from around the wound. Brem and colleagues
cultured fibroblasts from the edge of venous ulcers and compared those to fibroblasts
from adjacent skin (closer to the wound edge than our proximal region). They found that
wound edge cells migrated significantly slower and assumed a flattened polygonal
morphology typically associated with senescence (Brem et al., 2007). In a subsequent
study, they subdivided the wound edge into tissue removed during debridement and
tissue that remained after debridement. Fibroblasts were isolated from these tissues and
again assessed for morphology and migration (Brem et al., 2008). They found that wound
edge fibroblasts from the tissue remaining after debridement migrated faster in response
to GM-CSF and adopted a spindle shape. We have found that wound edge fibroblasts are
responsive to TGFβ1 and TNFα (significantly increased compared to non-involved
fibroblasts with respect to POSTN and ACTA2), and that they proliferate and contract
collagen gels significantly more than HDFa. From our data, and the work of others, we
hypothesize that fibroblasts from the open wound likely are few and exhibit senescent
qualities. The wound edge however seems to contain a population of fibroblasts that are
highly capable of up-regulating profibrotic genes and assuming a myofibroblastic
phenotype. The samples we collected likely spanned both wound edge regions described
by Brem and colleagues, and it is possible that that our populations represent an
enrichment of those fibroblasts that were able to migrate and proliferate quickly.
Nevertheless, those fibroblasts are a resource that should be harnessed in future treatment
designs.
Previous reports have documented dysregulation of other matricellular proteins in chronic
skin wounds, including thrombospondin 1, tenascin-X (Shih et al., 2012) and galectin-3
(Pepe et al., in press). However, to our knowledge the use of matricellular proteins as a
therapeutic for chronic skin wounds has never been previously investigated. We have
shown here that local delivery of rhPN and rhCCN2 electrospun with collagen are
potential therapeutics for the treatment of chronic skin wounds. Both periostin and CCN2
significantly increased would closure rates, an effect that could not be attributed to the
electrospun collagen scaffold vehicle alone. Although we only employed one dose of PN
and CCN2, these doses were carefully chosen to represent physiologically relevant
concentrations. Our scaffolds, cut to 8 mm disks, contained approximately 50 ng rhPN or
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25 ng rhCCN2 per disk. With two scaffolds per wound, treatments consisted of 100 ng
rhPN or 50 ng rhCCN2. Serum concentrations of periostin in patients with skin sclerosis
ranged from 95.6 to 146.8 ng/mL depending on the severity of the disease (Yamaguchi et
al., 2013). Using the same PN scaffolds, we have previously demonstrated a rescue of αSMA immunoreactivity in Postn-/- mouse wounds (Elliott et al., 2012). Others have used
a higher concentration of periostin (2 µg) to demonstrate therapeutic effects in Postn-/mice (Ontsuka et al., 2012), however such a high dose is not only expensive, it is on par
with that found in fibrotic pathologies such as Dupuytren’s contracture (Vi et al., 2009),
raising questions of safety. Serum concentrations of CCN2 in systemic sclerosis vary
considerably but their central tendency ranges from 42 to 83 ng/mL depending on
severity (Dziadzio et al., 2005). At 100 ng/cm2 CCN2 produced favourable outcomes in a
model of burn wound healing (Liu et al., 2007). Our 8 mm disks have a surface area of
0.503 cm2, representing a 100 ng/cm2 dose with 2 disks. For the combination treatment,
one scaffold of each was added to the wounds, thereby halving the dose of both PN and
CCN2.
At the doses of PN and CCN2 used in this study, we observed significant changes in gene
expression patterns, including robust enrichments of contractile gene sets. CCN2
produced a larger and very distinct list of differentially regulated genes compared to PN,
indicating that they function through different mechanisms despite their similar effects on
wound closure rate. PN had a strong influence on genes associated with early
inflammation, the defense response, and surprisingly, down-regulation of several genes
associated with protease inhibitors. It is not completely unexpected that periostin can
influence inflammatory processes. In models of allergic airway inflammation periostin is
up-regulated by IL-13 and periostin-deficiency leads to reduced eosinophil infiltration
and a bias towards type-1 helper T cell (Th1) cytokine profiles, including stimulation of
IFNγ (Blanchard et al., 2008; Sehra et al., 2011). Th1-type inflammation is associated
with cell death and tissue damage, whereas Th2-type inflammation is associated with
wound healing and fibrosis (Wynn, 2004). The balance between these profiles may be of
critical importance in understanding how increased inflammation can lead to the
divergent pathologies of both chronic skin wounds and fibrosis. In a model of allergy-
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induced atopic dermatitis fibroblast-derived periostin is not just induced by IL-13, a key
Th2 cytokine, it goes on to shift the cytokine profile towards a Th2 balance. Periostin does
this by stimulating keratinocytes to produce various Th2 cytokines but not the potent Th1
cytokine, IFNγ (Masuoka et al., 2012). In our microarray data we saw a modest but
statistically significant increase in IL-13 (1.2 fold) in all treatments. In the PN treatment
we saw reduced expression of the key inflammatory mediators FasL and Csf1. FasL is a
well-known inducer of apoptosis and is elevated in Th1 cells (Suda et al., 1995). Csf1 (MCSF) is an important modulator and chemoattractant for monocytes and macrophages. It
is curious that PN treatment did not induce α-SMA expression, as was the case in Postn-/mice (Elliott et al., 2012). It is possible that this is a consequence of the complex
inflammatory state of db/db wounds compared to Postn-/- wounds. Certainly elevated
TNFα could be the involved in this observation (Goldberg et al., 2007). Further research
is needed to sort through the specific interactions of periostin and the inflammatory cells,
but there is considerable evidence to suggest that periostin can be utilized as a modifier of
early inflammation in skin healing.
Addition of CCN2-containing scaffolds caused a down-regulation of a number of genes
associated with fatty acid synthesis, obesity and PPARγ signaling. PPARγ expression is
dramatically reduced in systemic sclerosis and its signaling directly apposes the
profibrotic actions of TGFβ. In dermal fibroblasts, TGFβ has been shown to reduce
PPARγ expression and block the PPARγ-dependent adipogenic differentiation of
mesenchymal cells (Wei et al., 2010). We did not see an up-regulation of TGFβ in our
microarray data despite the fact that CCN2 is an important downstream mediator of
TGFβ. It is possible that exogenously added CCN2 might act as a surrogate for TGFβ
with respect to PPARγ regulation. When CCN2- and PN-containing scaffolds were
combined in the same wound, a pattern of differential gene expression was observed
which included a large number of genes that were not changed in either of the individual
treatments, indicating a synergistic effect of PN and CCN2 delivery. Granulation tissue
thickness also increased significantly more with the combined treatment than with either
individual treatment. Conversely, a large number of genes that were differentially
expressed in the individual treatments were lost in the presence of the combination
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scaffold. The likely explanation for this is that halving the dose of both PN and CCN2
meant their individual effects were diminished. Future work should include higher doses
of PN and CCN2 in the combined treatments to determine if all of these effects can be
preserved. Still, many of the gene clusters enriched in the individual treatments were
further enriched in the combination treatment, including those associated with contractile
machinery.
With the diversity of roles matricellular proteins play in a multitude of tissues,
developing them into effective treatment options for chronic skin wounds will require
additional research. Unraveling the context-dependent nature of their functions is a
challenge in itself. In this report we have shown that periostin and CCN2, two
matricellular proteins intimately tied to fibrosis, are reduced in human chronic skin
wounds that are stalled in an inflammatory state. We attribute this to the environment of
the chronic skin wound, as fibroblasts removed from that environment express both
periostin and CCN2, and exhibit a myofibroblast phenotype in response to TGFβ1.
Addition of periostin or CCN2 to a model of impaired diabetic healing via a biologically
compatible collagen scaffold resulted in recovery of wound closure. The mechanisms
employed by PN and CCN2 were largely distinct but by combining both treatments in the
same wound we saw a synergistic effect. We believe this to be the first account of
matricellular proteins being used to aid in the closure of chronic skin wounds. Based on
their apparent biological functions, it will be of great interest to further explore
combination treatments of various matricellular proteins with other established
therapeutics, such as growth factors. The outcome of TGFβ signaling has been shown to
depend on both periostin and CCN2, where deletion of these proteins attenuates or
redirects TGFβ-induced cell behaviours (Garrett et al., 2004; Shi-wen et al., 2006; Lorts
et al., 2012). Reduced matricellular protein expression might be why clinical trials of
TGFβ treatment did not work. More work is needed to confirm this.
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3.4
3.4.1

Materials and Methods
Human Skin Sample Collection

Procedures involving human tissue were approved by the University of Western Ontario
Review Board for Health Sciences Research Involving Human Subjects and are in
accordance with the 1964 Declaration of Helsinki. Skin samples were obtained with
informed consent from patients exhibiting non-healing skin wounds and undergoing
elective lower extremity amputation for the affected limb (Table 3.1). Eighteen patients
were enrolled with a median age of 71.5 years (ranging from 34 to 88). Of these, four
were female. The majority of patients were type-two diabetic (n = 15) and one was typeone diabetic. Diagnosis of the patients’ condition was almost exclusively peripheral
vascular disease, making it likely that the samples collected were representative of
arterial wounds. Sets of skin samples were collected from the wound site as well as from
a non-involved region of the limb (Figure 3.1). At each site, samples were collected for
histology, RNA isolation and cell culture, which were immersed in 10% neutral buffered
formalin (Sigma Aldrich, St. Louis, Missouri), RNAlater® (Ambion, Carlsbad,
California) or growth media, respectively, until they could be further processed. For
RNA, tissues were snap frozen in liquid nitrogen and stored at -86°C. To culture human
dermal fibroblasts, tissue samples were washed extensively in Dulbecco’s Modified
Eagle Medium (High Glucose) supplemented with 10% fetal bovine serum and 2% AA
(200 units penicillin/200 µg streptomycin/0.5 µg/mL amphotericin B) (Gibco, Carlsbad,
California). Skin was then incubated at 37°C, 5% CO2 to allow fibroblasts to migrate
onto the culture surface. For use, skin was removed and cells were cultured for two to
three passages. Healthy adult human fibroblasts (HDFa) were from a commercial source
(C-013-5C, Invitrogen, Carlsbad, California).

3.4.2

Tissue Preparation and Immunohistochemistry

Tissues were processed to paraffin and sectioned at 5 µm. Tissue sections were stained as
previously described (Jackson-Boeters et al., 2009). Sections were blocked with 10%
horse serum followed by primary antibody overnight at 4°C (Table 3.2). Detection was
by ImmPRESS Ig peroxidase kits (Vector Laboratories, Burlingame, California) and
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visualized

with

3,3-diaminobenzidine

(Vector

Laboratories).

Sections

were

counterstained with haematoxylin. Trichrome staining was carried out as previously
described (Liu et al., 2008). To quantify periostin and CCN2 staining, slides were stained
in one batch and photographed at low magnification with identical exposure settings.
Images were masked for background/empty space (yellow) and positive DAB staining
(red) in Image Pro Plus v7.0 (Media Cybernetics Inc., Rockville, Maryland). The same
masking parameters were then applied to all images. The area occupied by these masks
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Table 3.2: Antibodies and dilutions used in this study
Target

Product #

Dilution

Antigen
Retrieval

Supplier

Periostin

sc49480

1/200

No

Santa Cruz Biotechnology, Santa
Cruz, CA

α-Smooth Muscle Actin (IHC-P)

ab5694

1/100

No

Abcam plc, Cambridge, UK

α-Smooth Muscle Actin (WB, IF)

A5228

1/500

No

Sigma Aldrich, St. Louis, MO

CCN2

ab6992

1/100

No

Abcam plc, Cambridge, UK

TNF-α

ab6671

1/200

Heat Mediated

Abcam plc, Cambridge, UK

CD68

MCA1957

1/200

Heat Mediated

AbD Serotec, Oxford, UK

Neutrophil Elastase

ab68672

1/2000

Heat Mediated

Abcam plc, Cambridge, UK

TGF-β

ab66043

1/100

Heat Mediated

Abcam plc, Cambridge, UK

Vimentin

ab92547

1/400

No

Abcam plc, Cambridge, UK

GAPDH

MAB374

1/1000

No

Millipore, Billerica, MA
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was recorded separately for the wound bed and the intact tissue, demarcated by a
verticalline at the leading edge of the epidermis. Percent positively stained tissue area
was calculated as:
% = [Area of red mask/(area selected – area of yellow mask)] x 100
Immunofluorescent labeling of human tissue was carried out as above except detection
was

with

appropriate

fluorescently

labeled

secondary

antibodies

(Jackson

ImmunoReaserch, West Grove, Philadelphia). Granulation tissue thickness and wound
size were measured from images of sections from the centre of the wounds using Image
Pro Plus v7.0.

3.4.3

RT-qPCR

Pieces of snap frozen tissue samples were homogenized in 1 mL of TRIzol® reagent
(Invitrogen). Total RNA was extracted as per the manufacture’s recommendations. Realtime quantitative PCR was carried out on 50 ng of total RNA using TaqMan® One-Step
RT-PCR Master Mix and gene-specific TaqMan® probes (Applied Biosystems, Carlsbad,
California). Gene expression was normalized to the endogenous control gene, 18S. PCR
efficiency was verified to fall between 90 and 110%, via dilution series, and relative
expression was calculated using the ΔΔCT method (Livak and Schmittgen, 2001).

3.4.4

In Vitro Gene Expression and Western Blotting

Primary human dermal fibroblasts (P2-3) were seeded at 30,000 cells/well in 6 well plates.
24 hours prior to treatment, cells were starved in serum free media. Treatment was with 5
ng/mL TGFβ1 (R&D Systems Inc., Minneapolis, Minnesota), 1 ng/mL TNFα (R&D
Systems) or both for 24 hours in serum free media. RNA was harvested with 1 mL of
TRIzol® reagent (Invitrogen). Protein was with RIPA buffer containing protease and
phosphatase inhibitor cocktails (Sigma Aldrich), and concentration was determined by
BCA assay (Pierce, Waltham, Massachusetts). Proteins were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
nitrocellulose membranes. Membranes were washed with tris-buffered saline containing
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0.05% tween-20 (TBST). Membranes were blocked with 5% milk TBST. Unequal
loading was controlled for with GAPDH (Millipore, Billerica, Massachusetts). Detection
was

with

appropriate

peroxidase-conjugated

secondary

antibodies

(Jackson

ImmunoResearch) and enhanced chemiluminescence (Pierce). Bands were quantified
using Image J software.

3.4.5

Proliferation

Primary human dermal fibroblasts were seeded at 2,000 cells/well in 24 well plates in
10% FBS supplemented media. Media was changed every 48 hours throughout the course
of the experiments. At the desired time-points, media was completely aspirated and the
plate was frozen at -86°C. Once all time-points were captured, the CyQUANT cell
proliferation assay kit (Invitrogen) was used to determine cell number as per the
manufacturer’s protocol. A standard curve was used to obtain cell number. Cell number
was transformed to a Log2 scale to calculate population doublings.

3.4.6

Gel Contraction

Gel contraction assays were conducted essentially as previously described (Shi-wen et
al., 2004; Elliott et al., 2012). Collagen was prepared as follows: 10% 0.2 M HEPES (pH
8), 40% bovine collagen type-1 (Advanced BioMatrix Inc., San Diego, California) and
50% 2X Dulbecco’s Modified Eagle Medium (High Glucose). Dermal fibroblasts were
suspended in 0.5% FBS DMEM and mixed 1:1 with the collagen preparation to a final
density of 100,000 cells/mL. 24 well tissue culture plates were pre-coated with BSA
overnight then washed with PBS. Collagen/cell mix (0.5 mL) was added to each well and
allowed to set at 37°C. Following polymerization, wells were flooded with 1 mL 0.5%
FBS DMEM. After 24 hours, gels were separated from the surface of the plate and
incubated for an additional 24 hours. To ensure that contraction of gels horizontally and
vertically was accounted for, quantification of gel contraction was assessed by loss of gel
weight, whereby contraction of the collagen matrix excluded growth media, thus
reducing the weight of the gel (Tingstrom et al., 1992).

140

3.4.7

Scaffolds

Collagen type-1 (Sigma-Aldrich) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol to
make a 15% (w/v) solution. Recombinant hPN (R&D Systems) was dissolved in PBS to
make a 1 mg/mL solution. Twenty µL of the periostin solution was mixed with 20 µL
BSA solution (100 mg/mL in PBS) and 3 mL of collagen solution. The mixture was
injected at a speed of 1 mL/h by a syringe pump into a capillary charged with a voltage of
+15 kV. The generated nanofibers were collected on a negatively charged (-10 kV)
rotation mandrel. Control scaffolds contained 20 µL of PBS. To crosslink the scaffolds,
they were immersed in 5% glutaraldehyde/ethanol solution for 30 min. Scaffolds were
spun onto aluminum foil, and an 8 mm biopsy punch was used to cut the scaffolds. Each
scaffold was sterilized in 100% ethanol and rinsed 3 times with PBS. The fabrication
conditions for CCN2 scaffolds were the same except that the rhCCN2 (R&D Systems)
solution was 0.5 mg/mL.

3.4.8

Electron Microscopy

Collagen scaffolds were mounted on 15 mm SEM stubs with adhesive disks and were
then sputter coated with palladium-gold for 5 minutes at 8 mV using a Hummer VI
sputter coater (Anantech Ltd., Battle Creek, Michigan). Images were obtained with a
3400-N Variable Pressure Scanning Electron Microscope (Hitachi Ltd., Tokyo, Japan)
using an accelerating voltage of 10 kV.

3.4.9

Animals

All animal procedures were in accordance with protocols approved by the University
Council on Animal Care at The University of Western Ontario. Wild-type C57BL/6J
(000664, JAX® Mice and Services, Bar Harbor, Maine) and genetically diabetic db/db
(B6.BKS(D)Leprdb/J, 000697, JAX®) mice were housed in conventional caging and
provided water and food ad libitum. All animals were subjected to 12 h light/dark cycle
and temperature in accordance with the guidelines of the Canadian Council on Animal
Care. For experiments, wild-type and db/db sex-matched adult mice (12 weeks of age)
were anesthetized with an intraperitoneal injection of buprenorphine (50 µg/kg), followed
by an injection of ketamine (100 mg/kg) and xylazine (5 mg/kg). Backs were shaved,
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depilated and sterilized with iodine. Full-thickness excisional wounds were made on each
side of the dorsal midline with a 6 mm punch biopsy. Removed tissue was considered day
0 and was retained for RNA analysis. Some wounds were left untreated as controls while
others received: 2 x collagen, 2 x rhPN-containing (PN), 2 x rhCCN2-containing (CCN2)
or 1 x rhPN- and 1 x rhCCN2-containing (PN+CCN2) scaffolds. Eight mm diameter
scaffolds were inserted into each wound immediately following wounding. The larger 8
mm scaffolds aided in retention of the scaffolds within the wound by partially slipping
under the surrounding skin. Wounds were photographed immediately after wounding and
again at 3, 5, 7, 9 and 11 days post wounding. Wound area was assessed from
photographs using Northern Eclipse v7.0 software (Empix Imaging Inc., Mississauga,
Ontario) and expressed as a fraction of initial area. Mice were caged individually
following wounding.

3.4.10

Blood Glucose

Animals were euthanized following 4 hours of fasting. Blood was collected via cardiac
puncture and glucose was measured using a OneTouch® Ultra®2 blood glucose
monitoring system (LifeScan, Inc., Milpitas, California).

3.4.11

Microarray

Total RNA from the Collagen-, PN-, CCN2- and PN+CCN2-treated wounds of 3 db/db
mice and Collagen-treated wounds were used to generate cDNA. All sample labeling and
GeneChip processing was performed at the London Regional Genomics Centre (Robarts
Research Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto,
California) and the RNA 6000 Nano kit (Caliper Life Sciences, Mountain View,
California). Single stranded complimentary DNA (sscDNA) was prepared from 200 ng of
total RNA as per the Ambion WT Expression Kit for Affymetrix GeneChip Whole
Transcript WT Expression Arrays (Applied Biosystems) and the Affymetrix GeneChip
WT Terminal Labeling kit and Hybridization (Affymetrix, Santa Clara, California).
Total RNA was first converted to cDNA, followed by in vitro transcription to make
cRNA. Single stranded cDNA (5.5 µg) was synthesized, end labeled and hybridized for
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16 hours at 45°C to Mouse Gene 2.0 ST arrays. A GeneChip Fluidics Station 450
performed all liquid handling steps and GeneChips were scanned with the GeneChip
Scanner 3000 7G (Affymetrix) using Command Console v3.2.4. Probe level (.CEL file).
Data were summarized to gene level data in Partek Genomics Suite v6.6 (Partek, St.
Louis, MO) using the RMA algorithm (Irizarry et al., 2003). Partek was used to
determine gene level ANOVA p-values and fold changes. Gene Ontology (GO), KEGG
Pathway and SwissProt and Protein Information Resource (SP PIR) keyword enrichments
were generated using DAVID Bioinformatics Resources 6.7, NIAID/NIH (Huang da et
al., 2009b; Huang da et al., 2009a). Enrichments were filtered by p-value and the
Benjamini-Hochberg method was used to control for false discovery rate (FDR).
Differentially expressed genes were selected based on an ANOVA p-value of less than
0.05 and 1.5 fold increase or decrease from db/db Collagen samples.

3.4.12

Statistical Methods

Statistical analysis was by Graphpad Software v4 (Graphpad Software, La Jolla,
California) (p ≤ 0.05 was considered significant). Normality was assessed with the
Kolmogorov–Smirnov test where sufficient replicates allowed. Unless stated otherwise
data was found to be normally distributed. Two-tailed t-tests were used for periostin and
CCN2 tissue staining quantification (paired) and for blood glucose measurements
(unpaired). In vivo human tissue gene expression data was not normally distributed so the
non-parametric paired Friedman test with a Dunn’s multiple comparisons test was
applied. A one-way ANOVA followed by a Bonferroni correction was used to analyze
HDFa in vitro gene expression data. Comparative gene expression, protein expression
and proliferation analysis of isolated non-involved and wound fibroblasts (and HDFa), as
well as in vitro mouse wound gene expression were assessed with a two-way ANOVA
followed by a Bonferroni correction. Gel contraction data was analyzed with a repeated
measure two-way ANOVA for comparison of non-involved vs. wound cells (followed by
Bonferroni correction), a two-tailed t-test was used to compare wound cells to HDFa.
Wound closure kinetics in mouse punch wounds were analyzed with a two-way ANOVA
(with Bonferroni correction). Wound size and granulation tissue thickness were analyzed
with a one-way ANOVA (with Bonferroni correction).
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Chapter 4

4

Discussion

The overall research focus of this thesis was to investigate the specific roles of two
matricellular proteins in skin pathology and the wound healing process, and to determine
if local delivery of these proteins could be used as novel therapeutics for enhancing
wound healing. Specifically, the focus was on periostin and CCN2, matricellular proteins
that are associated with many types of tissue fibrosis, including hypertrophic and keloid
scarring of the skin. In fibrotic conditions, periostin and CCN2 have been shown to
regulate

cellular

processes

associated

with

matrix

accumulation,

increased

myofibroblastic phenotype and increased profibrotic growth factor signaling; all of which
are reduced in chronic skin wounds. The role of CCN2 in skin healing had been
previously documented, but it was necessary to identify the specific molecular roles of
periostin in skin healing.
The specific objectives of this project were:
1. To determine how genetic deletion of periostin alters dermal wound healing
kinetics and the underlying changes in regulation of dermal and epithelial
behaviours.
2. To determine mRNA and protein expression patterns of periostin and CCN2 in
human chronic skin wound tissue.
3. To quantify the phenotypic response of human chronic skin wound fibroblasts by
exogenous TGFβ and TNFα.
4. To assess the efficacy of local delivery of periostin and CCN2 containing
electrospun scaffolds as a therapeutic for enhancing wound healing using a
diabetic murine model.
The results from objective one are documented in Chapter 2. In summary, deletion of
periostin resulted in a delay in wound closure rate, which coincided with peak periostin
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expression in wild-type animals. Delayed closure was attributed to a defect in
myofibroblast differentiation based on failed α-SMA induction in vivo and a
compromised myofibroblast phenotype in vitro. Addition of rhPN to Postn-/- wounds
recovered α-SMA immunoreactivity, demonstrating potential for the delivery of
extracellular periostin to dermal wounds to modulate fibroblast function.
Objectives two, three and four are presented in Chapter 3. In human chronic skin wound
tissue, CCN2 was not increased compared to non-involved skin and periostin was
significantly reduced within the wound. Inappropriate expression of these matricellular
proteins may be a result of the inflammatory environment of the wounds, since
fibroblasts isolated from wound tissue, and therefore removed from that environment,
were able to respond to TGFβ, proliferate and contract collagen gels. Furthermore, the
proinflammatory cytokine TNFα, which was abundant in the wound tissue, suppressed
induction of periostin and CCN2 in human dermal chronic skin wound fibroblasts,
supporting the contention that the wound environment was responsible for reduced
periostin and CCN2.
The expression patterns of periostin and CCN2 in human chronic skin wounds, combined
with the fibrotic potential of wound edge fibroblasts, indicated that delivering these
proteins as therapeutics designed to recruit fibroblasts and induce their differentiation
might be beneficial for would healing. Delivery of rhPN and rhCCN2 electrospun with
collagen to dermal wounds in a mouse model of impaired diabetic skin healing resulted in
rescue of wound closure to rates similar to wild-type mice. Whole genome transcriptional
analysis indicated that the two proteins functioned through distinct mechanisms. A
combination of the rhPN- and rhCCN2-containing scaffolds added to a single wound
showed synergistic effects in gene expression changes, and also showed up-regulation of
additional genes neither protein did on their own. This work represents the first
matricellular protein-based biomaterial therapeutic designed with an aim to enhance
chronic skin wound healing.
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4.1
Periostin and wound healing in skin: a multifaceted player?
This section contains excerpts modified from our published work (Appendix E):
Elliott. C.G., Kim, S.S., and Hamilton, D.W. (2012) Functional Significance of Periostin
in Excisional Wound Healing: Is the Devil in the Detail? Cell Adh Migr. 6(4): 319-26
Although originally implicated in skin healing in 2005 (Lindner et al., 2005), the first
report describing the impact of periostin deletion on healing was not described until 2011.
Within one year, three independent papers were published describing potential roles for
periostin in dermal wound healing from experiments performed using different
derivations of periostin knockout mice (Postn-/-). Beginning with Nishiyama and
colleagues (Nishiyama et al., 2011), followed by our report (Elliott et al., 2012b) and
finally Ontsuka et al (Ontsuka et al., 2012), all three independent studies confirm that
periostin is significantly up-regulated following dermal wounding in mice, peaking at day
7. In normal skin periostin is localized at the dermal-epidermal junction (DEJ) and in hair
follicles. Following excisional wounding in Postn+/+ mice, periostin is predominantly
expressed in the granulation tissue and in neighboring hair follicles. The absence of
periostin results in delayed wound healing, which is most pronounced between days 3
and 7. The similarities in the studies begin to diverge, however, when we begin to look at
the underlying mechanisms proposed by each of these reports (Table 4.1). The three
studies proposed three very different mechanisms to explain the delay in Postn-/- wound
healing, each supported by in vitro evidence.
It is surprising that three independent groups could come up with three divergent
accounts of how the deletion of periostin resulted in delayed wound healing. The
relevance of each proposed mechanism (contraction, keratinocyte proliferation and
fibroblast migration/proliferation) to the in vivo wound healing phenotype is debatable.
But the in vitro results are not and there is certainly support in the literature for each
proposed cellular mechanism individually (Table 4.2). The differences were likely a
consequence of the experimental variables between each study (discussed below). The
diversity of cellular behaviours affected by the presence of periostin can serve as a lesson
for the importance of the context dependent nature of matricellular protein influence in

152

Table 4.1: Major findings from three reports on skin healing in Postn-/- mice
Elliott et al 2012

Nishiyama et al 2011

Ontsuka et al 2012

Wound Model

6 mm punch biopsy

3 mm punch biopsy

8 mm or 10 mm punch biopsy

Main Effect

KO delay at D5 and D7

KO delay at D3, D5 and D7

KO delay at D3, D5, D7 and
D11

Proposed In
vivo Cause

Myofibroblast differentiation

Re-epithelialization via
keratinocyte proliferation

Fibroblast proliferation and
migration

In vivo
Evidence

Reduced α-smooth muscle actin
gene expression and
immunoreactivity in KO

Measurements from H&E
stained sections

No data

Adult KO fibroblasts showed
reduced:

No data

In vitro
Support

Reduced Ki-67
immunoreactivity around KO
hair follicles

Force generation,

Newborn KO fibroblasts show
reduced proliferation
KO MEFs show reduced
migration

Collagen gel contraction,
α-smooth muscle actin
immunofluorescence,
α-smooth muscle actin protein
Rescue Tool(s)
(in vitro)

Recombinant full-length human
periostin (R&D systems)
produced in a mouse myeloma
cell line (NS0)

Expression vector for mouse
periostin

Recombinant full-length
mouse periostin (R&D
systems) produced in an insect
ovarian cell line (Sf21)
Expression vector for fulllength mouse periostin

Rescue?
(in vitro)

Adult KO fibroblasts showed
restored:
Collagen gel contraction,
α-smooth muscle actin staining,
α-smooth muscle actin protein.

Conflicting results:
Over-expression of Ms Postn
in human keratinocyte cell line
(HaCaT) resulted in no
difference in cell number
when cultured for 96 hours.

Proliferation of newborn
mouse fibroblasts (vector and
recombinant)
Proliferation of normal human
dermal fibroblasts
(recombinant)

(Force generation not tested for
rescue)

However, the same cells
cultured for one week beyond
confluence showed an increase
in BrdU labelling.

Rescue Tool
(in vivo)

Recombinant full-length human
periostin (R&D systems)
incorporated into an electrospun
collagen scaffold

No in vivo rescue

Recombinant full-length
mouse periostin (R&D
systems) added directly onto
wounds

Rescue?
(in vivo)

Increased α-smooth muscle
actin immunoreactivity at D7

No in vivo rescue

Restored wound closure
kinetics
No evidence for mechanism

No wound closure kinetics
Additional
Findings

No difference in fibroblast
migration
No difference in reepithelialization

Similar Ki-67 numbers in
granulation tissue and
migrating keratinocytes
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Table 4.2: Evidence from the literature supports all three mechanisms
Myofibroblast

Proliferation

Migration

Shimazaki 2008: Postn mice had an
increased incidence of ventricular
rupture following myocardial infarction
due to reduced α-SMA positive cells
and impaired collagen formation
(Shimazaki et al., 2008).

Ben 2011: Transfection of pancreatic
cancer cell lines (BxPC-3 and Panc1) with a periostin expression vector
(Ad5-PN) promoted anchorageindependent growth (Ben et al.,
2011).

Shimazaki 2008: Recombinant
periostin (ΔbΔe splice variant)
enhanced chemotaxis of cardiac
fibroblasts from Postn-/- mice. This
increase was attenuated by an antiperiostin antibody (Shimazaki et
al., 2008).

Erkan 2007: Addition of rhPN to
pancreatic stellate cells resulted in
increased expression of α-SMA,
collagen 1, fibronectin, TGFβ1 and
periostin. Silencing periostin decreased
α-SMA expression (Erkan et al., 2007).

Erkan 2007: Under serum
deprivation, rhPN stimulated growth
of Panc1, SU86.86, and T3M3
(pancreatic cancer cell lines) (Erkan
et al., 2007).

Ben 2011: Cells (BxPC-3 or Panc1) infected with Ad5-PN migrated
and invaded faster than controls in
transwell assays (Ben et al., 2011).

Vi 2009: Fibroblasts isolated from
Dupuytren’s disease (DD) overexpressed periostin and had an
increased ability to contract a collagen
matrix, which was further enhanced by
addition of rhPN. DD cells in 3D
culture induced α-SMA in response to
rhPN (Vi et al., 2009).

Vi 2009: Growth on rhPN coated
plates resulted in an increase in
proliferation of palmar fascia
fibroblasts (Vi et al., 2009).

Sidhu 2010: Transfection of bronchial
epithelial cells (BEAS2B) with a rhPN
expression vector resulted in increased
α-SMA protein and mRNA (Sidhu et
al., 2010).

Liu 2011: Periostin-silenced gastric
cancer cells exhibited reduced cell
proliferation (Liu and Liu, 2011).

Bozyk 2012: Hyperoxia exposure
increased α-SMA positive
myofibroblasts in the lungs of Postn+/+,
but not Postn-/-, mice (Bozyk et al.,
2012).

Bozyk 2012: Periostin induced
human mesenchymal stromal cell
DNA synthesis in the presence of
TGFβ1 (Bozyk et al., 2012).

-/-

Liu 2011: Periostin-silenced
gastric cancer cells exhibited
reduced invasion using a Boyden
chamber invasion assay (Liu and
Liu, 2011).

Bozyk 2012: Periostin treatment
increased α-SMA expression in
neonatal lung mesenchymal stromal
cells (Bozyk et al., 2012).
Hakuno 2010: High fat diet-induced αSMA in cardiac valve complexes is
attenuated in Postn-/- mice (Hakuno et
al., 2010).

Kuhn 2007: rhPN induced
proliferation of neonatal
cardiomyocytes in a PI3K/Akt
dependent manner. Injecting rhPN
into the myocardium induced DNA
synthesis and division of nearby
differentiated cardiomyocytes (Kuhn
et al., 2007).

Hakuno 2010: Conditioned media
from periostin transfected cells
increased migration of human
coronary artery endothelial cells
(Hakuno et al., 2010).

Yoshida 2011: Silencing of periostin
splice variant III attenuated TGFβ2
induced α-SMA production in primary
human retinal pigment epithelial cells
(Yoshida et al., 2011).

Zhu 2011: Neutralizing monoclonal
antibody to periostin inhibited
anchorage-independent growth of the
periostin-expressing ovarian cancer
cell line A2780 (Zhu et al., 2011).

Zhu 2011: Neutralizing
monoclonal antibody to periostin
inhibited periostin-induced cancer
cell migration and invasion (Zhu et
al., 2011).
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Table 4.2: Evidence from the literature supports all three mechanisms, continued
Myofibroblast

Proliferation

Migration

Jackson-Boeters 2009: Periostin
expression coincides with α-SMA
expression within the granulation tissue
of excisional wounds of mice (JacksonBoeters et al., 2009).

Liu 2010: Inhibition of periostin
expression via RNA interference
suppressed proliferation of a human
osteosarcoma cell line (U2OS) (Liu
et al., 2010).

Liu 2010: Inhibition of periostin
gene expression via RNA
interference suppressed migration
and invasion of U2OS cells in
transwell assays (Liu et al., 2010).

Lindner 2005: Acquisition of a smooth
muscle cell phenotype (α-SMA
expression) correlated with acquisition
of periostin expression both in vitro and
in vivo (Lindner et al., 2005).

Yan 2006: Mice that received
periostin-producing 293T cells at the
mammalian fat pad tissue had
significantly larger local tumours
than did mice receiving control cells
(Yan and Shao, 2006).

Lindner 2005: Periostin overexpressing C3H10T1/2 cells had
greater migratory response to
serum, which was attenuated by a
periostin-blocking antibody
(Lindner et al., 2005).

Hong 2010: Periostin over-expressing
A549 cells expressed higher levels of
vimentin mRNA (Hong et al., 2010).

Hong 2010: Periostin overexpressing A549 cells displayed
increased proliferation (Hong et al.,
2010).

Hong 2010: Periostin overexpressing A549 cells migrated
and closed scratch wounds at an
increased rate (Hong et al., 2010).

Kikuchi 2008: Close approximation of
periostin immunoreactivity to α-SMA
positive cells (periocryptal fibroblast) in
normal colonic mucosa. Decreased
periostin immunoreactivity preceded a
decrease of α-SMA positive cells
(Kikuchi et al., 2008).

Kikuchi 2008: Ki-67–positive
epithelial cells were significantly
decreased in the colonic crypts of
Postn-/- mice (Kikuchi et al., 2008).

Yan 2006: Using transwell assays,
significantly more periostinexpressing 293T cells migrated
into the membrane relative to
control cells (Yan and Shao, 2006).
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general. For example, we did not detect a difference in migration (Figure 2.6) or
proliferation (Elliott et al., 2012a) between Postn+/+ and Postn-/- adult dermal fibroblasts.
Ontsuka reported significantly reduced proliferation in newborn Postn-/- fibroblasts and
significantly reduced migration in Postn-/- mouse embryonic fibroblasts (MEF),
compared to their respective Postn+/+ controls. We attributed these discrepancies to the
use of adult vs. embryonic or newborn cells (Table 4.1).
We have previously reported that periostin expression/localization is very different in
developing and newborn mouse skin when compared to that of skin in the adult animal
(Zhou et al., 2010). From embryonic day 13.5 forward, periostin is expressed in the
developing skin. At 2 and 9 days old, periostin is heavily expressed at the dermal
epidermal junction (DEJ) and in the dermis of the newborn skin. This pattern changes
dramatically by day 19 where periostin expression in the dermis is largely absent. By day
60, periostin is restricted to hair follicles and the DEJ, although at a reduced level.
Perhaps the role of periostin in development, and thus newborn fibroblasts or MEFs, is
vastly different from its role in adult skin and the residing dermal fibroblast. If this is true
then we must be careful when choosing our in vitro tools to confirm in vivo findings. To
emphasize this, we have shown that in 2D culture Postn-/- fibroblasts do differentiate into
myofibroblasts and it is only when the substrate rigidity is reduced (Figure 2.11) or 3D
culture employed (Figure 2.8 and 2.10), that the periostin deficiency and loss of the
myofibroblast phenotype manifests in knockout cells.
Deletion of periostin consistently resulted in delayed wound healing across the three
studies. But in vitro explanations for this are difficult to interpret due to the use of
different tools and differing experimental designs. Understanding how the presence of
periostin effects wound healing may be facilitated through in vivo rescue experiments.
We have shown that the addition of rhPN to Postn-/- wounds results in increased α-SMA
protein at day 7, demonstrating that rhPN can modulate fibroblast to myofibroblast
transition during wound healing. Whether this increase in α-SMA translates into
accelerated wound closure kinetics was reserved for future publication, but is now
available (Figure 3.5) and will be commented on below. Ontsuka also recognized the
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importance of in vivo rescue experiments using recombinant periostin. In their
experiments, they documented the closure kinetics of Postn+/+ and Postn-/- wounds, with
and without addition of recombinant periostin. Their findings were very encouraging;
showing a complete restoration of normal closure kinetics in Postn-/- wounds and
accelerated closure in Postn+/+ wounds. Together these two outcomes paint a very
promising picture for periostin as a therapeutic. Interestingly, in both rescue attempts
periostin was added to the wounds earlier than the endogenous peak (day 0 in our report,
day 1 and every second day to day 9 for Ontsuka). The wound closure kinetics provided
by Ontsuka show an immediate response to exogenous periostin, statistically significant
at day 3. We now know that addition of rhPN to the wounds of db/db mice results in a
similar increase in wound closure rate (Figure 3.5), including an early departure from the
control kinetics. We observed an increase in closure rate as early as day 3, although not
statistically significant until day 5.
We show that in Postn-/- wounds exogenous periostin increases α-SMA by day 7 (Figure
2.12), but can myofibroblast differentiation be a major contributor to wound closure at
day 3? At such an early time point fibroblast migration into the wound is a key event.
There is support for the hypothesis that tractional forces of fibroblast migration alone, as
opposed to myofibroblast based contraction, can generate sufficient force to initiate
wound contraction (Ehrlich et al., 1999; Au and Ehrlich, 2010). As resistance in the
newly formed matrix increases, fibroblasts differentiate into myofibroblasts to complete
closure. It is possible that the presence of exogenous periostin influences fibroblast
migration at earlier time points. However, there is no in vivo evidence to support this and
our data argues against a migratory role for periostin in vivo.
The day 3 wound is largely a pool of inflammatory cells and relatively few fibroblasts.
Periostin has been shown to regulate chemokine release in lung fibroblasts, thereby
modulating neutrophil and macrophage recruitment (Uchida et al., 2012). Additionally, as
discussed in Chapter 3, periostin has been linked to the balance of T-helper cell type
cytokine profiles, where its presence shifts the cytokine profile towards a Th2, profibrotic
bias (Masuoka et al., 2012). In our microarray data we saw statistically significant
reductions in the expression of the key inflammatory mediators FasL and Csf1 in the PN-
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treated wounds (Figure 3.5). Therefore, several lines of evidence demonstrate that
periostin can modulate the inflammatory response. The observation that PN-containing
treatment did not induce α-SMA expression, as was the case in Postn-/- mice (Elliott et
al., 2012b), may be a consequence of the complex inflammatory state of db/db wounds
compared to Postn-/- wounds. One hypothesis is that TNFα inhibits myofibroblast
differentiation in the db/db wounds (Figure 3.3) (Goldberg et al., 2007). More work is
needed to sort through the specific interactions of periostin and the immune response.
Whether these inflammatory effects or another discrete pathway are involved in
periostin-dependant α-SMA expression has yet to be determined.

4.2
Are matricellular protein expression patterns and
the models we used relevant to human healing?
Our understanding of human skin healing is largely based on what we have learned from
mouse models of wound healing. However, there are known differences between murine
skin and human skin that raise questions about the accuracy of mouse models. For
example, murine skin is thin compared to human skin and contains an additional muscle
layer known as the panniculosus carnosus (Wong et al., 2011). Human skin is relatively
rigid, tight and is firmly anchored to the underlying tissue. Murine skin, on the other
hand, is loose, compliant and freely moves independently of the underlying tissue (Wong
et al., 2011). The consequences of these differences for wound healing is that murine
wounds are free to close primarily by contraction, whereas human wound healing is
largely accomplished through re-epithelialization and granulation tissue deposition
(Wong et al., 2011). These differences contribute to difficulty in translating therapeutic
developments validated in mice into effective treatments for use in the clinic. On a larger
scale, these differences call into question how closely the expression pattern and function
of factors such as matricellular proteins in mice mimic their homologues in humans. To
attempt to address this, we can draw on examples from other tissues where matricellular
proteins have been studied in both human pathology and the corresponding murine
models.
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Periostin is heavily expressed in the periodontal ligament (PDL) of mice (Horiuchi et al.,
1999). In mice, periostin is essential for PDL integrity, where deletion of periostin results
in degradation of the PDL (Hamilton, 2008; Rios et al., 2008). Removal of occlusal
loading, however, is protective of the PDL in Postn-/- mice, suggesting periostin’s role in
PDL is associated with adapting to mechanical stress. Periostin is also heavily expressed
in human PDL (Wen et al., 2010). Moreover, in human PDL from teeth where occlusal
loading has been removed, periostin expression is reduced (Wen et al., 2010). Therefore,
periostin expression in the PDL of both humans and mice seems to be mechanically
regulated in a similar manner.
Five days after induced myocardial infarction, periostin expression is up-regulated in the
murine ventricular wall (Shimazaki et al., 2008). Deletion of Postn-/- results in reduced
fibrosis of the infarct area; characterized by reduced collagen fibril formation and
myofibroblast differentiation. In infarct tissue from human hearts, periostin is increased
compared with healthy tissue surrounding the infarct. Furthermore, elevated periostin
expression in human infarct tissue is associated with fibrosis, suggesting, again that
periostin expression is regulated similarly in mouse and human tissues (Shimazaki et al.,
2008).
Confirming that periostin has a parallel role in murine and human skin healing would be
difficult due to ethical concerns. However, periostin has been studied in human fibrotic
skin conditions where its expression is congruent with murine models of skin fibrosis. In
mice, periostin is significantly up-regulated in bleomycin-induced skin fibrosis, and
deletion of periostin is protective against skin fibrosis (Yang et al., 2012). In human skin,
elevated periostin expression is associated with keloid and hypertrophic scars (Naitoh et
al., 2005; Zhou et al., 2010). In SSc, periostin expression correlates with the degree of
skin fibrosis (Yamaguchi et al., 2013). The same is true for CCN2 in skin. CCN2 is
required for bleomycin-induced skin fibrosis in mice (Liu et al., 2011), and the level of
CCN2 correlates with the severity of SSc in human skin (Takehara, 2003). The roles of
periostin and CCN2 in human skin healing are unknown, and ethical concerns prohibit
determining their expression patterns following wounding. However, the similarities
between their expression patterns in human pathologies and corresponding murine
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models strongly suggests that the roles of periostin and CCN2 in murine models of skin
healing are relevant to human healing.
Of particular importance for our study was selecting a model that was relevant to human
chronic skin wounds. The majority of human samples obtained for this study were from
patients with type-2 diabetes. A suitable model for studying our PN- and CCN2containing treatments should therefore model the impaired skin healing associated with
diabetes. For this, we chose the db/db model of type-2 diabetes. The db/db mouse was
first described in 1966 (Hummel et al., 1966) and has since become the most widely
studied mouse model of diabetes (Michaels et al., 2007). The db/db mouse carries a point
mutation in the leptin receptor (Lepr) gene, termed db, which results in defective leptin
signaling. Shortly after birth, homozygous Leprdb (db/db) mice become obese and exhibit
hyperglycemia by four to eight weeks (Hummel et al., 1966). These mice are polyphagic,
polydipsic, and polyuric. They are insulin resistant, hypertriglyceridemic, and have
impaired glucose tolerance. Most importantly, they exhibit severely impaired skin wound
healing. We have shown that the histology of day 7 skin wounds in db/db mice is similar
with respect to periostin, α-SMA, collagen and TNFα (Figure 3.4d) to the human chronic
skin wound tissues we examined (Figure 3.2). Additionally, Ccn2 expression is not
induced in day 7 db/db wounds (Figure 3.4e). Therefore, the db/db mouse represents an
excellent model for the study of PN- and CCN2-containing scaffolds with an aim towards
treating human chronic skin wounds.
There are, however, criticisms of the db/db mouse model. One such criticism is that the
monogenetic etiology (defective leptin signaling) does not match the complexity of
human diabetes (Fang et al., 2010). In humans the influence of leptin on obesity and
metabolic disorders is far subtler than in mice. Therefore, the model is centered on the
role of leptin more than on diabetes as a whole. Furthermore, leptin has been shown to
influence skin healing independent of metabolic disorders. Topical application of leptin
to wild-type and leptin-deficient ob/ob mice, but not db/db mice, accelerated wound
healing (Frank et al., 2000; Ring et al., 2000; Stallmeyer et al., 2001). Leptin receptors
have been detected on keratinocytes at the wound margins in mice and leptin can increase
keratinocyte proliferation in vitro, far removed from the metabolic disorders present in
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the animal (Frank et al., 2000). The direct effects of leptin on skin healing suggest that
the impaired healing in db/db mice is independent of a diabetic state. However, topical
administration of leptin to wounds in ob/ob mice did not completely correct impaired
healing. Deficits in angiogenesis persist even though blood vessels in the granulation
tissue of ob/ob mice present the leptin receptor (Ring et al., 2000; Stallmeyer et al.,
2001), suggesting there is more to this model than leptin dependant effects.
The two most commonly used alternatives to the db/db model of diabetes are the
streptozotocin-induced and Akita models (Michaels et al., 2007). These mice model type1 diabetes and therefore were not an appropriate comparison for our human tissue
samples. Moreover, the existence of wound healing impairments in these models is
questionable and, when present, not as severe as in the db/db mice (Keswani et al., 2004;
Michaels et al., 2007). For example, in a study comparing these models Akita mice did
not show a closure defect following incisional wounding (Fang et al., 2010). Streptozocin
mice showed an incisional defect (Fang et al., 2010) but in another study they did not
show an excisional defect (Michaels et al., 2007). An alternative to murine models is the
ischemic rabbit ear model of impaired healing (Sisco and Mustoe, 2003). However, this is
not a diabetic model and the surgical procedures involved are complex and technically
difficult. Additionally, rabbits are far more costly to maintain than rodents.
Alternatives to the standard excisional punch biopsy wound model used in this study are
available. Examples include the ischemia/re-profusion injury model (Reid et al., 2004),
which requires additional technical expertise and equipment, and the ischemic skin flap
model (Wong et al., 2011), which produces difficult to control ischemic gradients. These
more specialized models have the advantage of mimicking the ischemic environment that
is important in human chronic skin wound pathogenesis. However, these wound models
are technically demanding and do not lend well to comparison of multiple topically
applied treatments. Furthermore, significantly increased tissue ischemia is one of the
many defects that is well documented in db/db excisional wound healing (Ring et al.,
2000; Stallmeyer et al., 2001; Botusan et al., 2008). Therefore, although there are
criticisms of the db/db model of impaired diabetic healing, it remains an appropriate and
cost effective choice. Our histological comparison of day 7 db/db wounds with human
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chronic skin wounds, with respect to periostin and CCN2, underscore the relevance of the
db/db model.

4.3

Matricellular proteins as therapeutics

The idea of targeting matricellular proteins in conditions of pathological remodeling was
first suggested by Midwood and colleagues in 2004 following review of the many ways
matricellular proteins influence wound healing (Midwood et al., 2004). Surprisingly, in
the intervening years since that publication, no studies have actually investigated the
efficacy of these proteins in skin healing.
Matricellular proteins are typically not expressed in the adult except during wound
healing or tissue remodeling (Bornstein and Sage, 2002; Hamilton, 2008). Targeted
deletion of matricellular proteins produces animals that are grossly normal or display a
very subtle phenotype (Bornstein and Sage, 2002; Hamilton, 2008). As a result,
matricellular proteins represent a highly localized, highly selective target for
manipulating wound healing. Unlike the potentially life-threatening effects of systemic
blockade of pleiotropic molecules like TNFα (Wolbing et al., 2009), systemic targeting
of matricellular proteins produces few side effects. Intravenous delivery of an anti-CCN2
monoclonal antibody to patients with microalbuminuric diabetic kidney disease was well
tolerated in Phase I clinical trials (Adler et al., 2010), as was subcutaneous administration
of the anti-angiogenic thrombospondin-1 mimetic, ABT-510, to patients with advanced
solid tumors (Gietema et al., 2006). Recently, thrombospondin-1 was identified as being
consistently elevated in biopsies taken of venous ulcers, as well as biopsies of the same
locations 7 and 14 days later. This was compared to acute wounds created in the same
patient where the acute wounds were re-sampled at days 7 and 14 (Shih et al., 2012).
Interruption of thrombospondin-1 signaling with an antibody against its receptor, CD47,
was shown to be protective against ischemia-reperfusion injury in mice (Maxhimer et al.,
2009). Perhaps it is time to test anti-thrombospondin-1 treatments on human chronic skin
wounds.
Inhibiting or targeting the downstream effects of over-expressed matricellular proteins,
which by their over-expression are imposing deleterious effects on wound healing (i.e.
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thrombospondin-1), might enhance healing of chronic skin wounds. However, given that
the skin is readily accessible, local delivery of matricellular proteins that promote wound
healing can be easily achieved. This is the approach we have chosen to pursue. We
selected periostin and CCN2 because they are functionally associated with the profibrotic
aspects of wound healing, including matrix accumulation, myofibroblast differentiation
and profibrotic growth factor signaling. There are, however, other potential choices that
may be useful in targeting different aspects of wound healing. Deletion of angiopoietinlike 4 (ANGPTL4), a recent addition to the matricellular protein family, results in
delayed re-epithelialization of wounds in mice (Goh et al., 2010b), suggesting ANGPTL4
has a role in positively effecting re-epithelialization. Furthermore, topical application of
an anti-ANGPTL4 antibody significantly delayed re-epithelialization in wild-type mice,
showing that its effects are initiated from outside the cell. Of particular interest, delivery
of recombinant ANGPTL4 fully recovered delayed re-epithelialization in Angptl4-/- mice
(Goh et al., 2010a). Future work should determine if addition of ANGPTL4 to human
wounds could enhance re-epithelialization. The galectins are a large group of
matricellular proteins with diverse roles, including modulating inflammation. Galectin-1
can induce Th2 polarization by selectively killing Th1 cells. Additionally, galectin-1
promotes IL-10 production and attenuates IFNγ (Liu et al., 2012), furthering a Th2 bias.
Galectin-3 also exerts its influence on the Th1/Th2 balance, favouring a Th2 profile (Liu et
al., 2012). The interplay of the galectins and inflammation is complex and their role(s) in
chronic skin wounds is unclear. Recently, however, we have shown that galectin-3 is
absent in the epidermis surrounding human chronic skin wounds but is abundant in the
epidermis of non-involved skin (Pepe et al., in press). The implications of this are
currently unknown.
The importance of modulating the inflammatory phase of wound healing was not a focus
in our study. Clinically, debridement of a wound removes the bacterial load and necrotic
tissue responsible for perpetuating the inflammatory response and aims to “reset” the
chronic skin wound to an acute wound. We hypothesized that after debridement, addition
of periostin and CCN2 to a chronic skin wound could immediately initiate fibrotic wound
healing, by-passing the stalled inflammatory phase associated with chronic skin wounds.
However, with systemic disorders like diabetes still present, it is possible that following
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debridement the wound might revert to a state of excessive inflammation. It may
therefore be necessary to include another matricellular protein (i.e. galectin-1 or -3) to
modulate inflammation. Based on the matricellular proteins discussed here, a
hypothetical therapeutic device may incorporate galectins to shift inflammation to a Th2
profile, periostin and CCN2 to produce dermal fibrotic healing and ANGPTL4 to
accelerate re-epithelialization.

4.4

Different types of chronic skin wounds

The majority of chronic skin wounds can be classified as either diabetic ulcers, venous
ulcers or pressure sores (Mustoe et al., 2006), with arterial wounds being less prevalent.
Understanding the differences between these wounds is essential in prevention and
avoiding recurrence. Control of diabetic ulcers requires tight regulation of diet and blood
glucose as well as disciplined use of offloading devices. Venous ulcer occurrence is best
controlled with compression bandages. Pressure sores, like diabetic ulcers, require
offloading but also close monitoring and frequent proactive repositioning. Surgical
reperfusion and anti-platelet medications are the standard of care for arterial wound
treatment, however compression is contraindicated. These treatments are very deliberate,
specific and effective in controlling the different etiologies of chronic skin wounds.
There is evidence that once wounds have formed the different etiologies present differing
molecular profiles. For example, myofibroblasts (α-SMA positive stromal cells) were
detected at higher levels in venous ulcers greater than 3 months in duration compared to
acute 7 day-old wounds (Trostrup et al., 2011). In the wounds we observed, however, αSMA positive cells were restricted to the vasculature. The patients enrolled in our study
were almost exclusively diagnosed with peripheral vascular disease (PVD) (Table 3.1),
suggesting that the wounds we examined were primarily arterial in nature. The distinction
between wound etiologies is not rigid, however, and there is considerable overlap
between various chronic skin wounds (i.e. an arterial wound caused by large vessel
atherosclerosis but complicated by diabetes and pressure). Moreover, the diagnosis of a
patient’s limb does not always match the complexity of the specific wound. For example,
we have collected tissue from a wound on the heel of a diabetic patient’s foot, for which
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the diagnosis was PVD. Yet it is reasonable to expect that this wound may have been
complicated by pressure and diabetic neuropathy. Thus, the importance of molecular
differences between wound etiologies, once they have developed, may not be as
important as the similarities.
Regardless of the etiology of the chronic skin wound, there are common overarching
determinants of pathogenesis. They are: advanced patient age, repeated ischemiareperfusion injury, bacterial colonization and hypoxia (Mustoe et al., 2006). The complex
interaction of these factors results in an out-of-control, self-sustaining inflammatory
response (Menke et al., 2007). We suggest that future treatments may not need to be
tailored to the specific molecular profile of each chronic skin wound etiology. Successful
widely applicable treatments may be those that address the common dysfunctions of all
chronic skin wounds. With this in mind we did not employ exclusion criteria (i.e.
etiology, smoking, medications, infection) in our study. We hypothesize that any factors
consistently found to be inappropriately expressed in chronic skin wounds from a wide
range of patients would offer greater therapeutic applicability then those restricted to a
subset (i.e. venous ulcers in non-smoking patients). The wounds we examined were
mostly from patients with type-2 diabetes and PVD. To determine if the expression
patterns of periostin and CCN2 are consistent across a wider range of etiologies, we will
need to examine chronic skin wounds specifically classified as venous ulcers, diabetic
ulcers and pressure sores. It is possible that venous ulcers like those shown to contain
high numbers of α-SMA positive myofibroblasts (Trostrup et al., 2011) may also contain
high levels of periostin.

4.5

Future directions and implications

For the rhPN- and rhCCN2-containing scaffolds used in Chapter 3, the next step in
developing these into a treatment for chronic skin wounds is to test their efficacy in larger
animals, such as the pig. Mouse models of wound healing in skin are always difficult to
translate to human use due to the loose skin of mice (Ansell et al., 2012). Pigs, like
humans, have tight skin that heals primarily by re-epithelialization (Sullivan et al., 2001)
rather than from contraction, as in mice (Galiano et al., 2004). Mechanical tension in
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wound healing promotes scar formation, which creates cosmetic concerns but can also
compromise skin function (Gurtner et al., 2011). It will be interesting to see if mechanical
tension will work synergistically with rhPN or rhCCN2 to promote fibrosis. The presence
of a scar may be an acceptable outcome for patients suffering from chronic skin wounds
when the alternative is amputation. There are apparati (stents) available to mimic tight
skin in mice, however, porcine skin is still the superior choice for its ability to
accommodate wounds of a size comparable to human chronic skin wounds.
An important finding from our experiments with wound edge fibroblasts was that they
did not display a senescent phenotype. There is debate in the literature about the state of
chronic skin wound edge cells and their utility in wound healing. For years the evidence
supported the theory that chronic skin wound fibroblasts are senescent and are not
salvageable for wound healing. Brem and colleagues’ attempt to map out differences in
fibroblast senescence based on proximity to the wound bed challenged that theory (Brem
et al., 2007; Brem et al., 2008). Their work defined two subpopulations of cells defined
by the location they were harvested from. Those from the non-healing edge displayed
migration deficits and a polygonal morphology consistent with senescent cells. Those
from the healing edge (a few millimetres away from the wound bed) migrated faster and
displayed a spindle shape. Our results confirm that wound edge cells, even if only a
subpopulation, are capable of adopting an activated phenotype (Figure 3.3). The
implication that Brem and colleagues realized was that debridement of the wound edge
should be with care since there are valuable cell populations that could be lost. We agree,
but more work is needed to make the non-healing wound edge identifiable and
distinguishable from the healing wound edge in a surgical setting. Periostin may be a
potential marker for the region containing usable fibroblasts but periostin is not readily
detectable in a surgical setting. Our data shows that the localization of periostin coincides
with an area of hyper-vascularization around the wound edge. Non-invasive imaging
techniques, such as diffuse optical imaging, are available for detecting blood oxygen.
Such modalities might be used to detect the hyper-vascularization as a surrogate for
periostin, and therefore direction as to where debridement should occur.
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In addition to guiding debridement, we propose that the wound edge is a valuable
resource for use in cell-based therapies. Steinberg and colleagues recently compared the
therapeutic efficacy of adipose derived stem cells (ADSC) and dermal fibroblasts in an
ischemic rabbit model of wound healing (Steinberg et al., 2012). Both cell types
significantly increased wound healing rates. Surprisingly, they found no statistical
difference between the abilities of ADSC and fibroblasts to accelerate wound healing. In
light of our results with wound edge fibroblasts, and knowing that repeated debridement
is the standard of care for difficult-to-heal wounds, we propose that debrided wound edge
skin is a minimally invasive source of dermal fibroblasts to be used in cell-based
therapies.
The complexity of chronic skin wounds likely cannot be resolved by a single factor (i.e.
PDGF-BB, periostin or CCN2). Previously, we discussed how various matricellular
proteins could be combined in a treatment to influence many aspects of wound healing.
Future work should go beyond this and combine matricellular proteins with other
therapies like growth factor-based treatments. CCN2 is required for maximal induction of
α-SMA and collagen type-1 by TGFβ (Shi-wen et al., 2006). Similarly, CCN2 is required
for TGFβ induced myofibroblast differentiation and subsequent gel contraction (Garrett
et al., 2004). Deletion of periostin redirects the influence of TGFβ from fibrosis to
regeneration in a model of muscular dystrophy (Lorts et al., 2012). Perhaps the
disappointing clinical outcomes of TGFβ application to venous ulcers (Robson et al.,
1995) would have turned out differently if TGFβ was combined with rhCCN2 or rhPN.
SPARC has been shown to bind to and inhibit the function of both PDGF and VEGF
(Brekken and Sage, 2000). PDGF-BB combined with an anti-SPARC agent may increase
efficacy over PDGF-BB alone. By optimizing currently available agent-based therapies
through combinations with matricellular proteins, we may be able to produce a
therapeutic that is effective and widely applicable. The advantages that an agent-based
therapeutic has over negative pressure or cell-based therapies are a longer shelf life, ease
of use, ease of storage and no requirement for additional equipment. With the high cost of
chronic skin wounds around the world, these benefits should not be discounted.
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4.6

Summary

The overall hypothesis of this thesis was that the matricellular proteins periostin and
CCN2, two matricellular proteins associated with fibrotic healing, could enhance the
healing of chronic skin wounds. We have demonstrated that in a murine model of
impaired healing these proteins can enhance skin healing. Therefore, the potential exists
for these proteins to be used as therapeutics for healing of human chronic skin wounds.
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2.11E-03
MYPN, LRRN1,
3.24MYOM1, TTN,
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3.91E-02
TTN, MYH8, 1.58
TPM3, MURC, FSD2,
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acute phase
3
REG3B,
9.46E-04
SAA1, REG3G
63.76
2.40E-02
Lectin
4REG3B,
3.89E-03
ZG16, REG3G, 12.22
CLEC2H
5.82E-02
Secreted
REG3B, MUC2, SLURP1,- C1QTNF3,
11
2.19E-04
SAA1, ZG16, ANGPTL1,
3.95 REG3G, 8.38E-03
MUC13, CHAD, DMBT1
signal
MUC2, SKINT9, SLURP1, KLK1, CHAD, 2210415F13RIK,
16 REG3B,
1.54E-04
C1QTNF3, CDH17,
2.75 SAA1, ZG16,
1.18E-02
ANGPTL1, REG3G, MUC13, THBS4, DMBT1
glycoprotein
MUC2, SKINT9, TNMD, ATP1B4, KLK1,
- CHAD,
13 2210415F13RIK,
2.90E-02
CDH17,
1.84 ANGPTL1,
2.46E-01
CLEC2H, MUC13, THBS4, DMBT1
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GO TERM CELLULAR COMPARTMENT
Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
GO:0005859~muscle myosin complex
OBSCN,
5
MYH1,
9.13E-07
MYH2, MYH7,
59.54
TTN, MYH8 9.52E-06
GO:0005863~striated muscle thick filament
OBSCN,
4
3.04E-05
MYH1, MYH2, MYH7,
59.54
MYH8
2.61E-04
GO:0033018~sarcoplasmic reticulum lumen
2
3.29E-02
SRL, CASQ2 59.54
1.77E-01
GO:0031430~M band
3
MYOM1,
1.40E-03
SMTNL1, TTN
51.04
1.07E-02
GO:0016460~myosin II complex
OBSCN,
5
MYH1,
2.12E-06
MYH2, MYH7,
49.62
TTN, MYH8 2.07E-05
GO:0032982~myosin filament
2
3.31E-02
MYH3, MYH8 57.49
3.09E-01
OBSCN, MYH1,
6
1.02E-07
MYH3, MYH2, MYH7,
47.63
MYOM1, MYH8
1.24E-06
GO:0031674~I band
OBSCN, ACTC1,
3 TCAP,
ACTC1,
2.59E-02
CRYAB,
MYOZ2,
SYNC,
ANKRD1
11.80
LDB3, ANKRD2,
2.01E-01
PDLIM3, ACTN2,
21
MYOZ2,
5.85E-29
ANKRD1, SMTNL1,
47.18
FLNC,1.71E-27
TTN, CSRP3, MYOT, MURC, MYO18B, DMD, ITGB1BP2, JPH1
GO:0030018~Z disc
OBSCN, TCAP, CRYAB, SYNC, PDLIM3, LDB3, ACTN2,
17
MYOZ2,
1.26E-22FLNC, TTN,
44.01
CSRP3, MYOT,
3.06E-21
MURC, MYO18B, DMD, ITGB1BP2, JPH1
GO:0030017~sarcomere
TCAP, SYNC, ANKRD2, PDLIM3, ANKRD1,
4ACTC1,
SMTNL1,
6.34E-03
MYH7,
TTN,
MYOZ2,
MYOT,10.42
ANKRD1
DMD, ABRA, MYOM1,
1.19E-01
JPH1, 27
OBSCN,
1.53E-35
ACTC1, MYH1, CRYAB,
40.19 MYH2, LDB3,
7.46E-34
ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MURC, MYO18B, MYPN, ITGB1BP
GO:0031672~A band
MYH1,
4
MYH2,
1.16E-04
MYOM1, SMTNL1,
39.70 TTN
9.44E-04
GO:0016012~sarcoglycan complex
2
4.89E-02
SGCG, SGCA 39.70
2.45E-01
GO:0030016~myofibril
3
ACTC1,
1.75E-02
TCAP, MYH3,
SYNC, MYH8
ANKRD2,
14.21 PDLIM3,3.85E-01
ANKRD1, SMTNL1,
ACTC1,
5
MYH3,
8.80E-04
TTN, MYOT,
MYH7,DMD,
MYOZ2,
11.45
ABRA,
ANKRD1
MYOM1,5.15E-02
JPH1, OBSCN,
29ACTC1,
1.64E-37
MYH1, CRYAB,37.95
MYH3, MYH2, 2.40E-35
LDB3, ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MURC, MYO18B, NRAP, MYPN, IT
GO:0044449~contractile fiber part
TCAP, SYNC, ANKRD2, PDLIM3, ANKRD1,
4ACTC1,
SMTNL1,
7.74E-03
MYH7,
TTN,
MYOZ2,
MYOT,ANKRD1
9.69
DMD, ABRA, MYOM1,
1.10E-01
JPH1, 27
OBSCN,
1.39E-34
ACTC1, MYH1, CRYAB,
37.39 MYH2, LDB3,
5.06E-33
ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MURC, MYO18B, MYPN, ITGB1BP
GO:0043292~contractile fiber
3
ACTC1,
1.90E-02
TCAP, MYH3,
SYNC, MYH8
ANKRD2,
13.62 PDLIM3,2.96E-01
ANKRD1, SMTNL1,
ACTC1,
5
MYH3,
1.03E-03
TTN, MYOT,
MYH7,DMD,
MYOZ2,
10.97
ABRA,
ANKRD1
MYOM1,3.06E-02
JPH1, OBSCN,
29ACTC1,
6.65E-37
MYH1, CRYAB,36.35
MYH3, MYH2, 4.86E-35
LDB3, ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MURC, MYO18B, NRAP, MYPN, IT
GO:0016529~sarcoplasmic reticulum
TRDN, CACNA2D1, SLN,
10 SRL,
5.91E-12
RYR1, JPH1, CACNA1S,
35.03
HRC,1.23E-10
CASQ2, ART1
GO:0005916~fascia adherens
2
5.68E-02
NRAP, XIRP1 34.02
2.71E-01
GO:0032155~cell division site part
2
5.68E-02
MYH1, MYH2, TPM3
34.02
2.71E-01
GO:0032153~cell division site
2
5.68E-02
MYH1, MYH2, TPM3
34.02
2.71E-01
GO:0016011~dystroglycan complex
2
5.68E-02
SGCG, SGCA 34.02
2.71E-01
GO:0033017~sarcoplasmic reticulum membrane
2
5.68E-02
RYR1, HRC 34.02
2.71E-01
GO:0016528~sarcoplasm
TRDN, CACNA2D1, SLN,
10 SRL,
1.05E-11
RYR1, JPH1, CACNA1S,
33.08
HRC,1.91E-10
CASQ2, ART1
GO:0016010~dystrophin-associated glycoprotein complex
3
4.28E-03
SGCG, DMD, SGCA
29.77
3.08E-02
GO:0014704~intercalated disc
2
8.78E-02
NRAP, XIRP1 21.65
3.81E-01
GO:0030315~T-tubule
3 CACNA2D1,
8.59E-03RYR1, CACNA1S
21.02
5.56E-02
GO:0042383~sarcolemma
CACNA2D1, DMD,
8 SYNC,
1.07E-07
RYR1, ATP1A2,20.27
CACNA1S, MYOT,
1.21E-06
SGCA
GO:0016459~myosin complex
3
MYL6B,
3.35E-02
MYH3, MYH7
10.25OBSCN, MYO18B,
2.03E-01MYH1,
10MYL3,
1.62E-09
MYL6B, MYH3, MYH2,
19.52 MYH7, MYOM1,
2.16E-08
TTN, MYH8
GO:0015629~actin cytoskeleton
OBSCN, MYH1, MYL3, MYH3, MYH2, PDLIM3, ACTN2,
16
1.32E-10
MYH7, MYOZ2, FLNC,
9.29TTN, MYH8,
2.14E-09
TPM3, MYO18B, MYL6B, ABRA, MYOM1
GO:0016323~basolateral plasma membrane
ATP1B1,
5
3.00E-02
SLCO4C1, NRAP, HFE2,
4.22 DMD
1.69E-01
GO:0005856~cytoskeleton
MYL3,
- MYBPC1, SYNC, PDLIM3, TTN, MYOT, SYNPO2L, TPM3, MYOM2, MYL6B, DMD, ABRA, MYOM1, LMOD2, LMOD3,
33OBSCN,
2.27E-10
ACTC1, MYH1,3.50
MYH3, MYH2,3.32E-09
LDB3, ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MYO18B, RND1, KRT77, SGCG,
GO:0044430~cytoskeletal part
OBSCN, MYH1, MYL3, MYH3, MYH2, SYNC, ACTN2,
15
4.76E-03
MYH7, TTN, MYH8,
2.31
TPM3, MYO18B,
3.27E-02
KRT77, MYL6B, KRTAP3-2, MYOM1
GO:0043228~non-membrane-bounded MYL3,
organelle
MYBPC1,
- SYNC, PDLIM3, SYCP2, TTN, SYNPO2L, MYOT, TPM3, MYOM2, MYL6B, DMD, ABRA, MYOM1, LMOD2, LMOD3,35
OBSCN,
7.43E-06
ACTC1, MYH1, MYH3,
2.17 GM14475,
6.78E-05
MYH2, LDB3, ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MYO18B, RND1, KRT7
GO:0043232~intracellular non-membrane-bounded
MYL3, MYBPC1,
-organelle
SYNC, PDLIM3, SYCP2, TTN, SYNPO2L, MYOT, TPM3, MYOM2, MYL6B, DMD, ABRA, MYOM1, LMOD2, LMOD3,35
OBSCN,
7.43E-06
ACTC1, MYH1, MYH3,
2.17 GM14475,
6.78E-05
MYH2, LDB3, ACTN2, MYH7, MYOZ2, FLNC, MYH8, CSRP3, MYO18B, RND1, KRT7
GO:0005783~endoplasmic reticulum
CACNA2D1, YIPF7, SRL, CACNA1S,
14ART1,
2.14E-02
TRDN, SLN, FITM1,
1.99
FMO2, RYR1,
1.28E-01
ANO5, JPH1, CASQ2, HRC
GO:0044421~extracellular region part
MUC2,
SLURP1,
6
2.69E-02
SAA1, ANGPTL1,
3.34
CHAD, DMBT1
IGHG,
3.12E-01
FMOD, PRL2C5,
9
HMCN1,
2.81E-02
KERA, EGFL6,
2.42IGF2, ANGPTL1,
1.92E-01
CHAD
OLFR1051, AGTR2, OLFR1054, OLFR1489,
GO:0016021~integral
VMN1R93, OLFR1158,
to membrane
OLFR43, OLFR488, UPK1B,
OLFR576, OLFR969, OLFR1184, OLFR1181, OLFR1057,36OLFR1170,
2.39E-02
VMN1R135,1.31
VMN1R152, OLFR1386,
2.15E-01 VMN1R132, VMN1R112, OLFR402, VMN2R32, TNMD, VMN2R51, VMN2R33, VMN1R73, VMN1R15, VMN1R130, OLFR1287, IGHG,
R1386, VMN1R112, VMN2R32, VMN2R33,
GO:0031224~intrinsic
TNMD, VMN1R15,to
OLFR1287,
membraneIGHG, OLFR1471,- OLFR214, OLFR494, VMN1R107, VMN2R43, VMN1R143, VMN2R42,
37
2.35E-02
OLFR1085, OLFR1275,
1.30
OLFR728,
2.48E-01
GM10670, OLFR1489, LY6F, OLFR488, OLFR43, OLFR576, UPK1B, OLFR1184, OLFR969, OLFR1181, OLFR1170, VMN1R135, VMN1R1
GO:0005576~extracellular
REG3B,
regionMUC2, SLURP1, C1QTNF3,
12 SAA1,
5.95E-04
ZG16, ANGPTL1,
3.08
REG3G, MUC13,
3.22E-02
CHAD, THBS4, DMBT1
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Count P value
Genes
Fold Enrichment
GO:0055003~cardiac myofibril assembly
GO:0014823~response to activity
GO:0055013~cardiac muscle cell development
GO:0055006~cardiac cell development
GO:0045214~sarcomere organization
GO:0030239~myofibril assembly
GO:0031032~actomyosin structure organization
GO:0006936~muscle contraction
GO:0006941~striated muscle contraction
GO:0003012~muscle system process
GO:0002026~regulation of the force of heart contraction
GO:0007512~adult heart development
GO:0055002~striated muscle cell development
GO:0055007~cardiac muscle cell differentiation
GO:0010927~cellular component assembly involved-in morphogenesis
GO:0019229~regulation of vasoconstriction
GO:0055001~muscle cell development
GO:0048738~cardiac muscle tissue development
GO:0035051~cardiac cell differentiation
GO:0014706~striated muscle tissue development GO:0006937~regulation of muscle contraction
GO:0060537~muscle tissue development
GO:0009408~response to heat
GO:0007517~muscle organ development
GO:0051146~striated muscle cell differentiation
GO:0007519~skeletal muscle tissue development GO:0060538~skeletal muscle organ development GO:0048747~muscle fiber development
GO:0001756~somitogenesis
GO:0042692~muscle cell differentiation
Benjamini Count

PN + CCN2
Benjamini Count P value
Genes
Fold Enrichment Benjamini
3
6.98E-04
MURC, ACTC1, TTN
71.52
1.59E-02
2
MYH1,
4.08E-02
MYH2, SMTNL1
47.68
3.68E-01
4 MURC,
1.10E-04
ACTC1, XIRP1,
40.87
TTN
3.49E-03
4 MURC,
1.10E-04
ACTC1, XIRP1,
40.87
TTN
3.49E-03
3
2.50E-03
TCAP, XIRP1, TTN
39.01
4.94E-02
MURC,
5
7.69E-06
ACTC1, TCAP, XIRP1,
37.64TTN
3.24E-04
MURC,
5
2.43E-05
ACTC1, TCAP, XIRP1,
28.61TTN
8.78E-04
MYOM2, MYH1, MYBPC1, MYL6B,
11 MYH2,
8.72E-12
RYR1, ACTN2,26.22
MYH7, MYOM1,
2.21E-09
TTN, CACNA1S, MYH8
MYH1,
4
MYH2,
5.84E-04
MYH7, CACNA1S,
23.84 MYH8
1.40E-02
MYOM2, MYH1, MYBPC1, MYL6B,
11 MYH2,
2.76E-11
RYR1, ACTN2,23.48
MYH7, MYOM1,
4.65E-09
TTN, CACNA1S, MYH8
2
8.63E-02
ATP1A2, CSRP322.00
5.51E-01
2
8.63E-02
TCAP, TTN 22.00
5.51E-01
MURC, MYO18B,
8 ACTC1,
8.22E-08
TCAP, XIRP1,21.19
TTN, FLNC, CACNA1S
6.93E-06
4 MURC,
9.27E-04
ACTC1, XIRP1,
20.43
TTN
2.02E-02
MURC,
5
1.07E-04
ACTC1, TCAP, XIRP1,
19.87TTN
3.60E-03
2
9.89E-02
SMTNL1, ATP1A2
19.07
5.85E-01
MURC, MYO18B,
8 ACTC1,
1.95E-07
TCAP, XIRP1,18.76
TTN, FLNC, CACNA1S
1.41E-05
MURC, MYO18B,
7
2.55E-06
ACTC1, XIRP1, TTN,
17.57
CSRP3, TNNI1
1.43E-04
4 MURC,
1.51E-03
ACTC1, XIRP1,
17.34
TTN
3.13E-02
MYF6, ACTC1, PDLIM3, TTN, CSRP3,
13 CACNA1S,
6.55E-11
TNNI1, MURC,
14.64MYO18B, 8.29E-09
XIRP1, MYL6B, DMD, VGLL2
4TNNC1,
2.83E-03
RYR1, ATP1A2,13.95
CASQ2
5.16E-02
MYF6, ACTC1, PDLIM3, TTN, CSRP3,
13 CACNA1S,
1.47E-10
TNNI1, MURC,
13.67MYO18B, 1.49E-08
XIRP1, MYL6B, DMD, VGLL2
3
HSPA1L,
2.05E-02
CRYAB, HSPB7
13.41
2.72E-01
MYF6, ACTC1, CRYAB, PDLIM3, SMTNL1, TTN,16
CSRP3,
1.01E-12
CACNA1S, TNNI1,
13.00
MURC, MYO18B,
5.14E-10
XIRP1, MYL6B, DMD, VGLL2, JPH1
MURC, MYO18B,
8 ACTC1,
2.63E-06
TCAP, XIRP1,12.86
TTN, FLNC, CACNA1S
1.33E-04
MYF6, MYL6B,
6
1.38E-04
DMD, PDLIM3, VGLL2,
11.92 CACNA1S
4.10E-03
MYF6, MYL6B,
6
1.57E-04
DMD, PDLIM3, VGLL2,
11.60 CACNA1S
4.18E-03
3 MYO18B,
2.83E-02
FLNC, CACNA1S
11.29
3.18E-01
3
3.26E-02
MYF6, TCAP, TTN
10.47
3.43E-01
MURC, MYO18B,
8 ACTC1,
1.62E-05
TCAP, XIRP1,9.78
TTN, FLNC, CACNA1S
6.29E-04

CCN2
P value
Genes
Fold Enrichment

Term
PN
CCN2
PN + CCN2
GO TERM MOLECULAR FUNCTION
Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
GO:0008307~structural constituent of muscle
4 MYL6B,
2.32E-05
PDLIM3, TTN,65.14
JPH1
1.70E-03
GO:0005391~sodium:potassium-exchanging ATPase- activity
3 ATP1B1,
2.47E-03
ATP1B4, ATP1A2
39.08
5.88E-02
GO:0005523~tropomyosin binding
2
5.20E-02
LMOD2, LMOD337.22
6.24E-01
GO:0005200~structural constituent of cytoskeleton 4MYOM2,
1.35E-03
MYBPC1, MYOM1,
17.97
TTN
4.83E-02
GO:0051015~actin filament binding
2
8.15E-02
MYH3, MYH8 22.60
8.55E-01
3
TNNC1,
1.75E-02
MYH3, MYH7
14.53
3.37E-01
MYH1, TNNC1,
6
3.36E-05
MYH3, MYH2, ACTN2,
15.95MYH7, MYH8
1.85E-03
GO:0003779~actin binding
CAP2, MYH1, TNNC1, MYH3, MYH2, ACTN2, MYH7, FLNC,
19MYH8,
4.85E-12
MYOT, SYNPO2L,
8.59
TNNI1, TPM3,
5.34E-10
XIRP1, NRAP, XIRP2, DMD, MYPN, ABRA, LMOD2
GO:0008092~cytoskeletal protein binding
OBSCN, CAP2, MYH1, TNNC1, MYH3, MYH2, PDLIM3, ACTN2, MYH7, 22
FLNC, 3.64E-12
MYH8, MYOT, SYNPO2L,
6.92 TNNI1, TPM3,
8.02E-10
XIRP1, NRAP, XIRP2, MYPN, DMD, ABRA, LMOD2, LMOD3
GO:0005516~calmodulin binding
MYH1, MYH3,
6
KCNN3,
1.75E-03
MYH2, CAMK2B,
6.86 MYH7, TTN
5.36E-02
GO:0015662~ATPase activity, coupled to transmembrane
movement of ions, phosphorylative mechanism
3 ATP1B1,
6.97E-02
ATP1B4, ATP1A2
6.86
6.54E-01
GO:0003774~motor activity
MYO18B, MYH1,
7 MYL3,
6.36E-04
MYL6B, MYH3,6.61
MYH2, MYH7,2.76E-02
MYH8
GO:0005262~calcium channel activity
3 CACNA2D1,
9.44E-02RYR1, CACNA1S
5.75
7.02E-01
GO:0042625~ATPase activity, coupled to transmembrane
movement of ions
3 ATP1B1,
9.68E-02
ATP1B4, ATP1A2
5.66
6.92E-01
GO:0003712~transcription cofactor activity
LMCD1, 6ABRA,1.20E-02
VGLL2, ACTN2, SMYD1,
4.34
ANKRD1
2.15E-01
GO:0005198~structural molecule activity
KRT77, MYOM2, CRYAB, MYBPC1,
11
2.20E-03
MYL6B, KRTAP3-2,3.18
SYNC, PDLIM3,
5.88E-02
MYOM1, TTN, JPH1
GO:0008134~transcription factor binding
LMCD1, 6ABRA,6.84E-02
VGLL2, ACTN2, SMYD1,
2.71
ANKRD1
6.72E-01
GO:0005509~calcium ion binding
CACNA2D1, TNNC2, TNNC1, MYL3, SRL, ACTN2,
15
4.40E-03
TTN, CACNA1S, MYL6B,
2.33 DMD, ITGB1BP2,
9.25E-02 RYR1, ANO5, CASQ2, SGCA
GO:0043169~cationAPOBEC2,
binding SLC38A3, ATP1B1, FBXO40,
TNNC2, MYL3, TNNC1, SRL, PDLIM3, TTN, ADPRHL1, MYL6B, FMO2, DMD, ANO5, PRKAA2, MB, USP13, CACNA2D1,
38
6.51E-02
AGBL1, ADAMTS20,
1.27 LDB3, LMCD1,
6.80E-01
CHI3L1, ACTN2, SMYD1, ATP1A2, CACNA1S, CSRP3, ALOX15, NRAP, XIRP2, I
GO:0043167~ion binding
APOBEC2, SLC38A3, ATP1B1, FBXO40,
TNNC2, MYL3, TNNC1, SRL, PDLIM3, TTN, ADPRHL1, MYL6B, FMO2, DMD, ANO5, PRKAA2, MB, USP13, CACNA2D1,
38
7.63E-02
AGBL1, ADAMTS20,
1.26 LDB3, LMCD1,
6.64E-01
CHI3L1, ACTN2, SMYD1, ATP1A2, CACNA1S, CSRP3, ALOX15, NRAP, XIRP2, I
GO:0046872~metal ion APOBEC2,
binding
SLC38A3, ATP1B1,
- FBXO40, TNNC2, MYL3, TNNC1, SRL, PDLIM3, TTN, ADPRHL1, MYL6B, FMO2, DMD, ANO5, PRKAA2, MB, USP13,
37 CACNA2D1,
8.66E-02 AGBL1, ADAMTS20,
1.25
LDB3,
6.90E-01
LMCD1, ACTN2, SMYD1, ATP1A2, CACNA1S, CSRP3, ALOX15, NRAP, XIRP2, ITGB
GO:0016503~pheromone receptor activity
VMN1R152,
VMN1R135, VMN1R143, VMN1R132, VMN1R112,5VMN1R73,
2.33E-03
VMN1R15, VMN1R130,
8.79
GM10670,
7.83E-02
VMN1R93, VMN1R104, VMN1R107, VMN1R100
OLFR1386,
GO:0004984~olfactory
OLFR706, OLFR1085,
receptor
OLFR402,
activity
OLFR1275, OLFR728,
OLFR1287, OLFR1051, OLFR1054, OLFR1489, OLFR1158,
24
2.79E-11
OLFR488, OLFR43,
5.02
OLFR576, OLFR1471,
1.95E-09 OLFR1184, OLFR969, OLFR214, OLFR1022, OLFR1160, OLFR494, OLFR1181, OLFR1057, OLFR1170
GO:0005529~sugar binding
4REG3B,
3.60E-03
ZG16, REG3G, 12.24
CLEC2H
2.18E-01
GO:0030246~carbohydrate binding
4REG3B,
1.67E-02
ZG16, REG3G, CLEC2H
6.99
4.36E-01
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GO TERM BIOLOGICAL PROCESS, Continued
Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
GO:0008016~regulation of heart contraction
3
ATP1A2,
4.68E-02CSRP3, HRC
8.58
3.97E-01
GO:0009266~response to temperature stimulus
3
HSPA1L,
4.85E-02
CRYAB, HSPB7
8.41
4.02E-01
GO:0030029~actin filament-based process
MURC, ACTC1, NRAP,
10 TCAP,
3.46E-06
XIRP1, XIRP2, MYL6B,
8.13
PDLIM3,
1.59E-04
TTN, FLNC
GO:0035282~segmentation
3
5.37E-02
MYF6, TCAP, TTN7.95
4.04E-01
GO:0003007~heart morphogenesis
4 ACTC1,
1.46E-02
XIRP1, TTN, TNNI1
7.73
2.13E-01
GO:0007507~heart development
MURC, MYO18B, ACTC1, ALPK3,
12
TCAP,
3.80E-07
XIRP1, PDLIM3,
7.70SMYD1, TTN,
2.40E-05
CSRP3, TNNI1, MB
GO:0055074~calcium ion homeostasis
RYR1,
5
ATP1A2,
4.23E-03SYPL2, CSRP3,
7.53 HRC
7.38E-02
GO:0030036~actin cytoskeleton organization
MURC, ACTC1,
8 NRAP,
1.45E-04
TCAP, XIRP1, XIRP2,
6.93 PDLIM3,
4.06E-03
TTN
GO:0055065~metal ion homeostasis
RYR1,
5
ATP1A2,
6.23E-03SYPL2, CSRP3,
6.75 HRC
1.03E-01
GO:0046034~ATP metabolic process
ATP1B1,
4
2.44E-02
ATP1B4, MYH7,6.36
ATP1A2
3.08E-01
GO:0006874~cellular calcium ion homeostasis
4 RYR1,
2.51E-02
ATP1A2, SYPL2, 6.29
CSRP3
3.01E-01
GO:0006875~cellular metal ion homeostasis
4 RYR1,
3.20E-02
ATP1A2, SYPL2, 5.72
CSRP3
3.45E-01
GO:0009205~purine ribonucleoside triphosphate metabolic
process
ATP1B1,
4
3.28E-02
ATP1B4, MYH7,5.66
ATP1A2
3.38E-01
GO:0009199~ribonucleoside triphosphate metabolic-process
ATP1B1,
4
3.37E-02
ATP1B4, MYH7,5.61
ATP1A2
3.38E-01
GO:0009144~purine nucleoside triphosphate metabolic
- process
ATP1B1,
4
3.71E-02
ATP1B4, MYH7,5.40
ATP1A2
3.53E-01
GO:0044057~regulation of system process
TNNC1, RYR1,
7 SMTNL1,
2.69E-03
ATP1A2, CSRP3,
4.98 HRC, CASQ2
5.11E-02
GO:0009141~nucleoside triphosphate metabolic process
ATP1B1,
4
4.55E-02
ATP1B4, MYH7,4.98
ATP1A2
3.94E-01
GO:0055066~di-, tri-valent inorganic cation homeostasis
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ACE2,
RAB25,
47 MC5R,
1.35E-03
SCNN1B,
SUCNR1,
FGFBP1,
TSHR,
1.60
CLEC2G,
LIPE, SLC46A2
HSD17B7,
1.77E-02
GJB4, GJB6, GJB2, ARHGAP32, DSG1B, PROM2, DSG1A, DSG3, TM
hydrolase
ATP10B, ABHD6, SGPP2, FASN, KLK11, -C330005M16RIK,
LPL, ENPP2,
PLCD1,
ACER2,
TMPRSS13,
ACER1, KLK14,
EPHX2, KLK13,
MME, GZMB,
KLK6, PNPLA2,
CPA4,
19 1190003J15RIK,
PNPLA3,
4.32E-02
CMBL, KLK8,
ATP13A4,
1.62
KLK9,
PPP2CA,
PTPRF,2.77E-01
FASN,
PTPRZ1,
ACE2,
EPHX3,
MGLL,
39 KLK5,
GLB1L2,
9.23E-03
ACER1,
LIPE,
TREX2,
PLA2G2F,
1.52
PNPLA1,
LIPFPNPLA3,
8.37E-02
ATP13A4, TMPRSS4, AADAC, ATP2C2, LIPK, CASP14, TMPRSS11E, LIP
TMPRSS11BNL,
ACVR1C, SLC1A5,
RIPK4,
FAR2,
SLITRK6,
ELOVL3,FGFR2,
MC5R, FGFR3,
ELOVL6,IL22RA1,
membrane
AGPAT2,VMN1R148,
DHCR24, ODZ4,
ERBB3,
FA2H,
TMIGD1,
SLC7A10,
ITGB4,
PNPLA2,
PANX3,
-CYP2E1,
VMN2R45,
CHPT1,
PVRL4,
PNPLA3,
EPHB6,
CLIC3,
PPL, CYP2B19,
OTOP3, SDR16C5,
MC2R, SKINT1,
TMEM79,
TSHR,
64
ACER1,
FGFR2,
KCNK1,
2.22E-04
HSD3B6,
EPHA1,
MRAP,
REEP4,
1.48
MMD,
ATP13A4,
MME, 9.41E-03
PANX3,
AWAT1,
PAQR9,
DSG3,
143
ACSL1,
LASS3,
4.83E-09
PLIN4,
PARD6G,
ABCD2,
NAT8L,
1.52
SUCNR1,
SLC46A2,
SDR16C5,
SLC16A14,
1.28E-06
REEP6,
CLDN4,
SCD1,
SLC15A1,
LPL, MPZ,
ATP10B,
KLB, B3GALT2,
SGPP2, SLC5A1,
ACER2, ANO1,
SLC6A13,
DUOX1,
ACER1,
FER
3, NIPAL2, KLK11,
FGFR2,
C330005M16RIK,
SKINT9, ENPP2,
NIPAL1,
MME,
MUC15,
PANX3,
glycoprotein
TMPRSS13,
PSAPL1, SERPINA3C,
ODZ2, ANO9,
CD1D1,
ODZ4,SERPINA3B,
LOC665506,
ADORA1,
PTPRF,
PLXNB1,
SLC1A5,CAR12,
SMOC1,SPINT1,
ELOVL3,PNPLA3,
ABCD2,MOXD1,
MC5R, SUCNR1,
CWH43, AADAC,
ODZ4,
40 LPL,
DSG1B,
MPZ,
1.56E-02
DSG1A,
B3GALT2,
TACSTD2,
KLB,
1.42
ACER2,
SERPINB5,
SLC6A13,
1.25E-01
TMPRSS11E,
PNPLA2,
93IGSF3,
GZMB,
1.88E-05
NPR3,
ST14, SKINT1,
PNPLA3, 1.51
EFNA5,
ADIPOQ,TMPRSS11BNL,
TSLP,4.97E-04
ORM1, SERPINA3M,
SKINT3, PLA2G2F,
HPX, MC2R,
FGFR2,
ACE2,
GALNT3,
SKINT1,
FGFR3,
SLC5A7,
IL22RA1,
TSHR,
MAL2,
LIPF,SER
SLC
SS11BNL,
IK, AQP7, SLITRK6,
CD1D1, ADORA1,
FGFR2, FGFR3,
ACVR1C,
IL22RA1,
SLC1A5,VMN1R148,
FAR2,
transmembrane
ELOVL3,
ERBB3,
MC5R,
ITGB4,
ELOVL6,
TMIGD1,
AGPAT2,
PANX3,
DHCR24,
VMN2R45,
ODZ4,
-PVRL4,
FA2H,EPHB6,
SLC7A10,
OTOP3,
PNPLA2,
SDR16C5,
CHPT1,
TMEM79,
PNPLA3,ACER1,
CLIC3, KCNK1,
MC2R, SKINT1,
EPHA1,
57
REEP4,
TSHR,
3.61E-03
FGFR2,
ATP13A4,
HSD3B6,
AWAT1,
1.39MRAP,
DSG3,
MMD,
LASS3,
4.42E-02
MME,
NAT8L,
PANX3,
117
SLC46A2,
PAQR9,
6.14E-04
SLC16A14,
ACSL1, ABCD2,
CLDN4,
1.30
SDR16C5,
ATP10B,SUCNR1,
8.97E-03
SLC15A1,
REEP6,
SGPP2,
SCD1,
SLC5A1,
MPZ,ANO1,
KLB, B3GALT2,
DUOX1, MFSD2A,
ACER2, SLC6A13,
4833423E24RIK,
ACER1, CDC
GJB
obesity
3
8.84E-04
LEP, RETN, ENPP2
63.76
1.70E-02
diabetes mellitus
2
3.83E-02
LEP, RETN 51.01
2.65E-01
oxygen carrier
2
3.83E-02
HBA-A2, HBB-B1
51.01
2.65E-01
blood
2
4.58E-02
HBA-A2, HBB-B1
42.51
2.75E-01
lipid droplet
2
2.71E-02
PLIN1, PLIN4 71.42
4.89E-01
3
PLIN1,
2.60E-03
PLIN4, PNPLA2
38.26
3.41E-02
erythrocyte
2
6.06E-02
HBA-A2, HBB-B1
31.88
3.32E-01
oxygen transport
2
8.24E-02
HBA-A2, HBB-B1
23.19
3.75E-01
vldl
2
8.24E-02
LPL, APOC1 23.19
3.75E-01
chromoprotein
HBA-A2,
4
3.70E-03
CYP17A1, HBB-B1,
12.75
CYP2E1
4.29E-02
metalloprotein
HBA-A2,
5
CYP17A1,
9.44E-04
ADH1, HBB-B1,
11.39 CYP2E1 1.54E-02
pyridoxal phosphate
3
7.95E-02
ALAS2, FASN, GPT
6.38
3.72E-01
chloride
3
9.84E-02
CLIC3, ACE2, NPR3
5.63
4.16E-01
peroxisome
4 FAR2,
3.91E-02
ACSL1, EPHX2, ABCD2
5.31
2.62E-01
manganese
PCX, B3GALT2,
6
5.53E-03
PPP2CA, CHPT1,5.28
ACVR1C, PCK1
6.03E-02
Symport
SLC1A5,
4
5.34E-02
SLC16A14, SLC6A13,
4.68SLC5A7 3.06E-01
polymorphism
HBA-A2,
5
B3GALT2,
6.71E-02
FA2H, HBB-B1,
3.25 ADIPOQ 3.45E-01
transmembrane protein
FGFR2, SLC1A5, 9CYP17A1,
8.48E-03
GJB4, MC5R, UCP1,
3.10 CYP2E1, 7.91E-02
NPR3, TSHR
mitochondrion
PCX, ACSL1, ALAS2, ADHFE1,
11 HSD3B6,
8.91E-02
SLC25A10, BCKDHB,
1.78 MOSC1,
3.91E-01
ELOVL6, UCP1, CAR5B
transport
SLC27A1,
SLC16A14, FA2H, SLC6A13, APOC1, SLC7A10, AQP7, UCP1,
19
SLC1A5,
6.24E-02
HBA-A2, CLIC3,
1.54 HPX, SLC25A10,
3.32E-01
ABCD2, HBB-B1, SLC5A7, MUP8, ATP6V0D2, SLC46A2
thiol protease inhibitor
2 2010005H15RIK,
5.87E-02
BC100530
32.46
5.60E-01

Appendix D: Enrichment analysis of down-regulated genes from microarray
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Term
PN
CCN2
PN + CCN2
GO TERM CELLULAR COMPARTMENT
Count
P value
Genes
Fold Enrichment Benjamini
Count
P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
GO:0005914~spot adherens junction
2
3.85E-02
DSG3, PKP3 51.25
2.82E-01
GO:0030057~desmosome
JUP, DSG1B, DSG1A,
11 PKP1,
9.95E-13
DSG3, PPL, PKP3,
28.19
DSC3, DSP,1.76E-10
DSC2, DSC1
GO:0001533~cornified envelope
5HRNR,
4.29E-04
CST6, RPTN, TGM3,
13.49IVL
9.44E-03
GO:0005913~cell-cell adherens junction
5JUP, DSG3,
2.90E-03
PKP3, CDH1,
8.27
CDH3
3.88E-02
GO:0005922~connexon complex
3
5.18E-02
GJB4, GJB6, GJB2
8.09
3.36E-01
GO:0005921~gap junction
4 GJB4,
1.50E-02
PANX3, GJB6, 7.59
GJB2
1.54E-01
GO:0016327~apicolateral plasma membrane
CLDN4, GM5945, FZD6, JUP, DSG1B,
15DSG1A,
1.12E-08
PKP1, DSG3, PPL,
7.46PKP3, DSC3,
6.59E-07
DSC2, DSP, DSC1, PARD6G
GO:0043296~apical junction complex
CLDN4, GM5945, JUP, DSG1B, DSG1A,
14
7.33E-08
PKP1, DSG3, PPL,7.10
PKP3, DSC3, DSC2,
2.60E-06
DSP, DSC1, PARD6G
GO:0070161~anchoring junction
FERMT1, CDH1, CDH3, JUP, TNS4, PVRL4,
16 DSG1B,
1.50E-08
DSG1A, PKP1,
6.67DSG3, PPL,6.64E-07
PKP3, DSC3, DSC2, DSP, DSC1
GO:0005911~cell-cell junction
CLDN4, GJB4, PANX3, GM5945, CDH1, GJB6, CDH3, GJB2,
20
JUP,
1.03E-09
DSG1B, DSG1A,
5.92
PKP1, DSG3,
9.16E-08
PPL, PKP3, DSC3, DSP, DSC2, DSC1, PARD6G
GO:0045095~keratin filament
KRTAP12-1,
4
2.45E-02
KRT77, KRT78, 6.35
KRTAP10-10 5.17E-01
KRTAP12-1,
6 KRT80,
7.99E-03
KRT5, KRT79,
4.80
KRT78, KRT14
9.03E-02
GO:0005912~adherens junction
JUP, TNS4, 8
PVRL4,
4.58E-03
DSG3, PKP3, FERMT1,
3.87 CDH1, CDH3
5.64E-02
GO:0005882~intermediate filament
KRTAP12-1,
5
KRT77,
4.50E-02
KRT15, KRT78,
3.71KRTAP10-10
KRTAP12-1,
6.86E-01
KRT80, KRT5,
10 KRT17,
1.41E-03
KRT16, KRT79,
3.74
KRT15, KRT78,
2.47E-02
KRT14, KRT23
GO:0045111~intermediate filament cytoskeleton
KRTAP12-1,
5
KRT77,
4.81E-02
KRT15, KRT78,
3.63KRTAP10-10
KRTAP12-1,
6.62E-01
KRT80, KRT5,
10 KRT17,
1.64E-03
KRT16, KRT79,
3.66
KRT15, KRT78,
2.61E-02
KRT14, KRT23
GO:0016324~apical plasma membrane
EPCAM, ERBB3,
6
SLC6A20A,
4.37E-02 SLC5A1,
3.11
GJB6, ATP6V0A4
3.02E-01
GO:0045177~apical part of cell
EPCAM, ERBB3, SLC6A20A,
8
1.69E-02
SLC5A1, CDH1,
3.01
GJB6, ATP6V0A4,
1.63E-01
FZD6
GO:0016323~basolateral plasma membrane
EPCAM, TNS4,8COL17A1,
2.02E-02
FERMT1, ITGB4,
2.91DSP, CDH1,
1.82E-01
AQP3
GO:0030054~cell junction
CLDN4, FERMT1, PANX3, CDH1, GM5945, CDH3, PVRL4, COL17A1, PPL, GJB4,
25GJB6,
1.52E-05
GJB2, JUP, TNS4,
2.73
DSG1B, ARHGAP32,
3.83E-04DSG1A, PKP1, DSG3, PKP3, DSC3, DSP, DSC2, DSC1, PARD6G
GO:0042598~vesicular fraction
AADAC, CYP3A13, SQLE,
9 FA2H,
2.58E-02
CYP2B19, RAB38,
2.53
CYP2E1, CYP2B10,
2.07E-01ACSBG1
GO:0005792~microsome
AADAC, CYP3A13, SQLE,
8
5.62E-02
FA2H, CYP2B19, CYP2E1,
2.33
CYP2B10,
3.47E-01
ACSBG1
3B, SPINK7, SERPINA9, PGLYRP3, C330005M16RIK,
MUP7,
GO:0005576~extracellular
SPINK12,
KLK11, MUP15,
MUP1, MUP13,
PTPRZ1,
RETNLA,
region
KLK14,
CSF1,
FGFR2,
MUP19,
MUP12,
5730469M10RIK,
SPINK7,
KLK13, LAD1,
-SERPINA3M,
ENPP2,
KRTDAP,
13
NTS,
APOC1,
1.84E-03
CCL21A,
HPX,
SERPINA3C,
TMPRSS11E,
CCL21B, 2.62
SPINT1,
PSAPL1,
GLB1L2,
WFDC12,
TIMP4,
TMPRSS11BNL,
1.72E-01
SERPINA3B,
UCN2, GM7850,
MUP15,
26
SPINK7,
SERPINB5,
MUP8,
1.93E-02
SMOC1,
MUP13,
TMPRSS11E,
LPL, DEFB4,
CCL21B,
1.57TMPRSS11F,
MUP12,
ADIPOQ,
LIPF
4.96E-01
LEP,
ST14,
SFRP5,
GLB1L2,
RETN,
61 TMPRSS11BNL,
ORM1,
1.37E-06
TSLP, SERPINA3M,
WFDC5,
1.86PLA2G2F,
HPX, ACE2,
IL1F8,
4.05E-05
GLB1L2,
FGFR2, MUP8,
SPINK12,
PLA2G2F,
SERPINA12,
LIPF APOC1, TIMP4, PSAPL1, DEFB6, CO
GO:0019898~extrinsic to membrane
PLEK2, CYP3A13, LRRC1, STAP2, CYP2E1, CYP2B10,
15
7.59E-02
JUP, RASGRP1, CYP2B19,
1.63
PPL, 4.28E-01
ST14, TGM3, RIPK4, FGFBP1, PHLDA2
CLDN4, SLC6A20A, SLC5A1,
GO:0044459~plasma
FERMT1, GM5945,
membrane
AQP3, ACVR1C,
part
EPCAM, H60C,
ROBO1, RAB25, ODZ2, SLC7A10, TNS4, JUP, DSG1B, ARHGAP32, DSG1A, TMPRSS11E, ST14, TMPRSS11F, DSP, TMPRSS11BNL,
51
6.38E-04FGFR3, AP1M2,
1.60 ERBB3, 1.25E-02
ITGB4, PANX3, CDH1, CDH3, PVRL4, COL17A1, PPL, TGM3, SCNN1B, KC
GO:0005783~endoplasmic reticulum
SCD1, SLC27A1,
HSD3B6,
HSD3B6,
MRAP,
SGPP2,
ACER2,
4833423E24RIK,
FA2H, ACER1, CYP2E1,
ACSBG1,ADORA1,
FAR2,21
ELOVL4,
ADIPOQ,
1.66E-04
RASGRP1,
FAR2, AWAT1,
ELOVL3,
2.55
CYP17A1,
ELOVL7,ACSL1,
ELOVL6,
2.87E-02
LASS4,
HSD17B7,
CYP2B19,
26 DHCR24,
2.14E-02
ELOVL3,
CYP3A13,
ELOVL6,
SPTLC3,
1.59
AGPAT2,
FA2H,
RETSAT,
1.82E-01
ACER1,
DHCR24
CYP2E1, CYP2B10, MOXD1, AADAC, AWAT1, ARHGAP32, SQLE,
45, CDCP1, JAG1, GPR87, AQP3, ACVR1C, EPCAM,
GO:0005886~plasma
H60C, ROBO1, RAB25,
membrane
ODZ2, STAP2, SLC7A10, JUP,
- TNS4, ARHGAP32, DSG1B, DSG1A, TACSTD2, TMPRSS11E, TMPRSS11F, ST14, DSP, EFNA5, TMPRSS11BNL, AP1M2,77FGFR3,
2.30E-03
MAL2, PLEK2, ERBB3,
1.36 ITGB4, 3.33E-02
CDH1, PANX3, CDH3, VMN2R45, PVRL4, COL17A1, EPHB6, LY6D, PPL, R
GO:0012511~monolayer-surrounded lipid storage body
2
1.72E-02
PLIN1, PLIN4112.65
5.86E-01
2
5.71E-02
PLIN1, PLIN4 33.89
6.84E-01
GO:0005811~lipid particle
2
3.68E-02
PLIN1, PLIN4 51.99
7.21E-01
4 PLIN1,
2.41E-04
PLIN4, CIDEA, 31.28
PNPLA2
2.10E-02
GO:0005833~hemoglobin complex
2
7.55E-02
HBA-A2, HBB-B1
25.41
7.49E-01
GO:0034385~triglyceride-rich lipoprotein particle 2
9.34E-02
LPL, APOC1 20.33
7.35E-01
GO:0034361~very-low-density lipoprotein particle 2
9.34E-02
LPL, APOC1 20.33
7.35E-01
GO:0042579~microbody
4 FAR2,
8.13E-02
ACSL1, EPHX2, ABCD2
3.91
7.43E-01
GO:0005777~peroxisome
4 FAR2,
8.13E-02
ACSL1, EPHX2, ABCD2
3.91
7.43E-01
GO:0005829~cytosol
HBA-A2, GPD1, PPP2CA, PPARG,
12 EPHX2,
1.83E-02
GYS2, GSTZ1,2.22
PNPLA2, HBB-B1,
5.56E-01
CDO1, LIPE, CIDEC
GO:0005740~mitochondrial envelope
PCX, ACSL1, ALAS2,
8
SLC25A10,
8.80E-02 BCKDHB,
2.08
CIDEA, MOSC1,
7.41E-01
UCP1
GO:0005739~mitochondrion
GPD1, ADHFE1, -HSD3B6, 5730469M10RIK, BCKDHB, LGALS12, CIDEA, MOSC1,23
CAR5B,8.54E-03
UCP1, PCX, CYP17A1,
1.77 ACSL1, ALAS2,
3.95E-01
ADH1, SLC25A10, FASN, ABCD2, GSTZ1, ELOVL6, LIPE, RDH13, LIPF
GO:0031090~organelle membrane
ACER2, BCKDHB, ACER1, MOSC1, UCP1,
13
CD1D1,
9.61E-02
PCX, ALAS2,1.63
ACSL1, SLC25A10,
7.19E-01
ABCD2, ELOVL6, RETSAT

Term
PN
CCN2
PN + CCN2
KEGG PATHWAY
Count
P value
Genes
Fold Enrichment Benjamini
Count
P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
mmu00100:Steroid biosynthesis
4SQLE,1.54E-03
LSS, HSD17B7, DHCR24
16.67
5.06E-02
mmu00910:Nitrogen metabolism
4 CAR12,
3.78E-03
HAL, CAR5B,12.32
CAR2
7.37E-02
mmu00150:Androgen and estrogen metabolism
HSD3B6,
4
1.05E-02
SULT2B1, AKR1D1,
8.59
HSD17B7 1.63E-01
mmu00140:Steroid hormone biosynthesis
3 CYP17A1,
8.93E-02
HSD3B6, AKR1D1
5.89
4.72E-01
CYP3A13,
5 HSD3B6,
3.38E-03
SULT2B1, AKR1D1,
7.87 HSD17B7
8.20E-02
mmu00980:Metabolism of xenobiotics by cytochrome
- P450
4 ADH1,3.68E-02
CYP2B19, GSTZ1,5.35
CYP2E1
GSTA4,
4.01E-01
CYP3A13,
7 ALDH1A3,
2.84E-04
CYP2B19, GSTZ1,
7.51 CYP2E1,2.83E-02
CYP2B10
mmu00260:Glycine, serine and threonine metabolism
3
7.28E-02
CHDH, TDH, GCAT
6.64
5.00E-01
mmu00982:Drug metabolism
3
ALDH1A3,
2.25E-02FMO3, CYP2E1
12.08
5.70E-01
4 ADH1,5.07E-02
CYP2B19, GSTZ1,4.71
CYP2E1
GSTA4,
3.77E-01
CYP3A13,
7 ALDH1A3,
5.69E-04
CYP2B19, GSTZ1,
6.61 CYP2E1,2.83E-02
CYP2B10
mmu00590:Arachidonic acid metabolism
CYP2B19,
4
6.48E-02
EPHX2, CYP2E1,4.25
PLA2G2F
4.23E-01
CYP2B19,
5 ALOX12B,
2.81E-02
CYP2E1, CYP2B10,
4.27
PLA2G2F
3.37E-01
mmu00830:Retinol metabolism
4
ADH1, CYP2B19,
3.97E-02 ALDH1A7,
5.19
RETSAT
3.40E-01 CYP3A13,
4
6.86E-02
CYP2B19, ALDH1A7,
4.17
CYP2B10 5.12E-01
mmu05412:Arrhythmogenic right ventricular cardiomyopathy
(ARVC)
4
JUP,
8.64E-02
ITGB4, DSP, DSC2
3.78
5.32E-01
mmu04520:Adherens junction
4PVRL4,
8.91E-02
PTPRF, CDH1, ACVR1C
3.73
5.16E-01
mmu04360:Axon guidance
EPHB6, 6
PLXNB1,
3.54E-02
ROBO1, EFNA3,3.24
EFNA5, EPHA1
3.65E-01
mmu04144:Endocytosis
FGFR2, EPN3,
7 FGFR3,
6.17E-02
ERBB3, PARD6G,
2.45ARAP2, ACVR1C
5.11E-01
mmu03320:PPAR signaling pathway
SCD1, SLC27A1, LPL,
10 ACSL1,
1.67E-07
PLIN1, PPARG,11.17
AQP7, UCP1, ADIPOQ,
1.37E-05 PCK1
mmu00565:Ether lipid metabolism
4ENPP2,6.72E-03
CHPT1, AGPAT2,10.09
PLA2G2F
1.29E-01
mmu00561:Glycerolipid metabolism
5LPL, MGLL,
1.75E-03
PNPLA3, AGPAT2,
9.39 LIPF
6.94E-02
mmu00350:Tyrosine metabolism
3
ADH1,
6.97E-02
GSTZ1, PNPLA3
6.79
4.17E-01
mmu00564:Glycerophospholipid metabolism
GPD1,
5 CHPT1,
6.38E-03
PNPLA3, AGPAT2,
6.59PLA2G2F 1.60E-01
mmu04920:Adipocytokine signaling pathway
4
LEP,3.82E-02
ACSL1, ADIPOQ, 5.27
PCK1
3.67E-01
mmu04910:Insulin signaling pathway
PRKAR2B,
6
CALML3,
1.83E-02
FASN, GYS2,
3.84
LIPE, PCK12.62E-01
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Term
PN
CCN2
PN + CCN2
GO TERM MOLECULAR FUNCTION
Count
P value
Genes
Fold Enrichment Benjamini
Count
P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment Benjamini
GO:0005007~fibroblast growth factor receptor activity
2
6.58E-02
FGFR2, FGFR329.53
5.78E-01
GO:0042153~RPTP-like protein binding
2
8.15E-02
JUP, CDH1 23.62
6.25E-01
GO:0004030~aldehyde dehydrogenase [NAD(P)+] activity
2
8.15E-02
ALDH1A3, ALDH3B2
23.62
6.25E-01
GO:0017134~fibroblast growth factor binding
3
FGFR2,
1.16E-02
FGFR3, FGFBP1
17.72
2.91E-01
GO:0016628~oxidoreductase activity, acting on the -CH-CH group of donors, NAD or NADP as acceptor
3
FASN,
6.30E-03
AKR1D1, DHCR24
24.61
1.63E-01
3 FASN,
2.57E-02
AKR1D1, DHCR24
11.81
3.77E-01
GO:0004089~carbonate dehydratase activity
3
CAR12,
3.63E-02
CAR5B, CAR2
9.84
4.18E-01
GO:0004867~serine-type endopeptidase inhibitor
SERPINA3M,
activity
- SPINK12,
6
SERPINB3A,
2.60E-05 SERPINB12,
16.51 SERPINB9E,
SPINK12,
SERPINA3M,
8.77E-04
SPINK7
SERPINA12,
SERPINB7,
6 SPINT1,
SERPINB12,
2.35E-03
SERPINB3A,
SERPINA3C,
SERPINB3B,
6.42 SERPINA3B,
SPINK5,
8.42E-02
SERPINA3B,
SPINK7 16 SPINK7,
8.52E-10
WFDC12, SERPINA9,
8.22
SERPINB5,
8.12E-08
SERPINB6C, SERPINB10, SERPINB11, SERPINB12, SERPINB9E
GO:0016620~oxidoreductase activity, acting on the -aldehyde
2 or oxo
8.58E-02
ALDH1A3,
group of ALDH1A7
donors,
21.82
NAD or NADP7.80E-01
as acceptor
FAR2,
4 ALDH1A3,
1.25E-02ALDH3B2,8.15
ALDH1A7
2.74E-01
GO:0016229~steroid dehydrogenase activity
HSD3B6,
4
1.25E-02
SDR42E1, AKR1D1,
8.15
HSD17B7 2.74E-01
GO:0004866~endopeptidase
SERPINA3M,
inhibitor activity
SPINK12, 2010005H15RIK,
8
5.35E-07
SERPINB3A,
SPINK12, SERPINA12,
SERPINB12,
15.72 SPINT1,
BC100530,
SERPINA3M,
7.22E-05
TIMP4,
SERPINB9E,
SERPINB7,
SERPINB3A,
7 SPINK7
SERPINB12,
SERPINB3B,
1.90E-03SERPINA3C,
SPINK5,5.35
SERPINA3B,
TIMP4, SERPINA3B,
BC117090,
7.71E-02 SPINK7
STFA3,
21 SPINK7,
2.97E-12
WFDC12, SERPINA9,
7.70
CST6,
5.66E-10
SERPINB5, SERPINB6C, SERPINB10, SERPINB11, SERPINB12, CSTA, B
GO:0033764~steroid dehydrogenase activity, acting-on the CH-OH group of donors, NAD or NADP as acceptor
3HSD3B6,
5.68E-02
SDR42E1, HSD17B7
7.70
5.36E-01
GO:0004869~cysteine-type endopeptidase inhibitor -activity
CST6, CSTA,5 BC100530,
4.07E-03
SERPINB3B,
7.57
STFA3, BC117090
1.32E-01
GO:0030414~peptidase inhibitor
SERPINA3M,
activity SPINK12, 2010005H15RIK,
8
SPINK12,
9.76E-07
SERPINB3A,
SERPINA12,
SERPINB12,
14.38
SPINT1,
BC100530,
SERPINA3M,
TIMP4,
6.59E-05
SERPINB3A,
SERPINB9E,
SERPINB7,
7SERPINB3B,
SPINK7
SERPINB12,
2.97E-03
SPINK5,
SERPINA3C,
SERPINA3B,
4.89
TIMP4,BC117090,
SERPINA3B,
9.54E-02
STFA3,
SPINK7
22
SPINK7,
1.84E-12
WFDC12, SERPINA9,
7.38 CST6, SERPINB5,
6.99E-10 SERPINB6C, SERPINB10, SERPINB11, SERPINB12, CSTA, BC10
GO:0004364~glutathione transferase activity
3 GSTA4,
7.06E-02
GSTZ1, GM3776
6.81
5.93E-01
GO:0016836~hydro-lyase activity
4 CAR12,
3.35E-02
FASN, CAR5B,5.62
CAR2
4.18E-01
GO:0016712~oxidoreductase activity, acting on paired
- donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation
CYP3A13,
4
3.77E-02
CYP2B19,
of one atom
CYP2E1,
of oxygen
5.37
CYP2B10 4.19E-01
GO:0004857~enzyme inhibitor
SERPINA3M,
activity SPINK12, 2010005H15RIK,
8
SPINK12,
8.30E-06
SERPINB3A,
SERPINA12,
SERPINB12,
10.42
SPINT1,
BC100530,
SERPINA3M,
TIMP4,
3.73E-04
SERPINB3A,
SERPINB9E,
SERPINB7,
7SERPINB3B,
SPINK7
SERPINB12,
1.37E-02
SPINK5,
SERPINA3C,
SERPINA3B,
3.54
TIMP4,BC117090,
SERPINA3B,
2.52E-01
STFA3,
SPINK7
22
SPINK7,
8.45E-10
WFDC12, SERPINA9,
5.35 CST6, SERPINB5,
1.07E-07 SERPINB6C, SERPINB10, SERPINB11, SERPINB12, CSTA, BC10
GO:0004714~transmembrane receptor protein tyrosine
kinase activity
FGFR2,
5
EPHB6,
1.46E-02
FGFR3, ERBB3,
5.27 EPHA1
2.67E-01
GO:0004252~serine-type endopeptidase activity
KLK6, KLK8, KLK9, KLK5, TMPRSS4, TMPRSS11E,
14 TMPRSS11F,
1.91E-05 ST14, KLK11,
4.37 KLK10, TMPRSS11BNL,
1.04E-03
TMPRSS13, KLK14, KLK13
GO:0016298~lipase activity
LPL, MGLL,
7
PNPLA2,
5.78E-05
PNPLA3, LIPE,
10.25
PLA2G2F, LIPF
6.48E-03
AADAC,6ABHD6,
1.37E-02
PLCD1, PNPLA3,
4.22
PLA2G2F, LIPF
2.80E-01
GO:0008236~serine-type peptidase activity
KLK6, KLK8, KLK9, KLK5, ENDOU, TMPRSS4, TMPRSS11E,
15
1.44E-05
TMPRSS11F, ST14,
4.18
KLK11, KLK10,
1.09E-03
TMPRSS11BNL, TMPRSS13, KLK14, KLK13
GO:0050660~FAD binding
CHDH,
5
SQLE,
3.18E-02
DUOX1, AOX4,
4.16
DHCR24
4.14E-01
GO:0017171~serine hydrolase activity
KLK6, KLK8, KLK9, KLK5, ENDOU, TMPRSS4, TMPRSS11E,
15
1.51E-05
TMPRSS11F, ST14,
4.16
KLK11, KLK10,
9.61E-04
TMPRSS11BNL, TMPRSS13, KLK14, KLK13
GO:0015662~ATPase activity, coupled to transmembrane
movement of ions, phosphorylative mechanism
ATP2C2,
4
7.13E-02
ATP10B, ATP6V0A4,
4.14
ATP13A4
5.85E-01
GO:0020037~heme binding
3
HPX,
7.27E-02
HBB-B1, CYP2E1
6.59
8.17E-01
HBA-A2, CYP17A1,
7
1.07E-03
HPX, FA2H, CYP2B19,
5.98
CYP3A13,
HBB-B1,HPX,
CYP2E1
8.66E-02
FA2H, CYP2B19,
9
DUOX1,
3.05E-03
4833423E24RIK,
3.69
CYP2E1,
1.21E-01
CYP2B10, CYP4F39
GO:0046906~tetrapyrrole binding
3
HPX,
7.89E-02
HBB-B1, CYP2E1
6.29
7.95E-01
HBA-A2, CYP17A1,
7
1.37E-03
HPX, FA2H, CYP2B19,
5.70
CYP3A13,
HBB-B1,HPX,
CYP2E1
8.84E-02
FA2H, CYP2B19,
9
DUOX1,
4.07E-03
4833423E24RIK,
3.52
CYP2E1,
1.44E-01
CYP2B10, CYP4F39
GO:0019842~vitamin binding
5 PCX, ALAS2,
1.65E-02
FASN, MOSC1,
5.08GPT
2.80E-01
PCX, SPTLC3,
7
1.66E-02
CRABP2, RBP2, FASN,
3.42 TTPA, GCAT
2.85E-01
GO:0004091~carboxylesterase activity
LPL, MGLL, GM13178,
8
2.58E-05
PNPLA2, PNPLA3,
9.11
LIPE, PLA2G2F,
4.33E-03
LIPF
AADACL2,6 AADAC,
3.59E-02
ABHD6, PNPLA3,
3.28
PLA2G2F, LIPF
4.27E-01
GO:0048037~cofactor binding
GPD1,
6 ALAS2,
3.58E-02
FASN, MOSC1, 3.27
GPT, DHCR24
CHDH, 4.59E-01
SQLE, SPTLC3,10ALDH1A3,
1.45E-02
TDH, FASN, DUOX1,
2.61
GCAT,2.79E-01
AOX4, DHCR24
GO:0050662~coenzyme binding
CHDH, SQLE,
7 ALDH1A3,
5.38E-02
TDH, DUOX1,
2.58AOX4, DHCR24
5.29E-01
GO:0005506~iron ion binding
4 HPX,8.86E-02
HBB-B1, CYP2E1,3.69
CDO1 SCD1,7.51E-01
HBA-A2, CYP17A1,
10ALOXE3,
HPX,1.78E-03
PPP2CA,
CYP3A13,
FA2H,
FA2H,
CYP2B19,
3.59
DUOX1,HBB-B1,
4833423E24RIK,
8.23E-02
CYP2E1, CDO1
CYP2E1,
14
5.49E-03
CDO1, CYP2B10,2.41
CYP4F39, HPX,
1.60E-01
CYP2B19, ALOX12B, C330005M16RIK, AOX4
GO:0004175~endopeptidase activity
KLK6, KLK8, KLK9, KLK5, TMPRSS4, CASP14, TMPRSS11E,
15
1.22E-02
TMPRSS11F, ST14,
2.10
KLK11, KLK10,
2.85E-01
TMPRSS11BNL, TMPRSS13, KLK14, KLK13
GO:0005509~calcium ion binding
GALNT3, HRNR, ANO1, DUOX1, CDH1, JAG1, CDH3, ANXA8, PRRG4, CALML3, RPTN, RASGRP1,
28 FAT2,
9.29E-04
TGM3, PLCD1, TGM5,
1.97 ANO9, S100A14,
4.33E-02ATP2C2, DSG1B, DSG1A, DSG3, VSNL1, DSC3, CALM4, DSC2, D
GO:0008233~peptidase activity
KLK6, CPA4, KLK8, KLK9, KLK5, ENDOU, SPINT1, TMPRSS4, CASP14,
19 TMPRSS11E,
2.00E-02 ST14, TMPRSS11F,
1.78
ACE2,
3.19E-01
KLK11, KLK10, TMPRSS11BNL, TMPRSS13, KLK14, KLK13
GO:0070011~peptidase activity, acting on L-amino acid
peptides
KLK6, CPA4, KLK8, KLK9, KLK5, ENDOU, TMPRSS4, CASP14, TMPRSS11E,
18
2.65E-02
ST14, TMPRSS11F,
1.76 ACE2, KLK11,
3.72E-01
KLK10, TMPRSS11BNL, TMPRSS13, KLK14, KLK13
GO:0004977~melanocortin receptor activity
2
3.96E-02
MC2R, MC5R 49.21
4.77E-01
GO:0004806~triacylglycerol lipase activity
5 LPL, PNPLA2,
3.74E-06
PNPLA3, LIPE,
43.94LIPF
1.26E-03
GO:0017040~ceramidase activity
2
5.50E-02
ACER2, ACER135.15
5.64E-01
GO:0005416~cation:amino acid symporter activity 2
7.77E-02
SLC36A2, SLC6A13
24.61
6.36E-01
GO:0015175~neutral amino acid transmembrane transporter
activity
3 SLC1A5,
7.16E-03
SLC36A2, SLC7A10
23.07
1.59E-01
GO:0005344~oxygen transporter activity
2
8.51E-02
HBA-A2, HBB-B1
22.37
6.57E-01
GO:0004467~long-chain-fatty-acid-CoA ligase activity
2
9.98E-02
SLC27A1, ACSL1
18.93
7.05E-01
GO:0015171~amino acid transmembrane transporter
- activity
SLC1A5,
4
7.56E-03
SLC36A2, SLC6A13,
9.84
SLC7A10 1.57E-01
GO:0005275~amine transmembrane transporter activity
SLC1A5,
5 SLC36A2,
1.64E-03
SLC6A13, SLC7A10,
9.76
SLC5A7
8.83E-02
GO:0015370~solute:sodium symporter activity
3
SLC1A5,
5.29E-02
SLC6A13, SLC5A7
8.02
5.65E-01
GO:0070279~vitamin B6 binding
3
7.02E-02
ALAS2, MOSC1, GPT
6.84
6.25E-01
GO:0030170~pyridoxal phosphate binding
3
7.02E-02
ALAS2, MOSC1, GPT
6.84
6.25E-01
GO:0015294~solute:cation symporter activity
SLC1A5,
4
2.10E-02
SLC36A2, SLC6A13,
6.74
SLC5A7
3.28E-01
GO:0030145~manganese ion binding
PCX, B3GALT2,
6
6.86E-03
PPP2CA, CHPT1,4.99
ACVR1C, PCK1
1.63E-01
GO:0015293~symporter activity
SLC1A5,
5 SLC16A14,
2.19E-02
SLC36A2, SLC6A13,
4.66
SLC5A7
3.25E-01
GO:0005179~hormone activity
4 RETNLA,
6.30E-02
LEP, RETN, ADIPOQ
4.36
5.99E-01
GO:0046983~protein dimerization activity
SLC27A1, GPD1, SYCP3,
9
ADH1,
6.14E-03
PPP2CA, POU2F3,
3.26 CIDEA, NPR3,
1.72E-01
ADORA1
GO:0042803~protein homodimerization activity
SLC27A1,
5
7.04E-02
GPD1, ADH1, CIDEA,
3.19 NPR3
6.12E-01
GO:0004029~aldehyde dehydrogenase (NAD) activity
2
2.44E-02
ALDH1A3, ALDH1A7
79.10
4.87E-01
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GO:0060529~squamous basal epithelial stem cell differentiation
involved in prostate gland acinus development
2
3.26E-02
FGFR2, TRP6360.66
6.70E-01
GO:0043616~keratinocyte proliferation
4 KLK8,
4.81E-04
GM7850, IRF6,24.26
TRP63
3.38E-02
GO:0001736~establishment of planar polarity
2
7.94E-02
TRP63, FZD6 24.26
8.36E-01
GO:0060601~lateral sprouting from an epithelium 2
9.45E-02
FGFR2, TRP6320.22
8.46E-01
GO:0031424~keratinization
SPRR2J-PS,
7 HRNR,
5.09E-06
KRT17, PPL, TGM3,
15.17 SPRR4, IVL
6.06E-04
GO:0030216~keratinocyte differentiation
SPRR2J-PS, HRNR, KRT17, GM7850,
12
2.41E-10
IRF6, PPL, POU2F3,
15.17TRP63, TGM3,
8.61E-08
SPRR4, IVL, SCEL
GO:0009913~epidermal cell differentiation
SPRR2J-PS, HRNR, KRT17, GM7850,
12
4.87E-10
IRF6, PPL, POU2F3,
14.27TRP63, TGM3,
1.04E-07
SPRR4, IVL, SCEL
GO:0042573~retinoic acid metabolic process
2
4.29E-02
ALDH1A3, ALDH1A7
44.41
9.89E-01
3 ALDH1A3,
3.10E-02
CRABP2, ALDH1A7
10.70
6.64E-01
GO:0043588~skin development
GM7850,
5
1.38E-03
IRF6, TRP63, TGM3,
10.11
DHCR24 8.36E-02
GO:0008544~epidermis development
HRNR, KRTDAP, GRHL3, SCEL, SPRR2J-PS, FOXQ1, BARX2, CST6,
20 KRT17,
1.65E-13
GM7850, IRF6,
9.71PPL, POU2F3,
1.77E-10
OVOL1, TRP63, SPRR4, TGM3, IVL, KLK14, DHCR24
GO:0007398~ectoderm development
HRNR, KRTDAP, GRHL3, SCEL, SPRR2J-PS, FOXQ1, BARX2, CST6,
20 KRT17,
5.24E-13
GM7850, IRF6,
9.12PPL, POU2F3,
2.81E-10
OVOL1, TRP63, SPRR4, TGM3, IVL, KLK14, DHCR24
GO:0016101~diterpenoid metabolic process
2
6.97E-02
ALDH1A3, ALDH1A7
26.96
9.84E-01
3
ADH1,
2.14E-02
ALDH1A7, RETSAT
13.12
3.65E-01
ALDH1A3,
4
1.06E-02
CRABP2, RBP2,8.67
ALDH1A7
3.78E-01
GO:0001523~retinoid metabolic process
2
6.97E-02
ALDH1A3, ALDH1A7
26.96
9.84E-01
3
ADH1,
2.14E-02
ALDH1A7, RETSAT
13.12
3.65E-01
ALDH1A3,
4
1.06E-02
CRABP2, RBP2,8.67
ALDH1A7
3.78E-01
GO:0006721~terpenoid metabolic process
2
7.21E-02
ALDH1A3, ALDH1A7
26.03
9.79E-01
3
ADH1,
2.29E-02
ALDH1A7, RETSAT
12.66
3.78E-01
ALDH1A3,
4
1.16E-02
CRABP2, RBP2,8.37
ALDH1A7
3.95E-01
GO:0045104~intermediate filament cytoskeleton organization
3
KRT17,
4.99E-02
KRT16, KRT14
8.27
7.73E-01
GO:0048806~genitalia development
3
TRP63,
5.41E-02
GJB2, DHCR24
7.91
7.92E-01
GO:0048730~epidermis morphogenesis
3
FOXQ1,
5.41E-02
TRP63, KLK14
7.91
7.92E-01
GO:0006633~fatty acid biosynthetic process
SCD1,
6 FAR2,
4.99E-04
ELOVL3, FA2H, FAR2,
FASN,
9.07 ALOXE3,
ELOVL6 3.29E-02
ELOVL4, ELOVL3,
10 FA2H,
6.88E-06
FASN, ALOX12B,
7.49ELOVL7, 4833423E24RIK,
7.37E-04
ELOVL6
GO:0030855~epithelial cell differentiation
FGFR2, HRNR, SCEL, SPRR2J-PS, KRT17,
15IRF6,
1.36E-08
GM7850, PPL, POU2F3,
7.40
KRT14,2.43E-06
TRP63, SPRR4, TGM3, BMP7, IVL
GO:0060688~regulation of morphogenesis of a branching
structure
3
6.28E-02
FGFR2, CDH1, BMP7
7.28
8.17E-01
GO:0045103~intermediate filament-based process 3
KRT17,
6.28E-02
KRT16, KRT14
7.28
8.17E-01
GO:0006775~fat-soluble vitamin metabolic process 2
8.41E-02
ALDH1A3, ALDH1A7
22.20
9.77E-01
3
ADH1,
3.08E-02
ALDH1A7, RETSAT
10.80
4.42E-01
ALDH1A3,
4
1.80E-02
CRABP2, TTPA, 7.14
ALDH1A7
5.26E-01
GO:0006776~vitamin A metabolic process
2
6.49E-02
ALDH1A3, ALDH1A7
29.03
9.86E-01
3
ADH1,
1.86E-02
ALDH1A7, RETSAT
14.12
3.62E-01
3 ALDH1A3,
6.74E-02
CRABP2, ALDH1A7
7.00
8.24E-01
GO:0060512~prostate gland morphogenesis
3 FGFR2,
7.20E-02
SERPINB5, TRP63
6.74
8.25E-01
GO:0007435~salivary gland morphogenesis
3
7.20E-02
FGFR2, CDH1, BMP7
6.74
8.25E-01
GO:0007431~salivary gland development
3
9.14E-02
FGFR2, CDH1, BMP7
5.87
8.46E-01
GO:0007156~homophilic cell adhesion
DSG1B, DSG1A, PTPRF,
10
DSG3,
1.31E-04
FAT2, DSC3,5.18
DSC2, CDH1,1.16E-02
DSC1, CDH3
GO:0006694~steroid biosynthetic process
CYP17A1,
4
1.98E-02
HSD3B6, AKR1D1,
6.90
DHCR24
3.55E-01
HSD3B6, SDR42E1,
6
6.16E-03
LSS, AKR1D1, 5.13
HSD17B7, DHCR24
2.60E-01
GO:0008610~lipid biosynthetic process
SCD1, HSD3B6, HSD3B6,
FA2H, CHPT1,
ALOXE3,
PNPLA3,
FA2H,PCK1,
LSS, FAR2,
4833423E24RIK,
17 AWAT1,
1.10E-09
CYP17A1,
PNPLA3,PCX,
PCK1,
7.30
LASS4,
CWH43,
ELOVL3,
FAR2,
1.10E-06
FASN,
AWAT1,
ELOVL6,
PCX,
24 LASS3,
AKR1D1,
2.96E-10
ELOVL4,
AGPAT2,
SDR42E1,
DHCR24
5.11 ELOVL3,
7.93E-08
FASN, MBOAT1, ALOX12B, ELOVL7, ELOVL6, AKR1D1, HSD17B7, FABP5,
GO:0006720~isoprenoid metabolic process
3
ADH1,
5.97E-02
ALDH1A7, RETSAT
7.49
6.20E-01
ALDH1A3,
4
4.63E-02
CRABP2, RBP2,4.95
ALDH1A7
7.66E-01
GO:0046394~carboxylic acid biosynthetic process SCD1, FAR2,
7
ELOVL3,
9.93E-04
FA2H, FAR2,
FASN,6.08
ALOXE3,
ELOVL6, AKR1D1
ELOVL4,
5.41E-02
ELOVL3, FA2H,
11
FASN,
1.10E-04
ALOX12B, ELOVL7,
4.73
4833423E24RIK,
1.07E-02 ELOVL6, AKR1D1
GO:0016053~organic acid biosynthetic process
SCD1, FAR2,
7
ELOVL3,
9.93E-04
FA2H, FAR2,
FASN,6.08
ALOXE3,
ELOVL6, AKR1D1
ELOVL4,
5.41E-02
ELOVL3, FA2H,
11
FASN,
1.10E-04
ALOX12B, ELOVL7,
4.73
4833423E24RIK,
1.07E-02 ELOVL6, AKR1D1
GO:0060429~epithelium development
FGFR2, HRNR, FGFR3, JAG1, SCEL, FZD6, SPRR2J-PS, KRT17, IRF6,
21 GM7850,
2.08E-08
SERPINB5,4.70
PPL, ALDH1A3,
3.18E-06
POU2F3, KRT14, TRP63, SPRR4, TGM3, BMP7, IVL, CAR2
GO:0016042~lipid catabolic process
3
PLIN1,
4.65E-02
AKR1D1, LIPF
8.45 LPL, ENPP2,
9.83E-01
PLIN1, ACER1,
11 PNPLA2,
1.26E-07
ADIPOQ, AKR1D1,
10.05 PNPLA3,
LIPK, PLIN1,
6.35E-05
LIPE, LIPM,
PLA2G2F,
ACER1,
10LIPFPLCD1,
3.63E-04
PNPLA1, AKR1D1,
4.53 PNPLA3,
2.75E-02
PLA2G2F, LIPF
GO:0009063~cellular amino acid catabolic process 3
BCKDHB,
7.08E-02GSTZ1, CDO1
6.80
6.63E-01
4 HAL,5.87E-02
GSTZ1, CDO1, MOXD1
4.49
8.03E-01
GO:0045017~glycerolipid biosynthetic process
3
CHPT1,
8.01E-02
PNPLA3, PCK1
6.33
6.89E-01
4CWH43,
6.97E-02
PNPLA3, FABP5,
4.18
PCK1
8.28E-01
GO:0007498~mesoderm development
4 FGFR2,
7.26E-02
OVOL1, TRP63,4.11
BMP7
8.21E-01
GO:0001892~embryonic placenta development
4 FGFR2,
7.86E-02
TTPA, SPINT1, 3.98
PLCD1
8.39E-01
GO:0006665~sphingolipid metabolic process
LASS4,
5
FA2H,
1.58E-03
ACER2, ACER1,
9.87PSAPL1
6.99E-02
4LASS3,
8.16E-02
FA2H, ACER1, PSAPL1
3.91
8.33E-01
GO:0050678~regulation of epithelial cell proliferation
FGFR2,
4
8.47E-02
FGFR3, EPGN, SERPINB5
3.85
8.39E-01
GO:0006643~membrane lipid metabolic process
LASS4,
5
FA2H,
1.78E-03
ACER2, ACER1,
9.56PSAPL1
7.50E-02
4LASS3,
8.78E-02
FA2H, ACER1, PSAPL1
3.79
8.44E-01
GO:0046395~carboxylic acid catabolic process
BCKDHB,
5
GSTZ1,
4.19E-03
CDO1, ADIPOQ,
7.56 AKR1D1 1.40E-01
HAL,
5 GSTZ1,
4.41E-02
CDO1, AKR1D1,
3.74MOXD1
7.59E-01
GO:0016054~organic acid catabolic process
BCKDHB,
5
GSTZ1,
4.19E-03
CDO1, ADIPOQ,
7.56 AKR1D1 1.40E-01
HAL,
5 GSTZ1,
4.41E-02
CDO1, AKR1D1,
3.74MOXD1
7.59E-01
GO:0009310~amine catabolic process
3
BCKDHB,
9.73E-02GSTZ1, CDO1
5.65
7.29E-01
4 HAL,9.10E-02
GSTZ1, CDO1, MOXD1
3.73
8.50E-01
GO:0006631~fatty acid metabolic process
SCD1, FAR2, SLC27A1, PRKAR2B,
11
ACSL1,
2.36E-06
ELOVL3,
FAR2,
FA2H,
7.32
ALOXE3,
EPHX2,
ELOVL4,
FASN,
5.94E-04
ELOVL3,
ELOVL6, FA2H,
11
ADIPOQ
FASN,
9.21E-04
ALOX12B, ELOVL7,
3.63
4833423E24RIK,
5.99E-02 ELOVL6, ACSBG1
GO:0022612~gland morphogenesis
FGFR2,
5 SERPINB5,
4.93E-02 TRP63, CDH1,
3.61 BMP7 7.78E-01
GO:0016337~cell-cell adhesion
PTPRF, CLDN4, CDH1, CDH3, JUP,14
PVRL4,
1.43E-04
DSG1B, DSG1A,3.60
BARX2, DSG3,
1.17E-02
FAT2, DSC3, DSC2, DSC1
GO:0048839~inner ear development
FGFR2,
5
5.67E-02
FGFR3, JAG1, GJB6,
3.45FZD6
7.99E-01
GO:0008202~steroid metabolic process
LEP, CYP17A1,
7
HSD3B6,
1.96E-03
APOC1, AKR1D1,
5.32 LIPE,
LEP, HSD3B6,
DHCR24
7.90E-02
SDR42E1,
9 APOC1,
5.08E-03
SULT2B1, LSS,
3.39
AKR1D1, HSD17B7,
2.29E-01DHCR24
GO:0002009~morphogenesis of an epithelium
FGFR2, FGFR3, KRT17,
9 SERPINB5,
7.74E-03 ALDH1A3,
3.16
TRP63, JAG1,
3.04E-01
CAR2, FZD6
GO:0048729~tissue morphogenesis
FGFR2, FOXQ1, FGFR3, KRT17,12
SERPINB5,
1.93E-03
ALDH1A3, TRP63,
3.06 JAG1, BMP7,
1.09E-01
KLK14, CAR2, FZD6
GO:0043583~ear development
FGFR2,
5
9.18E-02
FGFR3, JAG1, GJB6,
2.92FZD6
8.42E-01
GO:0009967~positive regulation of signal transduction
3
HPX,
7.22E-02
CSF1, ALDH1A3
6.58
9.70E-01
FGFR2, FGFR3,8 HPX,2.34E-02
EPGN, ALDH1A3, 2.82
JAG1, FGFBP1,
5.83E-01
KLK14
GO:0055114~oxidation reduction
HSD3B6,
SCD1,
ALDH1A3,
- GPD1,
ALOXE3,
6 FMO3,
ADHFE1,
DUOX1,
2.77E-02
ALDH1A7,
HSD3B6,
4833423E24RIK,
CYP2E1,
FA2H,
3.37
BCKDHB,
CDO1,
CYP4F39,
AKR1D1
MOSC1,
9.92E-01
FAR2,
CYP2E1,
ALDH1A3,
CDO1,
20 FASN,
FAR2,
1.68E-06
ALOX12B,
CYP17A1,
SDR16C5,
ADH1,
3.64CYP2B19,
ALDH1A7,
5.64E-04
FASN,
SDR16C6,
ALDH1A7,
SDR9C7,
30 SDR16C5,
1.78E-06
HSD17B7,
AKR1D1,
DHCR24,
RDH13,
2.71 CHDH,
RETSAT,
CYP3A13,
2.39E-04
DHCR24
FA2H, ALDH3B2, CYP2E1, CDO1, CYP2B10, MOXD1, SQLE, SDR42
GO:0010647~positive regulation of cell communication
3
HPX,
8.49E-02
CSF1, ALDH1A3
5.99
9.70E-01
FGFR2, FGFR3,8 HPX,3.63E-02
EPGN, ALDH1A3, 2.57
JAG1, FGFBP1,
6.99E-01
KLK14
GO:0043065~positive regulation of apoptosis
BNIPL, FGFR3, GSDMA, CASP14,
10
2.14E-02
ALDH1A3, TRP63,2.45
LGALS12, BMP7,
5.76E-01
ACVR1C, CIDEC
GO:0043068~positive regulation of programmed cell- death
BNIPL, FGFR3, GSDMA, CASP14,
10
2.25E-02
ALDH1A3, TRP63,2.43
LGALS12, BMP7,
5.81E-01
ACVR1C, CIDEC
GO:0048812~neuron projection morphogenesis
KLK8, PTPRZ1,
7 ROBO1,
7.01E-02
BCL11B, EFNA5,
2.41 SLITRK6, 8.23E-01
BMP7
GO:0010942~positive regulation of cell death
BNIPL, FGFR3, GSDMA, CASP14,
10
2.34E-02
ALDH1A3, TRP63,2.41
LGALS12, BMP7,
5.71E-01
ACVR1C, CIDEC
GO:0031175~neuron projection development
KLK8, PTPRZ1, MTAP2,
8
6.73E-02
ROBO1, BCL11B,2.23
EFNA5, SLITRK6,
8.31E-01
BMP7
GO:0007155~cell adhesion
MPZL2, LYPD3, CLDN4, PTPRF, ITGB4, FERMT1, CDH1, CDH3,
20
JUP,
2.29E-03
PVRL4, DSG1B,
2.16
DSG1A, BARX2,
1.22E-01
PKP1, DSG3, PKP3, FAT2, DSC3, DSC2, DSC1
GO:0022610~biological adhesion
MPZL2, LYPD3, CLDN4, PTPRF, ITGB4, FERMT1, CDH1, CDH3,
20
JUP,
2.34E-03
PVRL4, DSG1B,
2.16
DSG1A, BARX2,
1.18E-01
PKP1, DSG3, PKP3, FAT2, DSC3, DSC2, DSC1
GO:0030030~cell projection organization
KLF5, KLK8, PTPRZ1, MTAP2,
10
8.05E-02
ROBO1, BCL11B, 1.90
ITGB4, EFNA5,8.34E-01
SLITRK6, BMP7
GO:0050995~negative regulation of lipid catabolic process
2
2.41E-02
CIDEA, ADORA181.61
3.82E-01
GO:0046503~glycerolipid catabolic process
4
LPL,1.01E-05
PNPLA2, PNPLA3,
81.61
LIPE
1.70E-03
GO:0046464~acylglycerol catabolic process
4
LPL,1.01E-05
PNPLA2, PNPLA3,
81.61
LIPE
1.70E-03

188

Term
PN
GO TERM BIOLOGICAL PROCESS, Continued
Count
P value
Genes
Fold Enrichment
GO:0044269~glycerol ether catabolic process
GO:0032328~alanine transport
GO:0019433~triglyceride catabolic process
GO:0010889~regulation of sequestering of triglyceride
GO:0046461~neutral lipid catabolic process
GO:0050994~regulation of lipid catabolic process GO:0006111~regulation of gluconeogenesis
GO:0015909~long-chain fatty acid transport
GO:0010883~regulation of lipid storage
GO:0019432~triglyceride biosynthetic process
GO:0020027~hemoglobin metabolic process
2
2.55E-02
ALAS2, HPX 75.49
GO:0050872~white fat cell differentiation
GO:0045833~negative regulation of lipid metabolic process
GO:0043255~regulation of carbohydrate biosynthetic
- process
GO:0042572~retinol metabolic process
GO:0034284~response to monosaccharide stimulus GO:0015671~oxygen transport
GO:0009749~response to glucose stimulus
GO:0009746~response to hexose stimulus
GO:0002793~positive regulation of peptide secretion
GO:0050873~brown fat cell differentiation
GO:0046463~acylglycerol biosynthetic process
GO:0046460~neutral lipid biosynthetic process
GO:0006641~triglyceride metabolic process
GO:0002021~response to dietary excess
GO:0009743~response to carbohydrate stimulus
GO:0002791~regulation of peptide secretion
GO:0006094~gluconeogenesis
GO:0006639~acylglycerol metabolic process
GO:0050796~regulation of insulin secretion
GO:0006662~glycerol ether metabolic process
GO:0006638~neutral lipid metabolic process
GO:0018904~organic ether metabolic process
GO:0019319~hexose biosynthetic process
GO:0006090~pyruvate metabolic process
GO:0046883~regulation of hormone secretion
GO:0044242~cellular lipid catabolic process
GO:0019216~regulation of lipid metabolic process GO:0045444~fat cell differentiation
GO:0046364~monosaccharide biosynthetic process GO:0006672~ceramide metabolic process
GO:0046165~alcohol biosynthetic process
GO:0046519~sphingoid metabolic process
GO:0034754~cellular hormone metabolic process GO:0034637~cellular carbohydrate biosynthetic process
GO:0032868~response to insulin stimulus
GO:0043434~response to peptide hormone stimulusGO:0016051~carbohydrate biosynthetic process
GO:0009894~regulation of catabolic process
GO:0008203~cholesterol metabolic process
GO:0006818~hydrogen transport
GO:0042445~hormone metabolic process
3 SLCO4A1,
2.24E-02
ALDH1A3, ALDH1A7
12.58
GO:0007188~G-protein signaling, coupled to cAMP nucleotide
second messenger
GO:0046486~glycerolipid metabolic process
GO:0040014~regulation of multicellular organism growth
GO:0016125~sterol metabolic process
GO:0046942~carboxylic acid transport
GO:0045761~regulation of adenylate cyclase activity
GO:0015849~organic acid transport
GO:0007187~G-protein signaling, coupled to cyclic nucleotide
second messenger
GO:0019933~cAMP-mediated signaling
GO:0051339~regulation of lyase activity
GO:0031279~regulation of cyclase activity
GO:0030817~regulation of cAMP biosynthetic process
-

CCN2
Count
P value
Genes
Fold Enrichment Benjamini Count
4
LPL,1.01E-05
PNPLA2, PNPLA3,
81.61
LIPE
1.70E-03
2
2.41E-02
SLC36A2, SLC7A10
81.61
3.82E-01
4
LPL,1.01E-05
PNPLA2, PNPLA3,
81.61
LIPE
1.70E-03
2
2.41E-02
CIDEA, PNPLA281.61
3.82E-01
4
LPL,1.76E-05
PNPLA2, PNPLA3,
69.95
LIPE
2.54E-03
3
CIDEA,
1.33E-03
PNPLA2, ADORA1
52.46
6.17E-02
2
4.76E-02
LEP, ADIPOQ 40.80
5.47E-01
2
5.53E-02
SLC27A1, PPARG
34.98
5.97E-01
2
5.53E-02
CIDEA, PNPLA234.98
5.97E-01
2
6.30E-02
PNPLA3, PCK130.60
6.29E-01
9.99E-01
2
7.81E-02
ALAS2, HPX 24.48
6.90E-01
2
7.81E-02
SCD1, PPARG 24.48
6.90E-01
2
7.81E-02
CIDEA, ADORA124.48
6.90E-01
2
7.81E-02
LEP, ADIPOQ 24.48
6.90E-01
2
7.81E-02
ADH1, RETSAT24.48
6.90E-01
4 NNAT,7.11E-04
GYS2, ADIPOQ, 22.26
ACVR1C
4.12E-02
2
8.56E-02
HBA-A2, HBB-B1
22.26
7.04E-01
4 NNAT,7.11E-04
GYS2, ADIPOQ, 22.26
ACVR1C
4.12E-02
4 NNAT,7.11E-04
GYS2, ADIPOQ, 22.26
ACVR1C
4.12E-02
2
8.56E-02
NNAT, ADORA122.26
7.04E-01
SCD1,
5
MRAP,
8.26E-05
PPARG, UCP1,
21.11
ADIPOQ
7.53E-03
2
9.30E-02
PNPLA3, PCK120.40
7.21E-01
2
9.30E-02
PNPLA3, PCK120.40
7.21E-01
LPL,
6 APOC1,
9.79E-06
PNPLA2, PNPLA3,
20.40
LIPE, PCK1 1.97E-03
2
9.30E-02
LEP, ACVR1C 20.40
7.21E-01
4 NNAT,1.17E-03
GYS2, ADIPOQ, 18.83
ACVR1C
5.73E-02
4 LEP, 1.17E-03
NNAT, ADORA1, ACVR1C
18.83
5.73E-02
3
1.12E-02
GPD1, PCX, PCK1
18.36
2.64E-01
LPL,
6 APOC1,
2.39E-05
PNPLA2, PNPLA3,
17.08
LIPE, PCK1 3.00E-03
3
1.35E-02
LEP, NNAT, ACVR1C
16.69
2.90E-01
LPL,
6 APOC1,
3.00E-05
PNPLA2, PNPLA3,
16.32
LIPE, PCK1 3.35E-03
LPL,
6 APOC1,
3.00E-05
PNPLA2, PNPLA3,
16.32
LIPE, PCK1 3.35E-03
LPL,
6 APOC1,
4.12E-05
PNPLA2, PNPLA3,
15.30
LIPE, PCK1 4.14E-03
3
1.73E-02
GPD1, PCX, PCK1
14.69
3.48E-01
3
1.73E-02
GPD1, PCX, PCK1
14.69
3.48E-01
4 LEP, 3.03E-03
NNAT, ADORA1, ACVR1C
13.60
1.11E-01
LPL, 6ACER1,8.73E-05
PNPLA2, ADIPOQ,13.12
PNPLA3, LIPE7.30E-03
LEP, ACER1,
6
CIDEA,
1.03E-04
PNPLA2, ADIPOQ,
12.66 ADORA1
7.97E-03
SCD1,
6 RETN,
1.32E-04
MRAP, PPARG, UCP1,
12.04 ADIPOQ 9.42E-03
3
2.59E-02
GPD1, PCX, PCK1
11.85
3.93E-01
3
LASS4,
3.42E-02
ACER2, ACER1
10.20
4.71E-01
3
3.60E-02
GPD1, PCX, PCK19.93
4.77E-01
3
LASS4,
3.78E-02
ACER2, ACER1
9.66
4.88E-01
4
CYP17A1,
8.56E-03
ADH1, ALDH1A7,
9.42
RETSAT
2.25E-01
4
GPD1,
1.05E-02
PCX, GYS2, PCK1
8.74
2.55E-01
4 LEP, 1.21E-02
SLC27A1, RETN, ACVR1C
8.30
2.69E-01
LEP, SLC27A1,
6
RETN,
1.03E-03
SERPINA3M, SERPINA3C,
7.73
ACVR1C
5.32E-02
5GPD1, PCX,
4.57E-03
B3GALT2, GYS2,
7.37PCK1
1.47E-01
3
CIDEA,
6.19E-02
PNPLA2, ADORA1
7.34
6.28E-01
4
LEP,1.91E-02
APOC1, LIPE, DHCR24
7.00
3.57E-01
3 SLC36A2,
6.85E-02
ADHFE1, ATP6V0D2
6.93
6.56E-01
1.00E+00
LEP,
5 CYP17A1,
6.09E-03
ADH1, ALDH1A7,
6.80 RETSAT 1.80E-01
3
NPR3,
7.31E-02
TSHR, ADORA1
6.68
6.70E-01
LPL, APOC1,
7
PNPLA2,
6.23E-04
CHPT1, PNPLA3,
6.64 LIPE, PCK1
3.85E-02
4 LEP,2.29E-02
FGFR2, TSHR, ACVR1C
6.53
3.73E-01
4
LEP,2.45E-02
APOC1, LIPE, DHCR24
6.36
3.81E-01
SLC1A5,
5 SLC27A1,
8.49E-03
SLC36A2, PPARG,
6.18 SLC7A10
2.29E-01
3
NPR3,
8.49E-02
TSHR, ADORA1
6.12
7.06E-01
SLC1A5,
5 SLC27A1,
8.79E-03
SLC36A2, PPARG,
6.12 SLC7A10
2.24E-01
3
NPR3,
8.49E-02
TSHR, ADORA1
6.12
7.06E-01
3
NPR3,
8.74E-02
TSHR, ADORA1
6.02
7.07E-01
3
NPR3,
8.98E-02
TSHR, ADORA1
5.92
7.13E-01
3
NPR3,
8.98E-02
TSHR, ADORA1
5.92
7.13E-01
3
NPR3,
9.73E-02
TSHR, ADORA1
5.65
7.29E-01
Benjamini
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GO TERM BIOLOGICAL PROCESS, Continued
Count
P value
Genes
Fold Enrichment Benjamini
Count
P value
Genes
Fold Enrichment Benjamini Count P value
Genes
Fold Enrichment
GO:0008217~regulation of blood pressure
3
EPHX2,
9.73E-02
NPR3, ADORA1
5.65
7.29E-01
GO:0019935~cyclic-nucleotide-mediated signaling 3
NPR3,
9.98E-02
TSHR, ADORA1
5.56
7.34E-01
GO:0010740~positive regulation of protein kinase cascade
4
FGFR2,
3.45E-02
KLB, HPX, ADIPOQ
5.56
4.68E-01
GO:0015837~amine transport
SLC1A5,
4
3.86E-02
SLC36A2, SLC7A10,
5.32
SLC5A7
4.89E-01
GO:0030534~adult behavior
4
LEP,
3.96E-02
SNCG, ADH1, TSHR
5.27
4.93E-01
GO:0006006~glucose metabolic process
LEP,
6 GPD1,
5.57E-03
PCX, GYS2, ADIPOQ,
5.25 PCK1
1.71E-01
GO:0009725~response to hormone stimulus
LEP, SLC27A1,7 RETN, 2.22E-03
SERPINA3M, ADH1,
5.19
SERPINA3C,8.55E-02
ACVR1C
GO:0051046~regulation of secretion
LEP,
5
SNCG,
1.87E-02
NNAT, ADORA1,
4.90
ACVR1C
3.57E-01
GO:0010817~regulation of hormone levels
3 SLCO4A1,
4.28E-02
ALDH1A3, ALDH1A7
8.85
9.96E-01
LEP,
5 CYP17A1,
2.02E-02
ADH1, ALDH1A7,
4.78 RETSAT 3.54E-01
GO:0010876~lipid localization
SLC27A1,
5
PPARG,
2.02E-02
APOC1, CIDEA,
4.78 ACVR1C 3.54E-01
GO:0009719~response to endogenous stimulus
LEP, SLC27A1,7 RETN, 3.80E-03
SERPINA3M, ADH1,
4.66
SERPINA3C,1.33E-01
ACVR1C
GO:0019318~hexose metabolic process
LEP,
6 GPD1,
1.20E-02
PCX, GYS2, ADIPOQ,
4.35 PCK1
2.75E-01
GO:0005996~monosaccharide metabolic process
LEP,
6 GPD1,
1.95E-02
PCX, GYS2, ADIPOQ,
3.85 PCK1
3.56E-01
GO:0060341~regulation of cellular localization
LEP,
5
SNCG,
4.17E-02
NNAT, ADORA1,
3.80
ACVR1C
5.05E-01
GO:0051094~positive regulation of developmental process
5 LEP, FGFR2,
9.58E-02
LPL, PPARG,2.86
CD1D1
7.27E-01
GO:0010033~response to organic substance
LEP, SLC27A1, RETN, SERPINA3M,
11
ADH1,
7.79E-03
NNAT, PPARG,
2.67
GYS2, SERPINA3C,
2.18E-01
ADIPOQ, ACVR1C
GO:0055085~transmembrane transport
SLC16A14, SLC25A10,
8 SLC7A10,
7.96E-02
AQP7, SLC5A7,
2.13
UCP1, ATP6V0D2,
6.92E-01
SLC46A2
GO:0042168~heme metabolic process
2
4.79E-02
ALAS2, HPX 39.73
9.73E-01
GO:0033013~tetrapyrrole metabolic process
2
6.49E-02
ALAS2, HPX 29.03
9.86E-01
GO:0006778~porphyrin metabolic process
2
6.49E-02
ALAS2, HPX 29.03
9.86E-01
GO:0002824~positive regulation of adaptive immune
- response
2
based
8.41E-02
on
HPX,
somatic
CD1D1
recombination
22.20
of immune
9.77E-01receptors built from immunoglobulin superfamily domains
GO:0002821~positive regulation of adaptive immune
- response
2
8.41E-02
HPX, CD1D1 22.20
9.77E-01
GO:0042440~pigment metabolic process
2
9.11E-02
ALAS2, HPX 20.40
9.70E-01
GO:0002708~positive regulation of lymphocyte mediated
immunity
2
9.82E-02
HPX, CD1D1 18.87
9.71E-01
GO:0002705~positive regulation of leukocyte mediated
immunity
2
9.82E-02
HPX, CD1D1 18.87
9.71E-01
Benjamini
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